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ABSTRACT 
Amyloids are highly ordered cross-β sheet aggregates that are associated with many diseases 
such as Alzheimer‟s, type II diabetes and prion diseases. Recently a progress has been made in 
structure elucidation, environmental effects and thermodynamic properties of amyloid 
aggregates. However, detailed understanding of how mutation, packing polymorphism and small 
organic molecules influence amyloid structure and dynamics is still lacking. Atomistic modeling 
of these phenomena with molecular dynamics (MD) simulations holds a great promise to bridge 
this gap. This Thesis describes the results of MD simulations, which provide insight into the 
effects of mutation, packing polymorphism and molecular inhibitors on amyloid peptides 
aggregation. Chapter 1 discusses the structure of amyloid peptides, diseases associated with 
amyloid aggregation, mechanism of aggregation and strategies to treat amyloid diseases. Chapter 
2 describes the basic principles of molecular dynamic simulation and methods of trajectory 
analysis used in the Thesis. Chapter 3 presents the results of the study of several all-atom 
molecular dynamics simulations with explicit solvent, starting from the crystalline fragments of 
two to ten monomers each. Three different hexapeptides and their analogs produced with single 
glycine replacement were investigated to study the structural stability, aggregation behavior and 
thermodynamics of the amyloid oligomers. Chapter 4 presents multiple molecular dynamics 
(MD) simulation of a pair polymorphic form of five short segments of amyloid peptide. Chapter 
5 describes MD study of single-layer oligomers of the full-length insulin with a goal to identify 
the structural elements that are important for insulin amyloid stability, and to suggest single 
glycine mutants that may improve formulation. Chapter 6 presents the investigation of the 
mechanism of the interaction of polyphenols molecules with the protofibrils formed by an 
amyloidogenic hexapeptide fragment (VQIVYK) of Tau peptide by molecular dynamics 
iii 
simulations in explicit solvent. We analyzed the trajectories of the large (7×4) aggregate with 
and without the polyphenols. 
Our MD simulations for both the short and full length amyloids revealed adding strands 
enhances the internal stability of wildtype aggregates. The degree of structural similarity 
between the oligomers in simulation and the fibril models constructed based on experimental 
data may explain why adding oligomers shortens the experimentally observed nucleation lag 
phase of amyloid aggregation. The MM-PBSA free energy calculation revealed nonpolar 
components of the free energy is more favorable while electrostatic solvation is unfavorable for 
the sheet to sheet interaction. This explains the acceleration of aggregation by adding nonpolar 
co-solvents (methanol, trifluoroethanol, and hexafluoroisopropanol). Free energy decomposition 
shows residues situated at the interface were found to make favorable contribution to the peptide 
-peptide association. 
The results from the simulations might provide both the valuable insight for amyloid aggregation 
as well as assist in inhibitor design efforts. First, the simulation of the single glycine mutants at 
the steric zipper of the short segments of various pathological peptides indicates the intersheet 
steric zipper is important for amyloid stability. Mutation of the side chains at the dry steric zipper 
disrupts the sheet to sheet packing, making the aggregation unstable. Thus, designing new 
peptidomimetic inhibitors able to prevent the fibril formation based on the steric zipper motif of 
the oligomers, similar to the ones examined in this study may become a viable therapeutic 
strategy. The various steric zipper microcrystal structures of short amyloid segments could be 
used as a template to design aggregation inhibitor that can block growth of the aggregates. 
Modification of the steric zipper structure (structure based design) with a single amino acid 
changes, shuffling the sequences, N- methylation of peptide amide bonds to suppress hydrogen 
iv 
bonding ability of NH groups  or replacement with D amino acid sequence that interact with the 
parent steric zipper could be used in computational search for the new inhibitors.  
Second, the polyphenols were found to interact with performed oligomer through hydrogen 
bonding and induce conformational change creating an altered aggregate. The conformational 
change disrupts the intermolecular amyloid contact remodeling the amyloid aggregate. The 
recently reported microcrystal structure of short segments of amyloid peptides with small organic 
molecules could serve as a pharamcophore for virtual screening of aggregation inhibitor using 
combined docking and MD simulation with possible enhancement of lead enrichment.  
  Finally, our MD simulation of short segments of amyloids with steric zipper 
polymorphism showed the stability depends on both sequence and packing arrangements. The 
hydrophilic polar GNNQQNY and NNQNTF with interface containing large polar and/or 
aromatic side chains (Q/N) are more stable than steric zipper interfaces made of small or 
hydrophobic residues (SSTNVG, VQIVYK, and MVGGVV). The larger sheet to sheet interface 
of the dry steric zipper through polar Q/N rich side chains was found to holds the sheets together 
better than non Q/N rich short amyloid segments.  The packing polymorphism could influence 
the structure based design of aggregation inhibitor and a combination of different aggregation 
inhibitors might be required to bind to various morphologic forms of the amyloid peptides. 
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CHAPTER 1 INTRODUCTION 
1.1 Protein structure and function 
Proteins are the major macromolecular component of the cell that are synthesized in the 
ribosomes and are responsible for most of the cell‟s biological activity. Proteins play a variety of 
roles in the cell, including structural (cytoskeleton), mechanical (muscle), biochemical 
(enzymes), and cell signaling (hormones). Proteins consist of a linear polycondensate of amino 
acids linked together by peptide bonds in a specific sequence. This specific sequence is 
responsible for the protein‟s structure and function. A peptide bond formed between two amino 
acids is the primary element of peptide and protein structure. Protein structure has four main 
organizational levels: primary, secondary, tertiary and quaternary.
1
 
Primary structure of proteins and peptides is defined by the linear sequence of amino 
acids. There are 20 naturally occurring amino acids, which differ in size, shape, charge, 
hydrogen bonding ability, hydrophilicity, and chemical reactivity. The sequence of the amino 
acid in the primary structure is unique to each protein. A one-letter or  a three-letter 
abbreviations are used to identify sequence of amino acids in a protein.
1
  The amino acids 
chemically combine via amide bonds to from polypeptide chains. The biosynthesis of proteins 
starts at the N terminus and ends at the C terminus, which carry positive and negative charges 
respectively at the physiological pH. The sequence of amino acids in the primary structure is 
unique to each protein and dictates its overall function. Depending on the number and nature of 
substitution, changes in the primary sequence may or may not change the overall structure.
1
 If 
the change is due to substitution between closely related residues (such as tyrosine and 
phenylalanine) the three dimensional structure and its function is generally conserved. However, 
2 
changes in primary sequence which does not conserve the three dimensional structure leads to 
protein misfolding which is associated with protein misfolding diseases.
2
 
Secondary structure is a localized spatial arrangement of amino acids. It is the first step in 
the folding of proteins and polypeptides. There are three types of secondary structures: helices, 
beta sheet and turns. 
A helix is characterized by the number of residues per turn, the number of atoms making 
the cycle formed by the hydrogen bond and the repeat distance. The most common helix is the -
helix with a 3.6 residues per turn where hydrogen bonds are formed between C=O of residue n 
and N-H of residue n+4 (Figure 1-1).  The other less common helices are the 310-helix and π-
helix. The 310-helix has 3 residues per turn forming a hydrogen bond between C=O of residue n 
and N-H n+3. The π-helix is a more loosely coiled helix between C=O of residue n and N-H 
n+5.
3
 The amino acids proline, hydroxyl proline and glycine break -helices. Other amino acids 
such as glutamine, methionine, leucine tend to stabilizes helical structures.
4
  
The β-sheets are the other most common structural element in protein. The β-sheet, 
unlike the -helix, can be built from a combination of several regions of the polypeptide chain. 
The β-sheets are made up of two or more strands laterally pack together such that hydrogen 
bonds can form between C=O groups of one β–strands and N-H groups on an adjacent β –strands 
and vice versa. β –strands can arrange next to each other to form sheets. The directionality of 
adjacent β –strands leads to the formation of “parallel”, “antiparallel” and “mixed” β-sheets.1 
Among amino acids valine, isoleucine and phenylalanine have been found to stabilize β-sheets. 
3 
Proline which cannot participate in the formation of hydrogen bonds between strands destabilizes 
β-sheets. 
Most proteins structures based on combinations of -helices and β-sheets are connected 
by turns or loops of various lengths and irregular shapes. Turns have the universal role of 
enabling the polypeptide backbone to change direction and are important elements that allow and 
drive protein compaction. Analysis of the amino acid composition in turns reveals that bulky or 
branched side chains occur rarely while residues with Gly, Asp, Asn, Ser, Cys and Pro with 
small side chains are observed predominantly in turns.
3,4
  
The tertiary structure represents the three dimensionally folded polypeptide chain. The 
secondary structure is stabilized through hydrogen bonding while the tertiary structure stability is 
mainly due to hydrophobic/hydrophilic interactions as well as salt and disulfide bridges. The 
nonpolar residues tend to collect in the center of the protein while the hydrophilic residues are in 
the surface of the protein. The size and the shape of a protein is determined by the length of the 
amino acids and by how the secondary structure is arranged inside the protein.
1
  
Many proteins are made up of more than one polypeptide chain. The structure formed 
upon the interaction between single tertiary structures of more than one polypeptide chain is 
called quaternary structure. The interactions responsible for the quaternary structure are the same 
as in the tertiary structures. The subunits in the quaternary structure could be based on either 
identical or different subunits. Quaternary structure of proteins allows greater regulation of 
transport function and enzyme activity.
3,1
 Following their synthesis protein molecules must fold 
into native conformation to perform their biological functions. However under some conditions 
4 
proteins fail to fold correctly leading to protein aggregation both in vivo and in vitro. The 
aggregated proteins lack the biological activity of the native protein and are associated with 
pathological conditions
5
 and are a major problem in the manufacturing of proteins.
6
 
 
1.2 Protein aggregation 
The ability of proteins to fold from the linear sequence of amino acid forming a 
functional conformation is one of the most important biological processes. Certain conditions 
(such as environmental conditions
7
, and mutation
8
) initiate misfolding of protein. Protein 
misfolding leads to a loss of the function carried out by that protein. The correct folding of a 
protein involves temporary interactions with helper protein or molecular chaperones and is 
governed by evolutionary pressures that adjust the folding rates according to physiological 
requirements. Incorrect folding of a protein results in protein aggregation. Protein aggregates are 
insoluble molecular self-assembly that have lose of their native conformation and function. It has 
been shown that the protein aggregation can be influenced by a number of variables that 
includes: a) environmental factors which include concentration of protein, type of solvent, salt 
content, metal ions, pH of medium, temperature and pressure and b) structural factors involving 
hydrophobicity, polarity and β-sheet secondary structure content.9 Protein aggregation that is 
commonly found in biopharmaceutical industries is unwanted in protein drug production.
6
 The 
aggregates are major concern in the manufacturing process such as purification, freeze drying 
and storage. Protein aggregation is also associated with a number of human diseases and is 
gaining an increasing role in human health.
9
 The mechanism explaining how amyloidoses cause 
cell death in neurodegenerative diseases still evades our knowledge. Plaques of aggregated 
5 
amyloid fibrils, originally suggested as the cause of the disease are no longer considered to be 
the pathogenic factor. Instead, the small soluble oligomers 
10,11
 formed at the beginning of the 
aggregation process are now believed to be the main cytotoxic entities. Amyloid forming 
proteins have been demonstrated to form pore-like(channel) structures in artificial as well as 
biological membranes.
12
 These ion channel structures have been proposed as the reason for cell 
pathophysiology and degeneration in amyloid diseases.
13
 
 
1.3 Amyloid aggregation and occurrence of amyloid disease 
Amyloid and amyloid like fibrils are elongated, insoluble protein aggregates deposited in 
vivo in amyloid disease or formed in vitro from soluble proteins. Many amyloid proteins are now 
known (Table 1-1) and although they vary in primary sequence, origin and significance in 
normal versus aberrant physiology, they all share the property of forming water-insoluble stable 
aggregates with β-sheet structures. In recent years, amyloid proteins have been found throughout 
the human body, in a variety of different species, and playing a key functional role in some 
cases.
14
 These discoveries have challenged the previous implication that amyloids occur through 
defective protein folding and cause disease, suggesting instead that amyloids may comprise 
evolutionally conserved folds that perhaps have important, as yet unidentified, roles in normal 
cellular physiology.
15
 Over 30 human diseases are now associated with amyloidogenesis (Table 
1-1), the formation of aggregated β-sheet structures that appear as water-insoluble deposits of 
“amyloid” fibrils. Amyloidosis can be classified very broadly into either localized or systemic 
amyloidosis, depending on the location of the amyloid fibres and the genetic (hereditary) or 
acquired nature of the precursor protein. 
6 
1.4 Structure of amyloid fibrils 
Amyloid fibrils are linear unbranched protein aggregates associated with several 
degenerative diseases as well as denatured globular proteins, bacterial inclusion bodies and 
several normal cellular functions.
16,17
 Fibrils appear to arise from the spontaneous unfolding of 
the proteins, the exposure of fibril-forcing segments and subsequent self-assembly.
18
 These 
fibrils share enriched β-structure reflected in a cross-β diffraction pattern and Congo red 
birefringence.
19,20
 The atomic-resolution structures of amyloid-forming peptides have been 
recently determined using X-ray diffraction, electron microscopy, atomic force microscopy, solid 
state NMR (ssNMR), and computational methods.
21,22,23
 It is challenging to investigate the 
structure and dynamics of amyloid fibrils at the residue and atomic resolution because of their 
high molecular weight and heterogeneous properties. The one-dimensional nature of the order in 
the fibrils makes them poor candidates for three-dimensional crystallization. To date, the only 
representative crystal structures are of amyloidogenic peptides that are short enough to pack in a 
three-dimensional lattice.
24
 These structures indicate that the most basic cross-β structure is in 
fact a one-dimensional crystal with single translational and rotational symmetry elements. Being 
neither 2D nor 3D-crystalline nor soluble, protein fibrils are difficult to investigate by X-ray 
diffraction or solution NMR methods, and ssNMR is the method of choice for the 
characterization of their structure and dynamics.
25
  
As reported by Eisenberg et al.,
26
 almost all complex proteins, even though not 
structurally similar, have short segments that if exposed to an appropriate environment (and 
sufficiently flexible) are capable of triggering amyloid formation. The modern biophysical 
description of amyloid is unbranched protein fiber whose repeating substructure consists of β 
7 
strands that run perpendicular to the fiber axis (Figure 1-2), forming a cross-β sheet of indefinite 
length.
2
 Thus, amyloids are composed of an ordered arrangement of many (usually thousands) 
copies of a peptide or protein. They are easily identified using electron microscopy (EM) as long 
filaments with diameters of 6–12 nm.27 The repeating cross-β sheet motif gives rise to 
characteristic X-ray fiber diffraction pattern with meridional reflections at ~4.7 Ǻ corresponding 
to the inter-β strand H-bonding and equatorial reflections at 6–11 Å corresponding to the 
distance between stacked β sheets.28,29 
Eisenberg et al. were able to grow three-dimensional microcrystals
16
 and determine 
atomic resolution structures, using short fibril-forming peptide segments of amyloid proteins. 
These structures provided the atomic details of the cross-β spine architecture: a steric zipper 
made of two β-sheets (8.5 Å apart in this case) mating at a dry, complementary interface of 
interdigitated side-chains. Each sheet is built by hydrogen bonding (H-bonding) of identical 
segments along the fibril direction, separated by 4.9 Å.
22,30
 While H-bonds hold each sheet 
together, van der Waals interactions bind the two sheets into the zipper spine. In contrast to the 
microcrystals, the fibrils show an interstrand twist angle that contributes to their stability, 
providing self-assembling and self-healing properties
31,32
 Twist reflects the fact that successive 
protein chains in a β-sheet are not stacked exactly above one another but with a small angular 
offset.
32
 This twisting optimizes the H-bonds, side-chain stacking, and electrostatic 
interactions.
33
 
Even though amyloids were originally primarily associated with neurodegenerative 
diseases, in recent years, a steadily growing number of specific amyloids have been discovered 
that demonstrate biologically functional properties. Some of the amyloids were found to cause 
8 
amyloidosis in mammals by infection (termed Prions, from “infectious proteins”), others are not 
infectious and may be accumulated for internal reasons. While pathological for mammals, some 
Prions are functional in yeast and fungi (such as HET-s).  Atomistic amyloid models have been 
recently classified into three types (see Figure 1-3). Type 1, characteristic of disease amyloids, is 
formed by lateral stacking of identical β-arches (strand-loop-strand motif). Type 2 is also 
pathological; it consists of superpleated β-arches with more than two strands. The functional 
amyloids (FA), in contrast, were found to belong to Type 3 that is called β-solenoids. The β-
solenoids are built of repeated coils of two or more β-arches long with non-identical but related 
sequence alternates along the fibril
34
  
 
1.5 Nucleation and template assisted self assembly of amyloid peptides 
Molecular self assembly governed by noncovalent interactions is common in nature. The 
spontaneous organization of peptides or proteins is of biomedical significant as they are 
associated with various amyloid diseases (Table 1-1). Amyloid fibril formation appears to be a 
multistep process during which a number of intermediate aggregates are formed. The 
aggregation starts with the coalescence of peptide monomers to form small oligomeric 
aggregates such as dimers, trimers, etc. These small oligomers then grow further in size and 
complexity evolving into protofibrils and then mature amyloid fibrils. The full mechanism of 
amyloid aggregation is still unclear. The formation of amyloid can be considered to involve at 
least three steps (Figure 1-4) and are generally referred to as lag phase, growth phase (or 
elongation) phase and an equilibration phase. The lag phase represents the early stage of the 
amyloid fibril formation, prior to any detection of fibrils. During the fibril growth phase, the 
9 
initially soluble fibrils may become insoluble and precipitate as they exceed certain size and 
solubility limit. The equilibrium phase (or steady state phase) refers to a situation where the 
system, consisting of for example fibrils and monomers, appears to be in equilibrium. Although 
the first step is under kinetic control, fibril growth is under thermodynamic control and can be 
evaluated quantitatively in terms of equilibrium properties such as association constants. 
Among amyloid formation and other nucleated processes a shared feature is that the lag 
phase can be accelerated on addition of aggregate which is referred to seeding.
35
 Seeding 
involves the addition of a preformed fibrils to a monomer solution thus increasing the rate of 
conversion to amyloid fibrils.
36
  Addition of seeds decreases the lag phase by eliminating the 
slow nucleation phase. Seed can be homogenous (same peptide) or heterogeneous (related or 
unrelated peptide) as long as it can provide its growth face as a template for the polymerization 
of the complement monomers. Recent studies of amyloid growth indicate that, in addition to the 
self-interactions mediating pathogenic self association, cross-amyloid interactions (also referred 
as cross seeding) may play a critical role in amyloid diseases.  Examples of such interactions 
include the Aβ–tau, Aβ-amylin, tau–-synuclein, and Aβ–transthyretin interaction.37, 38, 39, 40,41 
 
1.6 Designing of aggregation inhibitors 
In the case of protein aggregation disease the development of therapeutics agent is 
focused on interfering with aggregation pathway or increase degradation of misfolded 
aggregates.
42,43
 At least five different targets have been proposed to intervene against 
aggregation in amyloid disease (Figure 1-5) which includes: A) decrease the expression of the 
protein associated with the misfolding and aggregation; B) native protein stabilization; C) 
10 
inhibition aggregation and reversal of protein conformational changes; D) increase the clearance 
of the misfolded protein; and E) prevent tissue degeneration induced by misfolded aggregates. 
 
11 
Table 1.1 Examples of the most common human protein aggregation diseases and the protein 
associated with the diseases.
44
 
 
Pathological condition Protein associated with the diseases 
Alzheimer‟s disease Aβ peptides (plaques); tau protein (tangles) 
Spongiform encephalopathies  Prion proteins (full length or fragments) 
Primary systemic amyloidosis  Immunoglobulin light chains (full length or fragments) 
Secondary systemic amyloidosis  Serum amyloid A (full length or 76-residue fragment) 
Fronto-temporal dementias  Tau (wild type or mutant) 
Senile systemic amyloidosis  Transthyretin (full length or fragments) 
Familial amyloid polyneuropathy I  Transthyretin (more than 45 mutants) 
Hereditary cerebral amyloid angiopathy  Cystatin C (minus a 10 residue fragment) 
Haemodialysis-related amyloidosis  β2-Microglobulin 
Familial amyloid polyneuropathy III  Apolipoprotein A1 (fragments) 
Atrial amyloidosis Atrial natriuretic factor 
Hereditary non-neuropathic systemic  
amyloidosis  
Lysozyme (mutants) 
Hereditary renal amyloidosis  Fibrinogen 
Injection localised amyloidosis Insulin 
Huntington's disease Huntingtin (intact or poly(Q) rich fragments) 
Spinocerebellar ataxias  Ataxins (intact or poly(Q) rich fragments) 
Medullary carcinoma of the thyroid Calcitonin 
Parkinson's disease  -Synuclein (aa 1-100) 
Type II diabetes  Amylin (aa 1-37) 
Glaucoma  Aβ peptides 
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 A      
B                  
Figure 1.1Alpha (A) and beta sheet (B) secondary structure of amyloid peptides. A) alpha-helix 
structure of A1-42 (Pdb code 1IYT), with helix I (residue 8-25) connected to helix II (residues 
28-38) by a turn (residues 26-27). B) β-sheets structure of a short peptide segment of amyloid 
peptides. The GNNQQNY segment from yeast prion amyloid with parallel (left panel pdb code 
1YJP) and VQIVYK segment from human tau amyloid protein (right panel pdb code 2ON9) 
with antiparallel conformation. Hydrogen and carbon atoms are colored gray, nitrogen blue and 
oxygen red. The hydrogen bonds are represented with green line. Image created with chimera.
45
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Figure 1-2 Structure of amyloid peptides (Adopted from 2) (A) Amyloid fibrils are composed of 
long filaments that are visible in negatively stained transmission electron micrographs; (B) 
Ribbon diagram of the cross-β sheets in a fibril, with the backbone hydrogen bonds represented 
by dashed lines; (C) the fiber diffraction pattern with a meridional reflection at  4.7 Å (black 
dashed box) and an equatorial reflection at  6–11 Å (white dashed box), that arise from the β-
strand and β-sheet spacing respectively. Adopted from Ref 2,24 
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Figure 1-3 Three types of cross beta models of amyloid protofibrils; top: axial views of the 
repetitive structural units (rectangles represent β strands); bottom: lateral views of protofibrils 
formed by stacking of these repetitive units. Orange circles in the insulin model show Cys 
residues forming disulfide bonds. Beneath, schematic diagram of a β arcade, considered to be 
structural motif common to all 3 types of models. One β arch is colored in blue, with depth 
cuing; arrows indicate β strands; dotted lines show H bonds. Adopted from Ref. 32 
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Figure 1-4 Amyloid aggregation growth curve (A) and effect of addition of seeds on the lag 
phase (B) Adopted from Ref. 
35 
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Figure 1-5 Mechanism of nucleation dependent amyloid fibril formation and cross seeding 
Adopted from Ref. 
46,47
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Figure 1-6 Amyloid aggregation and therapeutic intervention in amyloid diseases. The 
conversion of normally soluble peptides and proteins into insoluble aggregates illustrated in a 
schematic manner. The stages in the aggregation process where therapeutic intervention may be 
able to prevent or reverse aggregation are indicated. Therapeutic strategies include (A) 
stabilizing the native state; (B) inhibiting enzymes that process proteins into peptides with a 
propensity to aggregate; (C) altering protein synthesis; (D) stimulating clearance of misfolded 
proteins, for example, by boosting their proteasomal degradation; (E) perturbing fibril assembly; 
(F) neutralizing or preventing accumulation of fibril precursors. Adopted from Ref. 
9, 43 
 
18 
1.7 References 
1. Devlin, T. M., Text Book of Biochemistry with clinical correlations. Seventh ed.; John 
Wily and Sons, Inc New Jersey, 2010. 
2. Greenwald, J.; Riek, R., Biology of Amyloid: Structure, Function, and Regulation. 
Structure 2010, 18, (10), 1244-1260. 
3. Whitford, D., Protein structure and functions. John Wiley & sons, ltd: Chichester, 2005. 
4. Scheibel, J. P. Z. a. T., Protein folding-misfolding: some current concepts of protein 
chemistry. Nova Science Publishers: New York, 2007. 
5. Dobson, C. M., The structural basis of protein folding and its links with human disease. 
Philosophical Transactions of the Royal Society of London Series B-Biological Sciences 2001, 
356, (1406), 133-145. 
6. Groenning, M.; Frokjaer, S.; Vestergaard, B., Formation Mechanism of Insulin Fibrils 
and Structural Aspects of the Insulin Fibrillation Process. Current Protein & Peptide Science 
2009, 10, (5), 509-528. 
7. Stine, W. B.; Dahlgren, K. N.; Krafft, G. A.; LaDu, M. J., In vitro characterization of 
conditions for amyloid-beta peptide oligomerization and fibrillogenesis. Journal of Biological 
Chemistry 2003, 278, (13), 11612-11622. 
8. Senguen, F. T.; Doran, T. M.; Anderson, E. A.; Nilsson, B. L., Clarifying the influence of 
core amino acid hydrophobicity, secondary structure propensity, and molecular volume on 
amyloid-beta 16-22 self-assembly. Molecular Biosystems 2011, 7, (2), 497-510. 
9. Tyedmers, J.; Mogk, A.; Bukau, B., Cellular strategies for controlling protein 
aggregation. Nature Reviews Molecular Cell Biology 2010, 11, (11), 777-788. 
19 
10. Dahlgren, K. N.; Manelli, A. M.; Stine, W. B.; Baker, L. K.; Krafft, G. A.; LaDu, M. J., 
Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. 
Journal of Biological Chemistry 2002, 277, (35), 32046-32053. 
11. Walsh, D. M.; Selkoe, D. J., A beta Oligomers - a decade of discovery. Journal of 
Neurochemistry 2007, 101, (5), 1172-1184. 
12. Quist, A.; Doudevski, L.; Lin, H.; Azimova, R.; Ng, D.; Frangione, B.; Kagan, B.; Ghiso, 
J.; Lal, R., Amyloid ion channels: A common structural link for protein-misfolding disease. 
Proceedings of the National Academy of Sciences of the United States of America 2005, 102, 
(30), 10427-10432. 
13. Naqvi, S. H.; Wang, W. S.; Miao, J. Y.; He, R. Q., Pore-like Aggregates of Tau Protein 
Induced by Formaldehyde. Progress in Biochemistry and Biophysics 2010, 37, (11), 1195-1203. 
14. Fowler, D. M.; Koulov, A. V.; Alory-Jost, C.; Marks, M. S.; Balch, W. E.; Kelly, J. W., 
Functional amyloid formation within mammalian tissue. Plos Biology 2006, 4, (1), 100-107. 
15. Maji, S. K.; Perrin, M. H.; Sawaya, M. R.; Jessberger, S.; Vadodaria, K.; Rissman, R. A.; 
Singru, P. S.; Nilsson, K. P. R.; Simon, R.; Schubert, D.; Eisenberg, D.; Rivier, J.; Sawchenko, 
P.; Vale, W.; Riek, R., Functional Amyloids As Natural Storage of Peptide Hormones in 
Pituitary Secretory Granules. Science 2009, 325, (5938), 328-332. 
16. Wiltzius, J. J. W.; Landau, M.; Nelson, R.; Sawaya, M. R.; Apostol, M. I.; Goldschmidt, 
L.; Soriaga, A. B.; Cascio, D.; Rajashankar, K.; Eisenberg, D., Molecular mechanisms for 
protein-encoded inheritance. Nature Structural & Molecular Biology 2009, 16, (9), 973-U98. 
17. Sipe, J. D.; Benson, M. D.; Buxbaum, J. N.; Ikeda, S.; Merlini, G.; Saraiva, M. J. M.; 
Westermark, P., Amyloid fibril protein nomenclature: 2010 recommendations from the 
20 
nomenclature committee of the International Society of Amyloidosis. Amyloid-Journal of 
Protein Folding Disorders 2010, 17, (3-4), 101-104. 
18. Teng, P. K.; Eisenberg, D., Short protein segments can drive a non-fibrillizing protein 
into the amyloid state. Protein Engineering Design & Selection 2009, 22, (8), 531-536. 
19. Glenner, G. G.; Eanes, E. D.; Page, D. L., Relation of properties of congo red-stained 
amyloid fibrils to beta-conformation. Journal of Histochemistry & Cytochemistry 1972, 20, (10), 
821-828. 
20. Serpell, L. C.; Berriman, J.; Jakes, R.; Goedert, M.; Crowther, R. A., Fiber diffraction of 
synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proceedings of 
the National Academy of Sciences of the United States of America 2000, 97, (9), 4897-4902. 
21. Zheng, J.; Jang, H.; Ma, B.; Tsai, C. J.; Nussinov, R., Modeling the Alzheimer A beta(17-
42) fibril architecture: Tight intermolecular sheet-sheet association and intramolecular hydrated 
cavities. Biophysical Journal 2007, 93, (9), 3046-3057. 
22. Sawaya, M. R.; Sambashivan, S.; Nelson, R.; Ivanova, M. I.; Sievers, S. A.; Apostol, M. 
I.; Thompson, M. J.; Balbirnie, M.; Wiltzius, J. J. W.; McFarlane, H. T.; Madsen, A. O.; Riekel, 
C.; Eisenberg, D., Atomic structures of amyloid cross-beta spines reveal varied steric zippers. 
Nature 2007, 447, (7143), 453-457. 
23. Luca, S.; Yau, W. M.; Leapman, R.; Tycko, R., Peptide conformation and supramolecular 
organization in amylin fibrils: Constraints from solid-state NMR. Biochemistry 2007, 46, (47), 
13505-13522. 
24. Marshall, K. E.; Serpell, L. C., Fibres, crystals and polymorphism: the structural 
promiscuity of amyloidogenic peptides. Soft Matter 2010, 6, (10), 2110-2114. 
21 
25. Bockmann, A., 3D protein structures by solid-state NMR spectroscopy: Ready for high 
resolution. Angewandte Chemie-International Edition 2008, 47, (33), 6110-6113. 
26. Goldschmidt, L.; Teng, P. K.; Riek, R.; Eisenberg, D., Identifying the amylome, proteins 
capable of forming amyloid-like fibrils. Proceedings of the National Academy of Sciences of the 
United States of America 2010, 107, (8), 3487-3492. 
27. Sunde, M.; Blake, C., The structure of amyloid fibrils by electron microscopy and X-ray 
diffraction. In Advances in Protein Chemistry, Vol 50, Academic Press Inc: San Diego, 1997; 
Vol. 50, pp 123-159. 
28. Astbury, W. T., Dickinson, S, and Bailey, K., The X-ray interpretation of denaturation 
and the structure of the seed globulins. Biochem. J. 1935, 29, 2351–0. 
29. Sunde, M.; Serpell, L. C.; Bartlam, M.; Fraser, P. E.; Pepys, M. B.; Blake, C. C. F., 
Common core structure of amyloid fibrils by synchrotron X-ray diffraction. Journal of 
Molecular Biology 1997, 273, (3), 729-739. 
30. Nelson, R.; Sawaya, M. R.; Balbirnie, M.; Madsen, A. O.; Riekel, C.; Grothe, R.; 
Eisenberg, D., Structure of the cross-beta spine of amyloid-like fibrils. Nature 2005, 435, (7043), 
773-778. 
31. Xu, Z. P.; Paparcone, R.; Buehler, M. J., Alzheimer's A beta(1-40) Amyloid Fibrils 
Feature Size-Dependent Mechanical Properties. Biophysical Journal 2009, 98, (10), 2053-2062. 
32. Kajava, A. V.; Baxa, U.; Steven, A. C., Beta arcades: recurring motifs in naturally 
occurring and disease-related amyloid fibrils. Faseb Journal 2010, 24, (5), 1311-1319. 
33. Yu, X.; Wang, J. D.; Yang, J. C.; Wang, Q. M.; Cheng, S. Z. D.; Nussinov, R.; Zheng, J., 
Atomic-Scale Simulations Confirm that Soluble beta-Sheet-Rich Peptide Self-Assemblies 
22 
Provide Amyloid Mimics Presenting Similar Conformational Properties. Biophysical Journal 
2009, 98, (1), 27-36. 
34. Fowler, D. M.; Koulov, A. V.; Balch, W. E.; Kelly, J. W., Functional amyloid - from 
bacteria to humans. Trends in Biochemical Sciences 2007, 32, (5), 217-224. 
35. Harper, J. D.; Lansbury, P. T., Models of amyloid seeding in Alzheimier's disease and 
scrapie: Mechanistic truths and physiological consequences of the time-dependent solubility of 
amyloid proteins. Annual Review of Biochemistry 1997, 66, 385-407. 
36. Lasagna-Reeves, C. A.; Castillo-Carranza, D. L.; Guerrero-Munoz, M. J.; Jackson, G. R.; 
Kayed, R., Preparation and Characterization of Neurotoxic Tau Oligomers. Biochemistry 2010, 
49, (47), 10039-10041. 
37. Andreetto, E.; Yan, L. M.; Tatarek-Nossol, M.; Velkova, A.; Frank, R.; Kapurniotu, A., 
Identification of Hot Regions of the A beta-IAPP Interaction Interface as High-Affinity Binding 
Sites in both Cross- and Self-Association. Angewandte Chemie-International Edition 2010, 49, 
(17), 3081-3085. 
38. Guo, J. P.; Arai, T.; Miklossy, J.; McGeer, P. L., A beta and tau form soluble complexes 
that may promote self aggregation of both into the insoluble forms observed in Alzheimer's 
disease. Proceedings of the National Academy of Sciences of the United States of America 2006, 
103, (6), 1953-1958. 
39. Nicolls, M. R., The Clinical and Biological Relationship between Type II Diabetes 
Mellitus and Alzheimer's Disease. Current Alzheimer Research 2004, 1, (1), 47-54. 
23 
40. Wills, J.; Jones, J.; Haggerty, T.; Duka, V.; Joyce, J. N.; Sidhu, A., Elevated tauopathy 
and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without 
dementia. Experimental Neurology 2010, 225, (1), 210-218. 
41. Du, J. L.; Murphy, R. M., Characterization of the Interaction of beta-Amyloid with 
Transthyretin Monomers and Tetramers. Biochemistry 2010, 49, (38), 8276-8289. 
42. Aguzzi, A.; O'Connor, T., Protein aggregation diseases: pathogenicity and therapeutic 
perspectives. Nature Reviews Drug Discovery 2010, 9, (3), 237-248. 
43. Bartolini, M.; Andrisano, V., Strategies for the Inhibition of Protein Aggregation in 
Human Diseases. Chembiochem 2010, 11, (8), 1018-1035. 
44. Harrison, R. S.; Sharpe, P. C.; Singh, Y.; Fairlie, D. P., Amyloid peptides and proteins in 
review. In Reviews of Physiology, Biochemistry and Pharmacology, Vol 159, Springer-Verlag 
Berlin: Berlin, 2007; Vol. 159, pp 1-77. 
45. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. 
C.; Ferrin, T. E., UCSF chimera - A visualization system for exploratory research and analysis. 
Journal of Computational Chemistry 2004, 25, (13), 1605-1612. 
46. Han, H. Y.; Weinreb, P. H.; Lansbury, P. T., The core Alzheimers peptide NAC forms 
amyloid fibrils which seed and are seeded by beta-amyloid - is NAC a common trigger or target 
in neurodegenerative disease. Chemistry & Biology 1995, 2, (3), 163-169. 
47. Bhak, G.; Choe, Y. J.; Paik, S. R., Mechanism of amyloidogenesis: nucleation-dependent 
fibrillation versus double-concerted fibrillation. Bmb Reports 2009, 42, (9), 541-551. 
 
24 
CHAPTER 2 MOLECULAR DYNAMIC SIMULATION AND 
TRAJECTORY ANALYSIS 
2.1 Bimolecular Simulations 
Molecular simulation is a way to visualize a system by generating successive 
configurations of the system. While experimental techniques such as x-ray crystallography can 
generate a snapshot of a protein (or other macromolecule), the positions of mobile elements, such 
as flexible loops, may remain unclear. It is possible to visualize these mobile elements with 
simulations. Additionally, x-ray crystallography and NMR methods are often employed under 
non-physiological conditions (temperature, pressure, pH, solvent, etc.), which can affect their 
results in unpredictable ways. Many biologically important process involves a change in the 
three dimensional structures of bio-molecules such as protein, RNA and DNA.
48
 Protein folding, 
protein aggregation, enzymatic catalysis, signal transduction and other biological process involve 
conversion of proteins structures.
48
 Bimolecular simulations can provide information to the 
molecular modeler about how a biological system behaves over a certain time period, under 
physiological conditions 
49
 providing continuous trajectories that can help in connecting static 
experimental structures. Therefore computer simulations are used to complement and extend 
experiment.
50
 
There are two main types of simulation methods: Molecular Dynamics (MD) and Monte 
Carlo (MC) simulations. In MD, the configurations are produced by integrating Newton‟s laws 
of motion, resulting in a trajectory that specifies how the system behaves with time. The forces 
on the atoms are used with their current positions and velocities to predict new positions and 
velocities for the next time step. Over a given time period, a “trajectory” is generated that 
25 
describes how the system being studied changes over time. Time averages for thermodynamic 
properties such as internal energy, heat capacity, pressure, and temperature can be calculated.  
2.2 Molecular dynamic simulation 
Molecular Dynamics (MD) simulation is a computer simulation which uses molecular 
mechanics to describe the time evolution of a set of interacting atoms by integrating their 
equations of motion.
51, 52
 MD simulation follows the laws of classical mechanics (Newton's law) 
for system constituted by N atoms, each atom at position ri is treated as a point with a mass mi 
and a fixed charge qi: the force Fi acting upon each atoms is determined by: 
Fi = -U(R),      (1) 
Where, U(R) is the potential energy of the system as a function of the atoms positions. It is a sum 
of energy contributed from oscillations about the equilibrium bond length (Ubond), oscillations of 
3 atoms about an equilibrium bond angle (Uangle), torsional rotation of 4 atoms about a central 
bond (Udihedral) and non-bonded energy terms which consists of electrostatics and Lenard-Jones 
(Unonbond).
50
  
U(R)= Ubond +  Uangle + Udihedral + Unonbond    (2) 
Once the potential energy of the system is obtained using equation 2, the force on each atom can 
be obtained by solving equation 1. The calculated force determines the acceleration of the atoms, 
knowing the positions and velocities at time t one can calculate the positions and velocities of the 
atoms at time (t+t): 
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        (3) 
       (4) 
The continuation of the steps above is a trajectory of the position and velocity of the atoms 
which varies with time.
50
 Thus the MD simulation provides time dependent motions of the 
individual atoms in the system. 
2.2.1 Potential energy function 
MD simulations are based on knowledge of the potential energy surface which is 
represented by an empirical function called force fields. The force field is a collection of 
equations and associated constants designed to reproduce molecular geometry and selected 
properties of tested structures. The force fields are parameterized to approximately reproduce 
various experimental results from spectroscopy, calorimetry and/or quantum mechanical 
studies.
50
 The chief advantages of force fields are the incredible reduction in computational 
requirements. The disadvantage of force fields is they ignore electronic effects and cannot be 
used to describe molecular properties that depend upon electron distribution, such as chemical 
reactions. The functional form for typical force field in AMBER package is given by the 
following equation 
53
: 
 U bonded =    (5) 
U non bonded =     (6) 
27 
where U bonded is the contribution to the total energy from bonded interactions and U non bonded is 
the contribution from non bonded interactions. The total energy is then: U total = U bonded + U non-
bonded. The first term in Eq. 5 is a sum over all bonded pairs of atoms and describes the stretching 
of bonds; b is the inter-atom distance (i.e., bond length); and Kb and b0 are parameters describing 
the stiffness and the equilibrium length of the bond, respectively. The term has the same 
quadratic form as that of Hooke‟s law for the potential energy of a spring. The second term 
involves triplets of atoms, e.g., A, B, and C, where A is bonded to B and B is bonded to C, and 
describes the bending of angles. θ is the angle formed by the two bond vectors, Kθ and θ0 are the 
parameters describing the stiffness and equilibrium geometry of the angle, and, similar to the 
term for bond stretching, the term is quadratic. The third and final term in Eq. 5 is a sum over 
quadruplets of atoms A, B, C, and D, where A is bonded to B, B to C, and C to D, and describes 
the energetic associated with rotation of the dihedral angle defined by those four atoms. Because 
such rotation is necessarily periodic in nature, a cosine function is used. χ is the value of the 
dihedral, Kχ is the energetic parameter that determines barrier heights, n is the periodicity or 
multiplicity, and σ is the phase. It should be noted that the bonded terms are also referred to as 
internal or intra-molecular interactions.
49
 
The non-bonded interactions between atoms are defined as occurring either between 
atoms in separate molecules or between atoms separated by three or more bonds in the same 
molecule. Equation 6 is composed of two parts. The first, known as the Lennard-Jones (LJ) 
equation, is the portion in square brackets along with the prefactor εij , and models attractive 
dispersion and repulsive Pauli exclusion interactions and is commonly referred to as the van der 
Waals term. As two atoms are brought together from infinite separation, the negative term in the 
28 
brackets, which goes as the inverse of the inter-atomic separation rij to the sixth power, 
dominates the interaction and the atoms feel an increasing attraction with decreasing distance as 
the energy becomes progressively more negative. This part of the LJ equation models dispersion, 
and its (1/r )
6
 form derives from the interaction energy of an instantaneous dipole with an 
induced dipole, according to the definition of London‟s dispersion. As the atoms get 
progressively closer, an energy minimum is reached and, at closer distances, the (1/r)
12 
term, 
which is positive, starts to dominate and leads to increasing energy and, hence, repulsion. Its 
form was originally chosen based on its computational expedience because it is simply the 
square of (1/r)
6.
 Nonetheless, it serves as an adequate representation of the very steep repulsive 
energy wall that arises from Pauli exclusion as two atoms get closer than the sum of their van der 
Waals radii. The prefactor, εij, is a parameter based on the types of the two interacting atoms i 
and j. As its value increases, the interaction minimum becomes deeper and the repulsive wall 
steeper. Rmin,ij is a parameter that also depends on the types of the two interacting atoms and 
defines the distance at which the LJ energy is a minimum. The second part of Eq. 6 is Coulomb‟s 
law and is used to model the electrostatic interaction between non-bonded pairs of atoms. As 
with the LJ equation, ri j is the inter-atomic distance, while qi and q j are the parameters that 
describe the effective charges on atoms i and j. It is important to note that the effective charge 
parameters are not simply unit charges located on formally charged atoms. Rather they are 
partial atomic charges with non-integer values that are selected to represent the overall charge 
distribution of a molecule. Naturally, the sum of the partial charges in a molecule must equal the 
molecule‟s net formal charge. In addition, in the case of metal ions, the charge is typically 
assigned the formal charge (e.g., +1 for the sodium ion).
49
 MD packages available for 
29 
commercial or academic use frequently incorporate their own force field which has already been 
parameterized by the developers. Some commonly used dynamics packages that include their 
own force fields are AMBER, CHARMM, and GROMACS.
54,55,56
 There are a variety of 
integration methods currently employed by dynamics software packages, including the Verlet 
algorithm, 
57
 the „leapfrog‟ algorithm,58 the velocity Verlet method,59  and Beeman‟s algorithm.59  
The most widely employed integration methods today are Verlet and velocity Verlet methods. 
The Amber package employed in our MD studies uses the velocity Verlet integration method by 
default.
54
 
 
2.2.2 System setting in MD simulation 
Setting up and running a molecular dynamics simulation is a complicated process which 
requires many considerations, such as the initial configuration of the system being studied, 
choice of force field and dynamics integration method, time length of the simulation and time 
steps, type of ensemble and energy calculations, boundary conditions, and solvation. Each 
consideration can influence the outcome of the simulation as well as the computational expense 
and time requirements. The initial configuration of the system is usually obtained from 
experimental data, theoretical models, or a combination of both. For example, for a protein 
simulation, the structure of the protein may have been obtained from x-ray crystallography, 
NMR, or homology modeling. Atom types for the force field being used must be defined and 
parameters developed if necessary. The systems are frequently minimized prior to running 
dynamics to eliminate high energy interactions such as steric clash.
60
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Once the initial configuration of the system has been defined and the force field and integration 
method (software package) selected, decisions must be made as to the length of time and the 
time steps that will be required for the simulation. The length of time will be determined by the 
nature of the system being studied, the process being studied, and the computational resources 
available to the modeler.. The calculation time steps is another key consideration and it depend 
on the integration method being used, the system studied, and the computational resources 
available.
60
 The smaller the time step chosen, the more computational expensive will be the 
simulation. A standard recommendation is that the time step chosen should be one-tenth the time 
of the shortest motion being studied. In bio-molecular systems this is usually the C-H bond 
vibration which occurs on a 10 fs time scale, thus 1fs time steps would typically be chosen. If C-
H bonds are held constrained during the simulation using a method known as the SHAKE 
algorithm, then this time step can be doubled to 2 fs. 
61
 The next consideration is the type of 
ensemble to be studied and the types of energy calculations that will be used. Molecular 
dynamics are traditionally performed using the NVE or micro-canonical ensemble, which holds 
constant the number of particles (N), the volume (V) and the energy (E). When studying bio-
molecular systems, it is more practical to use the NTP, or isothermal-isobaric ensemble, which 
holds constant the number of particles (N), the temperature (T), and the pressure (P). This 
simulates physiological conditions more closely than the other types of ensembles.  
 
2.2.3 Treatment of long range columbic force  
The most time consuming part of a molecular dynamics simulation is the calculation of 
long range interactions and there are a variety of methods for handling this. The use of distance 
31 
cutoffs for energy calculations is one popular way to address this problem. Cutoffs present a 
problem with certain types of long-range interactions, such as charge-charge interactions which 
can still significantly contribute to the energy of the system beyond the standard cutoffs used in 
most dynamics simulations. Special methods have been developed to address this problem, 
including the Ewald summation. The version of Ewald summation method known as Particle-
Mesh Ewald (PME) is employed in the Amber simulations package.
54
 
 
2.2.4 Boundary condition and solvent models  
Finally, boundary conditions and solvation methods must be decided upon. Because 
interactions at the boundaries of the system being studied (i.e. vacuum, wall, etc.) can influence 
the energy calculations, the boundaries must be defined or taken into account in some manner. 
For bio-molecular simulations, the most common way to do this is to employ periodic boundary 
conditions. Periodic boundaries involve placing the system in a cell, typically a cubic box or 
other geometric shape, and then surrounding the cell with mirror cells containing replicas of the 
system. The interactions energies can be calculated across cell boundaries overcoming the 
boundary effect and enabling the simulation of a much larger system. If a particle leaves one side 
of the cell, it subsequently enters from the other side; keeping the number of particles in the 
system constant. The cell size chosen must be large enough so that the actual bio-molecule being 
studied does not “see” itself and affect its own energy calculations. Usually, it is desirable only 
for solvent molecules to cross the periodic boundary.
54
 
There are currently three different ways to take into account solvation: the first one 
involves simulating the system in vacuum using only a distance dependent dielectric screening 
32 
term in the force field to simulate the solvent screening effects on electrostatic charge 
calculations. This method is the least rigorous, and is the fastest in terms of computational 
expense; however it is also the least reliable and should be reserved only for simulations where 
solvent effects is not expected to play a key role. The second method is known as implicit 
solvation, or continuum solvation.
60
 This method uses special energy terms in the force field to 
represent the solvent as a continuous medium. The two commonly used algorithms to 
approximate the solvent electrostatic effects are the Poisson-Boltzmann equation, and the 
Generalized Born model, which is a linear approximation of the Poisson-Boltzmann equation 
which is computationally less expensive. Both of these equations are often combined with a 
hydrophobic solvent accessible surface area (SA) term. Implicit solvation models still have 
limitations. Entropic effects are not accounted for in these models, which can be a major factor in 
loop movements, ligand binding, and protein folding. The effect of solvent viscosity on the 
motion of solutes is also not accounted for when using implicit models, although in some cases 
this can be desirable. Finally, although H-bonding can be generally accounted for with implicit 
solvation algorithms, the directionality of H-bonds cannot. The third solvation method is the 
explicit solvation. In this method the solvent molecules are explicitly treated by surrounding the 
solute or bio molecule by solvent molecules. This method is the most accurate but is also 
computationally the most expensive as all energy calculations must now include the many 
solvent molecules. For bio-molecular simulations, there are several water models that have been 
designed for use, the most commonly used is the TIP3P water model, a 3-site model where the 
water is represented by a molecule with 3 interaction sites and a rigid shape 
62
 4, 5 and 6 site 
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models have been developed but they increase the computational expense of the simulation and 
are rarely used except for simulations modeling water dynamics.
49
 
Once the molecular dynamics methods have been determined and the system has been set 
up, the simulation can be run. A typical dynamics simulation of a bio-molecular system under 
explicit solvation is a multi-step process. An initial solvent minimization is required, where the 
solvent is minimized while the solute is held under constraint. This is followed by a solvent 
dynamics step, where the solvent (and any counter ions added to balance the solute charge) are 
allowed to equilibrate. The next step would be allowing the entire system to minimize while 
slowly loosening the constraints on the solute, or bio-molecule. This is followed by the dynamics 
simulation itself which occurs in two phases, an equilibrium phase and a production phase. The 
equilibrium phase brings the system to equilibrium from the starting configuration. Equilibration 
is reached when the calculated average temperature, pressure, and energies have stabilized. 
Finally, the production phase of the simulation can begin, where the system is allowed to fully 
evolve for the desired time period. Typically only data obtained from the production phase is 
used to calculate the desired properties.
49
 
 
2.3 Simulation protocol  
 Molecular dynamics (MD) simulations of various size short segment and full length 
amyloid peptides and their corresponding mutant as well as were performed using the MD 
simulation given below. 
 The molecular dynamic (MD) simulation in this thesis were performed using 
AMBER11
63
 package with an all atom amber99SB force field and explicit TIP3P water models. 
34 
Each of the amyloid peptides, the corresponding mutants and amyloid polyphenol complexes 
were solvated by explicit water molecules that extends 10 Å from any edge of the octahedral box 
to the protein atoms. Counterions were added to the box by randomly replacing water molecules 
to neutralize the system. Energy of each system was initially minimized by using conjugate 
gradient method to remove bad contacts with the peptide atoms first constrained, and then 
relaxed without position constrains. The system was then subjected to 50 ps of heating procedure 
while constraining the backbone atoms of the protein to allow relaxation of water and ions, 
followed by 500 ps equilibration run without position constraints on the peptides. Constant 
pressure (1 atm) and temperature (300 K) on the system was maintained by isotropic Langevin 
barostat and a Langevin thermostat. Electrostatic interactions were calculated by using the 
particle mesh Ewald (PME) method. The cutoff radius for the Lennard-Jones interactions was set 
to 12 Å. The SHAKE algorithm 
64
 was used for bond constraints and the time step was 2 fs for 
all simulations. Each system was simulated for 20 ns and the trajectories were saved at 4.0 ps 
intervals for further analysis. The VMD (Visual Molecular Dynamics) program was used for the 
visualization of the trajectories.
65
 The MM-PBSA single trajectory approach implemented as 
script (MMPBSA.py) in AMBER11, was used to calculate the binding energy. The length of the 
production simulation for the systems in chapter 3 was 10 ns. The simulation temperature was set 
at 330 K for the amyloid peptide models in chapter 5. The temperature 330 K was selected as a 
compromise so that amyloid fibrils are still experimentally stable
66,67,68
 but molecular system 
evolves more quickly in the limited simulation time and possible kinetic traps are avoided. The 
force parameter for curcumin, exifone and myricetin in chapter 6  was generated by GAFF utility 
69
 in AMBER11 suite. Geometry optimization and partial charges were obtained using 
35 
Gaussian03 
70
. After geometry optimization at HF/6-31G* level, the partial charges were derived 
by fitting to the gas-phase electrostatic potential at the same theory level using the restrained 
electrostatic potential (RESP) method.   
 
2.4 Analysis of MD trajectories 
The trajectory analysis of the simulations was performed using the analysis tools 
available in VMD, and in ptraj module of AMBER software. MD simulations produce 
trajectories for the atomic positions and velocities. These quantities are saved at regular intervals. 
Usually positional information is mainly used the analysis of MD simulations. Several analyses 
are done once the simulation has been completed to extract structural and energetic information 
from the production run. The goal of the trajectory analysis is to gain structural and dynamic 
insights and relating structure to function. The ptraj program in AMBER soft is capable of 
analyzing and processing trajectory created from MD simulations.
54
 The most frequently used 
trajectory analysis on amyloid peptide aggregates simulations are (a) RMSD and RMSF (b) 
Secondary structure analysis (c) interstrand distance (d) Intersheet distance (e) hydrogen bond 
analysis (f) Cluster analysis and (g) MMPBSA binding free energy calculation  
 A root mean square distance (RMSD) analysis of the amide backbone atoms is often a 
strong indicator of conformational changes of a protein. The root mean square distance (RMSD) 
between the backbone atoms of the trajectory frames of polypeptide chains and the 
corresponding atoms of the x-ray structure, calculated for the frame t, is given by equation 11, 
where x
m
, y
m
, z
m
 are the cartesian coordinates found at the X-ray structure and x
l
 y
l
 z
l
 are the 
Cartesian coordinates of trajectory frame t. N is the number of atoms.
71
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  (11) 
To obtain information on local structural flexibility, stability, and effect of mutations on the 
investigated amyloid peptides molecules a root mean-square fluctuations (RMSF) analysis was 
performed.
72
  RMSF of the C atoms of each residue are calculated as follows: RMSF 
RMSF =       (12) 
where T is the number of snapshots considered in the time trajectory, ri(t), the position of the C 
atom of residue i at time t, and ri, the time-averaged position of the C atom of residue I.
73
 
The secondary structure dynamics shows the conformational change that occurs for a 
peptide or protein during the simulation. The commonly used program for analysis of the 
secondary structure is the Dictionary of Protein Secondary Structure (DSSP). The DSSP 
algorithm was written by Kabsch
74
 and is based on identification of hydrogen-bonding (H-
bonding) patterns and recognizes seven types of secondary structures which can be grouped into 
three classes: helix (α-helix, 310-helix, π-helix), β-strand (isolated β-bridge, extended β-sheet) 
and loop (turn, bend). We carried out secondary structure analysis using the DSSP tool in 
AMBER11.
54
 
To examine the structural stability of the wildtype and the corresponding mutant 
oligomers we also analyzed the inter-strand (dstrand) and inter-sheet (dsheet). The dstrand is 
calculated by averaging the mass center distance between each residue in one strand and its 
corresponding residue in adjacent strand in the same sheet, whereas dsheet is calculated by 
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averaging the mass center distance between each strand in one sheet and its corresponding strand 
in the adjacent sheet.
75
  
A hydrogen bond is weak electrostatic attraction. It forms when a hydrogen atom 
covalently binds to an electronegative atom and is electro-statically attracted to another 
(electronegative) atom. The atom to which the hydrogen atom (H) is covalently bound is 
considered the hydrogen donor (D), and the other atom is the hydrogen acceptor (A).  In 
biological polymers, the donor and acceptor atoms are either nitrogen or oxygen., In protein for 
example in  helices and sheets, the D–H · ·A sequence is N–H ·· O=C.76 The strength of a 
hydrogen bond can be characterized by two geometric quantities which govern the hydrogen 
bond energy: hydrogen bond angle, D–H ·  A atoms  and optimal hydrogen bond length, H · ·A 
(or D ·  A) distance.
76
 Hydrogen bond  and hydrogen bond  occupancies was calculated using 
PTRAJ module available within AMBER. A hydrogen bond is assigned if the distance between 
donor D and acceptor A is ≤3.5 Å and the angle D–H ·  A A≥120o75 using PTRAJ module 
available within AMBER.  
Cluster analysis (“clustering”) places similar samples of data into groups called clusters, 
such that an ensemble of data (for example the different structures obtained from an MD 
trajectory) is partitioned into groups of similar objects. Structural clustering is useful for 
understanding the molecular motion within conformational space.
77
 To identify the most 
populated conformations sampled, clustering was applied to all snapshots from the trajectories 
using the Ptraj program of AMBER11. To perform the clustering, we utilized the average linkage 
algorithm implemented in Ptraj.
54
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Amyloid fibrils typically exhibit twisted β-sheets and twisting of β-sheets optimize the 
hydrogen bonds, side chain stacking, and electrostatic interactions, thus twisted sheets are more 
stable than flat ones. 
78
 Twisting angles have been computed by using the method reported by 
Simone et al 
79
 and Figure 1-2 shows the average twist angle calculation for the Elk prion 
segment NNQNTF.  
 
2.5 Binding free energy calculation  
Free energy calculation methods have become powerful tools as they can provide 
quantitative measurement of protein-ligand or protein-protein interactions. The molecular 
mechanic Poison-Boltzman or the generalized born solvent accessible surface area (MM-
PB(GB)SA) 
80, 81
 method as implemented in AMBER 11 was used to calculate the binding 
energy for non-covalent association of between the studied amyloid peptides.  The calculation of 
the binding free energy requires three independent MD simulations of the complex and both 
individual protein. However an assumption was made that no significant conformational changes 
occur upon binding i.e. structural change is negligible and the snap shots for all three species 
were obtained from the single trajectory carried out on the complex by separating the complex 
into its constituent parts.  
The free energy analyses in this thesis was done using a single trajectory approach, where 
the complex (C), receptor (B) oligomer aggregate), and ligand (A) snapshots were taken from the 
snapshot of the performed MD trajectory. According to the MM-GBSA/MM-PBSA method,
80,81
 
binding free is calculated using equation 11: 
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Gbind = GC  -  GA  - GB      (11) 
The bracket,  , indicates an average of these energy terms over extracted from the MD 
simulation. 
Gbind = EMM +   Gsolv - TS     (12) 
The free energy of each system X=A, B, or C was computed as a sum of the three terms: 
ΔGX = EMM + ΔGsolv - TS      (13) 
Where EMM is the molecular mechanics energy of the molecule expressed as the sum of the 
internal energy (bonds, angles and dihedrals) (Eint), electrostatic energy (Eele) and van der waals 
term (Evdw): 
EMM = Eint + Eele + Evdw     (14) 
∆Gsolv accounts for the solvation energy which can be divided into the polar and nonpolar part: 
∆Gsolv = ∆GGB + ∆GSA     (15A) 
The polar part ∆GGB accounts for the electrostatic contribution to solvation and is obtained from 
Generalized Born (GB) calculations in a continuum model of the solvent. The second term ∆GSA 
is nonpolar contribution to solvation free energy that is linearly dependent on the solvent 
accessible surface area (SASA): 
∆GSA = γSASA + b      (15B) 
The ΔGSA were calculated using AMBER11 default parameter for γ and b (15b).  The entropic 
contribution was calculated in chapter 4 and 6 using the normal mode module in AMBER11.
82, 81
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2.6 Application of MD simulation in the study of bimolecular system 
Various aspects of protein structure and function have been studied by Molecular 
dynamics in numerous fields, including structural biochemistry, biophysics, enzymology, 
molecular biology, pharmaceutical chemistry, and biotechnology.
50
 One notable important area 
of application MD simulation is structure aided drug design. Virtual compound screening using 
molecular docking is widely used in the discovery of new lead compounds for drug design. 
However, this method is not completely reliable and therefore unsatisfactory. Okimoto et al 
83
 
using combined docking and molecular dynamics simulations has found improvement of 1.6 to 
4.0 time in enrichment performance compared to docking method. In the study of protein 
aggregation MD simulation have provided insight into amyloid structure and aggregation 
mechanism.
84
 MD simulation have been used by various researchers. 
85, 86, 87 
in order to 
understand the mechanism of aggregation inhibitor effects of small organic molecules. 
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dstrand=   (9) 
A 
 
 
dsheet=    (10) 
 
 
Figure 2-1 Schematic definition of inter-sheet and inter-strand distances  Adopted from Ref. 
75
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Figure 2-2 Schematic definition of the average twist angle. The twisting of SH1-ST5 of 
NNQNTF calculated by determining the dihedral angle from the coordinates of the 2nd and the 
5th Cα-atom of the first and the last strand of the sheet. The calculated angle provides a measure 
of the overall twisting of each sheet. The twist angles were calculated by using the three inner 
strands and the average twist angles between consecutive strands were estimated by dividing the 
twist by three. 
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Figure 2-3 Thermodynamic cycle in MM-PB(GB)SA calculations. The gray surface represents 
the aqueous solvent. 
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CHAPTER 3 STERIC ZIPPER STABILITY IN WILDTYPE AND 
MUTANTS OF THREE AMYLOID FRAGMENTS 
 
Chapter 3, in part, is a reprint of the material as it appears in Journal of Molecular 
Modeling,2011, Workalemahu M. Berhanu  Artem E. Masunov, published online: 21 Dec. 
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3.1 Background 
Aggregation of polypeptide chains and formation of amyloid fibrils are associated with 
the development of a number of disorders, including Alzheimer‟s, Parkinson‟s, type II diabetes, 
and Creutzfeldt-Jakob disease. 
89
 Amyloid deposits develop when proteins misfold out of their 
native conformations and aggregate into insoluble fibrils.
90
 The amyloid fibrils share a sequence 
independent structure characterized by cross-β spine structural motif in which protein β-strands 
run orthogonal to the fibril axis and repetitive hydrogen bonding extends parallel to the axis.
91, 92
 
This cross-β spine may correspond to the global minimum energy conformation for a wide 
variety of proteins.
91
 Identifying this structural motif in small model peptide systems and 
characterizing it under different conditions can yield valuable clues about the molecular-level 
details of amyloid formation. Recently, the microcrystal structures of several amyloidogenic 
peptides have been determined by x-ray crystallography.
22, 93, 94
 These high resolution structures 
provided researchers with a unique opportunity to understand the structural details and on the 
factors that destabilize/stabilize the amyloid fibrils. Molecular dynamics (MD) simulations, 
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along with other theoretical approaches, based on these crystal structures, can often present 
significant contribution to this understanding.
79, 95-103
 By selecting an amyloid oligomer out of 
the crystal structure and evaluating its conformational stability in a crystal-free environment, 
these investigations have provided insights into the intrinsic propensities of peptide fragments to 
associate in amyloid-like states, the energetic factors stabilizing these aggregates, and the 
possible aggregation states of oligomeric precursors or larger assemblies up to 128 β-strands. 
One of the common structural features, observed in many available X-ray structures of 
amyloidogenic polypeptides is pairing of the β-sheets by interdigitated side chains in a dry „steric 
zipper‟. It is worth noting, that most of the theoretical investigations have been conducted on the 
systems where steric zipper interface is composed of the large polar and/or aromatic side chains. 
In this study we focus on aggregates stabilized by steric zipper interfaces formed by small 
hydrophobic residues (VQIVYK, MVGGVV) (Figure 3-1). A system with polar H-bonding side 
chains (LYQLEN) (Figure 3-1) is also considered for comparison. We perform all-atom MD 
simulations with explicit solvent on both wild type and mutant polypeptides at various degrees of 
aggregation. The initial structure of the aggregates is based high resolution X-ray study.
22
 The 
MVGGVV peptide represent the fragment (residues 35-40) from the C terminal of the A1-40 
peptide, associated with Alzheimer‟s disease.104, 105 The VQIVYK is a fragment (residues 306-
311) of the Tau protein, which is also involved in the pathogenesis of Alzheimer‟s disease. 
LYQLEN peptide is a fragment of a chain (residues 13-18) of Insulin that had been shown to 
form amyloid-like fibrils.
22
 
In Alzheimer‟s disease (AD), the Tau protein forms intracellular amyloid tangles in 
neurons.
106, 107
 The hexapeptide VQIVYK models the key amyloidogenic peptide sequence and 
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forms amyloid-like fibrils with the same cross- structure found in full Tau amyloid fibrils.22 
The structural organization of VQIVYK is a parallel β-strand within the same β-sheet layer while 
maintaining anti-parallel organization between the adjacent β-sheet layers.22 At the dry interface 
between the adjacent β-sheet layers, the shape complementarity is formed by the hydrpbobic 
steric zipper via the side chains of Val1, Ile3 and Tyr5 (Figure 3-2a) 
22
, packing against each 
other forming the sheet-sheet interface. Aggregation of A peptides, which are the natural 
products of cellular proteolytic, is also linked to Alzheimer‟s disease (AD). The most abundant 
A species are 40 residue peptides (A1-40). The MVGGVV peptide is a fragment (residue 35-
40) from the C terminal of the A1-40 consists of parallel and anti-parallel -strands within the 
same -sheet layers. At the dry interface between the adjacent -sheet layers, the shape 
complementarily is formed by the hydrophobic steric zipper via the side chains of Met1, Val2 
and Val5 (Figure 3-2b, c). 
22
 
Fibrils of Insulin are observed extracellularly in the rare medical condition termed 
injection amyloidosis. These Insulin fibrils formed in vivo display the defining characteristics of 
amyloid aggregates such as binding the dye Congo red 
30
 and the cross- X-ray diffraction 
pattern.
29
  Both A chain and B chain can form fibrils on their own 
108, 109
, and seeds of A chain or 
B chain can nucleate the fibrillation of full length Insulin.
108
 The atomic-resolution picture of the 
interactions between segments of Insulin which may be part of fibrillar spine came from crystal 
structures of the fibril forming peptide segments LYQLEN (residues A13–A18) and VEALYL 
(residues B12–B17).22 The structural organization of LYQLEN is anti-parallel β-strands within 
the same β–sheet layer while maintaining parallel organization between the adjacent β-sheet 
layers.
22
 At the dry interface between the adjacent β-sheet layers, the shape complementarity is 
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formed by the polar side chain steric zipper (Tyr2, Gln3, Leu4 and Asn6) and side chain H-
bonding (Figure 3-2d).
22
 Recently, serum samples from patients with Parkinson‟s disease have 
been found to display an autoimmune response to Insulin oligomers and fibrils 
110
, possibly 
indicating the presence of Insulin aggregates in this disease as well. Insulin also reported to form 
amyloid-like fibrils in vitro under elevated temperatures, low pH, and increased ionic 
strength.
111, 112
 This fibril formation has been a limiting factor in long-term storage of Insulin for 
treatment of diabetes. Thus, better understanding of Insulin fibrillation could lead to safer 
handling and more cost-effective storage of Insulin. 
Previous theoretical study has demonstrated the significant role of steric zipper in the 
structural stability of the GNNQQNY and GGVVIA oligomers stabilized with polar side chain 
and H-bonding.
102, 113
 Park et al. 
95
 address the structural selection mechanism of different double 
layer peptides including GNNQQNY, NNQQ, VEALYL, KLVFFAE and STVIIE, and find that 
the patterns with the lowest binding free energy correspond to X-Ray structures with high 
accuracy. The main contribution of the binding free energy of the double layer pattern is 
determined by the van der Waals and hydrophobic forces. These contributions can therefore 
serve as a quantitative measure of shape complementarity among side chains between the β-
sheets. The steric self-complementary (known as steric zipper) selects the most stable packing 
modes. It also makes parallel β-sheets generally preferred over anti-parallel ones. The presence 
of charged side chains appears to give anti-parallel β-sheets kinetic preference at the early stages 
of assembly, while the double layer formation is likely to be thermodynamically controlled. Xu 
et al. 
114
 investigated the β-sheets composed of seven antiparallel decapeptides, representing the 
20–29 segment of human Islet amyloid polypeptide (hIAPP). The amyloid nucleus of hIAPP was 
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mimicked with one -sheet of different initial separation distances between the strands. Multiple 
all-atom MD simulations with explicit water solvent showed that the assembly occurs not only in 
the lateral direction but also along the longitudinal direction. This provides a new insight into the 
assembly pathway at the early stage of fibril elongation. Based on the Poisson–Boltzmann free 
energy analysis and quasiharmonic configuration entropy estimation, the entropic contribution 
was found to play an important role in the longitudinal assembly. Moreover, a possible 
oligomeric state with cyclic form was suggested based on one assembly model found in the 
simulations. This evidenced the polymorphic nature of the amyloidogenic oligomerization and 
possible mechanism of its toxicity. The cyclic structures of amyloid oligomers have been 
reported to be the early intermediates in solution, capable to form ion-channel-like structures in 
the membrane that could be responsible for pathologic membrane permeability and 
destabilization of the cellular ionic homeostasis.
115,
 
12
 
Vitagliano et al 
116
 in their molecular dynamics simulation characterizing assemblies 
formed by steric zipper assemblies composed of a pair of 10-stranded -sheets of the peptides 
SSTSAA and VQIVYK show high fluctuations and significant distortion. The analysis of the 
VQIVYK crystal packing reveals two different double layers with significant interface area and 
surface complementarity.
22
 One is characterized by nonpolar dry interface made up essentially 
by the side chains of V1 and I3 of the two layers, while the other is polar and involves Tyr and 
Gln side chains.
22
 The nonpolar interface exhibits larger values of the surface area (113 vs. 89 
Å
2
), but slightly lower surface complementarity (0.76 vs. 0.82).
22
 The stability of the nonpolar 
hydrophobic interfaces was studied by Vitagliano et al. 
116
 in their MD simulations. They report 
56 
high fluctuations and significant distortion (RMSD c.a. 10 Å within 40 ns simulation) when 
investigate three layer assemblies formed by steric zipper and composed of a pair of 10-stranded 
-sheets of the peptides VQIVYK. In the contrast, they found RMSD below 6 Å within 40 ns 
simulation, when study the 10-stranded double layer with nonpolar interface. Hence, the stability 
of the nonpolar interface is system dependent. 
However, the atomic information for the early stage of the aggregation mechanism of the 
VQIVYK, MVGGVV and LYQLEN peptide is still limited so far. Thus, understanding the 
structural stability and aggregation behavior of the VQIVYK, MVGGVV and LYQLEN peptide 
is expected to provide knowledge for designing an inhibitor aimed to decrease the self-
aggregation into fibrils.  
In this study, several all-atom MD simulations with explicit water at 300 K were 
conducted to investigate the structural stability, aggregation behavior and thermodynamics of the 
VQIVYK, MVGGVV and LYQLEN peptides with various sizes and its single glycine 
replacement mutations. Our aim is to elucidate: (i) the influence of the number of the peptides on 
the structural stability and conformational dynamics of the oligomers; (ii) the possible minimal 
nucleus seed for the fibril formation of the peptides; (iii) the principle driving force for the 
association of the peptides; and (iv) the effects of single glycine replacement mutations on the 
structural stability of the oligomers. The results of this study may provide insight into the 
possible mechanism of fibrillogenesis of the amyloid peptides. It may also be helpful for 
designing new or modified capping peptides capable of breaking the driving force for 
aggregations and preventing the fibril formation of the peptides. 
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3.2 Methods 
The crystal structure of the VQIVYK, MVGGVV and LYQLEN had been determined by 
Sawaya et al.
22
 The atomic coordinates of the multiple unit cells were taken from the website 
117
, 
and the water molecules from the crystal structure were removed. The MVGGVV have two 
different polymorphic forms (form 1 and 2 with resolution of 2.0 Å and 1.8 Å) both of which 
were used in the simulation. The Sirius visualization program from San Diego Supercomputer 
Center (http://sirius.sdsc.edu) was used to construct the aggregates of various sizes. The initial 
geometry of the largest aggregate was taken as a pair of -sheets composed of 6 strands (5 
strands for VQIVYK), it is shown on Figure 3-2. In the following we denote the aggregates ShN-
StM, where N is the number of -sheets, and M is the number of strands per -sheet. The initial 
geometry of the largest wild type aggregate was taken as a pair of -sheets composed of 6 
strands (MVGGVV and LYQLEN) and 5 strands (VQIVYK), as shown on Figure 3-2. For the 
smaller size wild type systems, the initial structures of oligomers were obtained by removing the 
β-strands one by one from the Sh2-St5 (VQIVYK) or Sh2-St6 (MVGGVV and LYQLEN) 
models. To construct the mutant systems, several glycine replacements were made in the wild 
type aggregate. The mutants are denoted as XnG, where X is the replaced residue, and n is its 
position in the peptide sequence. Three or four mutants were designed for each peptide (V1G, 
I3G, and Y6G for VQIVYK; M1G, V2G, V5G, and V6G for MVGGVV; V2G, Q3G, L4G and 
V6G for LYQLEN). The simulation details for each model are summarized in Table 3-1, 3-2, 3-3 
and 3-4. The MM-PBSA single trajectory approach implemented as script in Amber10. 
118
 was 
used to calculate the steric zippers binding energy for non-covalent association between the -
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sheets within the double layer. The gas phase and the solvation free energies were calculated 
over 500 snapshots taken at 20 ps intervals from the last 8 ns of the MD trajectories. 
 
 
3.3 Results  
3.3.1 Size dependent structural stability of the wild type peptides aggregates 
Eight simulations of wild type VQIVYK were conducted for the aggregates build of one 
(models A1-A4) and two (models A5–A8) antiparallel β-sheets with parallel strands within each 
sheet. The relative stability of the model aggregates was measured by the backbone root mean-
squared deviation (RMSD). The reference structure for calculating backbone RMSD was the 
energy-minimized structure. As one can see on Figure 3-3A, for the model systems of A1 (Sh1-
St2) and A2 (Sh1-St3), the RMSDs remained below 2.Å for 10 ns, while for A3 (Sh1-St4) and 
A4 (Sh1-St5) the RMSDs increased to 4.5Å, indicating the lower relative instability of the one 
layer aggregate with larger number of strands. The larger two-layer model systems of A7 (Sh2-
St4) and A8 (Sh2-St5), maintained RMSDs c.a. 4.0 Å within 10 ns, indicating relative stability 
of the structures compared to the smaller bilayer models A5 (Sh2-St2) and A6 (Sh2-St3), which 
showed large fluctuations up to 7.0 Å (Figure 3-4A). The results of two-layer models suggested 
that the structural stability of the VQIVYK oligomers increases with increasing the numbers of 
β-strands, the four and five stands are more stable than two and three strands, while for one-layer 
models the trend is opposite. 
Our simulation for 5-stranded double layers of the wildtype VQIVYK oligomers was 
found to have a RMSD of 4 Å, in good agreement with the result reported by Vitagliano et al.
116
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The comparison of the RMSD values of the nonpolar interface models (VQIVYK and 
MVGGVV) with LYQLEN that has polar residues on the dry interface indicates the nonpolar are 
significantly less stable. The smaller RMSD values of the polar LYQLEN is in a good agreement 
with the result of Zhang et al.
113
, who found an RMSD of 2 Å by simulation of 4-stranded double 
layer GGNNQQNY, which has polar residues on the dry interlayer interface. Our results indicate 
that the polar dry interface significantly improves stability. 
Another eight wild type simulations of MVGGVV1 (models C1–C8) were conducted for 
anti-parallel β-sheets with parallel strands within the sheets. As shown in Figure 3-3B, for the 
model systems of C1 (Sh1-St2) and C2 (Sh1-St3), the RMSDs were below 4.50 Å within 10 ns. 
For C3 (Sh1-St4) and C4 (Sh1-St5) the RMSDs were maintained below 4.5 Å and 6 Å within 10 
ns respectively, the two layer model systems of C7 (Sh2-St4) and C8 (Sh2-St5), the RMSDs 
were below 3.0 Å within 10 ns as shown in Figure 3-4B. Aggregate C6 (Sh2-St2) maintained 
RMSDs below 4.0 and C5 (Sh2-St3) showed large fluctuations RMSD within the first 5 ns and 
then increased to 12 Å after 7 ns. Our results for one-layer models suggest that the structural 
stability of the MVGGVV1 oligomers increases as the number of stands decreases, while the 
results of two-layer models suggest that the structural stability of the MVGGVV1 oligomers 
increases remarkably with increasing the numbers of β-strands, the four and five stands are more 
stable than two and three strands.  
Four wild type MVGGVV2 peptide aggregates (two layer with different number of 
strands), simulations were conducted for antiparallel β-sheets with parallel strands within the 
sheets (models E1–E4). We did not do single layer simulation, assuming the result will be the 
same as for polymorphic form I. As shown in Figure 3-4C, E2 (Sh2-St3) and E3 (Sh2-St4), the 
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RMSDs were almost identical and remained < 6.0 Å within 10 ns. While E1 (Sh2-St2) showed a 
large fluctuations within 1ns and remained c.a. 7.0 Å within 10 ns. E4 (Sh2-St5) shows the same 
RMSD change as E2 and E3 for the first 4ns increasing to ~5.0 Å and maintained an RMSD  
5.0 Å during the 10 ns simulation. The results of two-layer models suggested that the structural 
stability of the MVGGVV2 oligomers increases with increasing the numbers of β-strands, the 
four and five stands are more stable than two and three strands.  
Finally eight wild type LYQLEN peptide aggregates (models G1–G8) were considered 
for antiparallel β-sheets, parallel strands within the sheets. As shown in Figure 3-3C, for the 
model systems G1 (Sh1-St2), G2 (Sh1-St3), G3 (Sh1-St4) and G4 (Sh1-St5) consisting of one 
layer and different number of strands, the RMSDs remained at 2.0 Å within 10 ns, indicating 
exceptional stability of these structures. Figure 3-4D show that for the model systems G5 (Sh2-
St2) and G7 (Sh2-St4), the RMSDs showed were maintained at ~4.50 Å, for G8 (Sh2-St5) 
RMSDs is c.a. 2.50 Å, and for G6 (Sh2-St3) RMSD demonstrates a large fluctuation within the 
first 4 ns and then stabilized at 7 Å after 8 ns, which indicated that they lost their original 
structural organization. The results of two-layer models suggested that the structural stability of 
the LYQLEN oligomers increases remarkably with increasing the numbers of β-strands, with 
four and five stands being the most stable. Our results for one-layer models suggested that the 
structural stability of the LYQLEN oligomers is the same irrespective of the number of strands. 
One layer with two, three, four and five stands (model G1-G4) are structurally stable with 
RMSD c.a 2.0 Å. The LYQLEN oligomers is stabilized with backbone to backbone and side 
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chain  hydrogen bonding while in the case of the  VQIVYK , MVGGVV1 and MVGGVV 2 are 
stabilized with back bone to back to bone  hydrogen bonding.  
Comparing single and double layer models, our results reveal that the extra β-sheet strand 
contributes significantly to the structural stability of the VQIVYK, MVGGVV1 and MVGGVV2 
oligomers for double layer model while in the case of single layer model it decrease. In the case 
of the LYQLEN our results also shows that an extra β-sheet strands contributes significantly to 
the structural stability of the LYQLEN oligomers for double layer models while in the case of 
single layer model it is almost the same irrespective of the number of strands. This is in 
agreement to previous studies done on different types of amyloid models. The above results all 
together suggest that the structural stability of the oligomers increases significantly with 
increasing the number of β-strands for double layer models implying extra sheet-sheet 
interactions are necessary for the formation of steric zipper to associate the strands, resulting in 
more stable oligomeric organizations. Our findings are in agreements with previous observations 
102, 113
 which indicate that the minimal nucleus seed for the amyloid fibril formation could be as 
small as three or four peptides.  
The evolution of the root mean square deviations (RMSDs) between initial and the 
current trajectory structures indicates that the system undergoes certain rearrangement. The 
initial structures are taken from X-ray and may be stabilized by the crystal environment. 
However, the simulations are performed in the solution state. Due to this different environment, 
relatively large RMSDs may not always correspond to the unstable structures. To further analyze 
the structural stability we also performed secondary structure analysis and binding free energy 
calculations.  
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3.3.2 The effect of single-glycine mutations on structural stabilities of the aggregates 
To investigate how the steric zipper interfaces influence the structural stability of the 
double-sheet aggregates of VQIVYK, MVGGVV and LYQLEN peptides, the side-chains 
participating in these interfaces were replaced by glycine (Table 3-1 to 3-4). As one can see from 
the Figure 3-5A, the largest aggregates composed of these mutants were less stable, compared to 
the respective wild type aggregates. The RMSD of I3G and Y5G are somewhat higher (c.a 
5.5Å), than those of V1G (c.a. 4.5Å), indicating that I3G and Y5G exhibit higher potential to 
destabilize the structure of the VQIVYK aggregate. Mutations of the nonpolar side chain Ile-3 or 
Tyr-5 to Gly were found to result in destabilization of the oligomeric structures. Figure 3-5B 
indicates that none of MVGGVV1 mutants were structurally stable compared to the value of the 
respective wild type model. It shows that the RMSD of M1G and V6G are significantly higher (< 
8.5 Å) than those of V2G and V5G (< 5.5.Å), indicating that V2G and V5G exhibit higher 
potential to destabilize the structural integrity of the MVGGVV1 oligomer. The result also 
(Figure 3-5B), shows that mutation of the non polar side chain Met-1 or Val-6 to Gly negatively 
affects the intersheet steric zipper destabilizing the structural integrity of the MVGGVV1 
oligomers to a greater extent than the V2G and V5G mutants and the wild type. Figure 3-5C 
shows that some of MVGGVV2 mutants (V2G and V6G) were structurally stable compared to 
the wild type model. It shows that the RMSD of the mutant V2G and V6G are lower (nearly 4.0 
Å) than those of M1G and wild type (nearly 6.0 Å), indicating that V2G and V6G exhibit higher 
potential to stabilize the structural integrity of the MVGGVV2 oligomer. The result also shows 
(Figure 3-5C), that Y5G (RMSD > 15.0 Å) destabilize the structural integrity of the MVGGVV2 
oligomers to a greater extent than the other mutants and the wild type. Our finding that the 
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MVGGVV2 wild type aggregates are less stable compared to certain mutants is in contrast to 
other oligomers in our study and to conclusions of the previous work done on the hexapeptide 
amyloid.
102, 113
 This apparent contraction could be explained based on the structural difference 
between this particular polymorph and other amyloid X–ray structure in that there is 900 bending 
in the upper sheet of MVGGVV form 2.
22
 As can be seen in Figure 3-5D, none of the mutants of 
LYQLEN are as structurally stable as the wild type, indicating that the side chain interactions 
play an important role in determining the stability of the LYQLEN oligomers. However, the 
N6G mutant have small RMSD values (2.5 Å), whereas the Y2G, Q3G and L4G mutants have 
large RMSD values (> 4.0Å). Comparison between the dynamics of the wild type and its mutants 
suggests that mutations N6G have little effect on the structural stability of the LYQLEN (low 
RMSD), whereas mutations Y2G, Q3G and L4G destabilize the oligomeric structures. The 
destabilization of the Q3G and L4G mutants is even more pronounced. As seen in Figure 3-5D 
mutations of the polar side chain Gln-3, or Leu-4 to Gly would affect the inter sheet steric zipper, 
leading to greater destabilization of the oligomeric structures. 
 
3.3.3 Secondary Structure Assessment 
We analyzed the secondary structure of the oligomers using the DSSP algorithm written 
by Kabsch and Sander.
74
 This algorithm is based on identification of hydrogen-bonding (H-
bonding) patterns and recognizes seven types of secondary structures which can be grouped into 
three classes: helix (-helix, 310-helix, π-helix), β-strand (isolated β-bridge, extended β-sheet) 
and loop (turn, bend). The result of the secondary structure analysis for a two layers models of 
the amyloid peptides show that the wild type of Tau (St2-St5 VQIVYK), Insulin (St2-St6 
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LYQLEN) and Aβ amyloids Polymorphic form I and II (Sht2-St6 MVGGVV) appear to be 
stable at 300K, which is confirmed by the conservation of high anti-parallel β-sheet content 
throughout the whole simulation time (as shown in Figures 3-6A-D). In all systems the contents 
of antiparallel β sheets are much greater than the turn or parallel β-sheet indicating the 
conservation of the original structure. The results also indicate that antiparallel β-sheet, parallel 
β-sheet and turn content were preserved throughout the 10 ns simulation. The analyses of the 
secondary structure evolution throughout the simulation for the mutant form of the amyloids are 
shown in Figures 3-6 to 3.9.  
The results for Tau mutant and the wild type the secondary structure is shown in Figure 
3-6A. In the case of the Tau mutants the content of the secondary structure declined specially in 
the last 3ns of the simulation. This result is in agreement with the RMSD results discussed 
above. The decline is largest in I3G which has the largest RMSD value. Figure 3-7B shows the 
results for Aβ peptide polymorph form I for both the wild type and mutants. The result for the 
wild type shows that the secondary structure is preserved as indicated with its high and content 
of antiparallel β-sheets (~0.7). Among the mutants the content of the secondary structure was 
more unstable for M1G indicating the greater destabilizing effects of replacing methione with 
glycine. This is in agreement with the RMSD result, the highest RMSD among the mutants was 
from the M1G mutant (see Figure 3-6B). Figure 3-8C shows the results for Aβ peptide 
polymorph form II for both the wild type and mutants. The result for the wild type shows that the 
secondary structure is preserved as indicated with its high and content of antiparallel β-sheets 
(~0.7). Among the mutants the content of the secondary structure was more unstable for M1G 
indicating the greater destabilizing effects of replacing methione with glycine. This is in 
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agreement with the RMSD result, the highest RMSD among the mutants was from the M1G 
mutant (see Figure 3-8B). 
The results for Insulin amyloid mutants (Figure 3-9D) and the wild type shows that the 
secondary structure is preserved as indicated with its high content antiparallel β–sheets (~0.7). In 
the case of the Q3G and Y2G mutants the content of antiparallel β-sheets declined specially in 
the last 2 ns of the simulation. This result is in agreement with the RMSD results. The RMSD for 
both Q3G and Y2G mutants was the largest ~5 Å. 
Two trajectory snapshots (at 5 ns and 10ns) are shown in Figures 3-10 to 3-13 for each of 
the two layer oligomer aggregates. As the structure evolves, some of the terminal strands break 
the β-sheet ordering and twist relative to the remaining strands although do not dissociate from 
the aggregate completely. Degree of this disorder correlates with the RMSD values reported on 
Figures 3-3 to 3-5. Among the most disordered structures are mutant I3G of the Tau fragment 
(VQIVYK), mutants V6G and M1G of the A fragment polymorph 1 (MVGGVV1) mutant V5G 
of the A fragment polymorph 2 (MVGGVV2) and the mutants Y2G and Q3G of the Insulin 
amyloid (LYQLEN). Apparently, the mutated amino acids were involved in the steric zippers, 
which were not holding the β-sheets together, but also preserving them from disaggregation. 
Inversely, the complementarity of the amino acids sidechains would be essential for the 
formation of the ordered aggregate. On the other hand, disordered random aggregation may take 
place for any polypeptide studied in this work, as suggested by the negative values of association 
free energies, reported in the next section. 
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3.3.4 Free energy calculations 
The binding free energies were calculated with the Molecular Mechanics Poisson-Boltzmann 
solvent accessible surface area (MM-PBSA) model 
80
, as implemented in AMBER. In this 
method, the total binding free energy in water is approximated by ΔGTOT = ΔEGAS + ΔGPB + 
ΔGSUR. The ΔEGAS is the gas phase interaction energy. The ΔGPB/GB is the polar part of the 
solvation free energy represented by Poisson-Boltzmann approaches. The ΔGSUR is the surface 
area term, approximating the non-polar part of the solvation free energy. In this formula, the 
conformational entropy of the solute is not considered, while the solvent entropy is implicitly 
considered in the ΔGPB and ΔGSUR. Although the MM-PBSA calculations may overestimate the 
absolute binding free energy due to the missing terms (e.g., conformational entropy change of 
the solute upon binding), they usually give a reasonable estimate on the relative binding free 
energy when the conformational entropy changes of two binding modes are comparable 
119
.  
The binding energy was calculated by MM-PBSA method and is specified in method 
section. The breakdown of binding energy components is listed in Table 3-4 to 3-7. The MM-
PBSA analysis allows us to separate the total free energy of binding into electrostatic, van der 
Waals interactions and solute-solvent interactions, and thereby gain additional insights into the 
monomer to monomer association process in the formation of the dimer of the amyloid 
oligomers. As shown in Table 3-4 and 3-7, van der Waals interactions play a very important role 
in the simulation, contributing significantly more to the total interaction energy than the 
electrostatic interaction for the Tau (VQIVYK) and Insulin (LYQLEN) aggregates. Nonpolar 
solvation energies favor the binding and the polar solvation energies disfavor it. In the case of 
Aβ oligomers, MVGGVV, electrostatic interaction play a very important role in the simulation, 
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contributing significantly more to the total interaction energy than the van der Waals interactions 
(Table 3-5 and 3-6). Nonpolar solvation energies favor the binding and the polar solvation 
energies disfavor it. Note that the internal component of the molecular-mechanical energy (bond, 
angle, and torsional energies) has zero contribution to the binding free energy, because the 
structures of the monomers in its unbound and bound states were assumed to be the same (data 
not shown). Table 3-4 to 3-7 also reports the contributions of apolar/hydrophobic and 
polar/electrostatic to the free energy. We found that the predicted binding free energy is 
dominated by the magnitudes of the apolar components (ΔEvdw + ΔEsur) in all the four oligomers 
and their mutants. In contrast, the polar interactions (ΔEelec + ΔGPB) show less contribution to the 
binding free energy. The result of the binding free energy calculation also indicated that the wild 
type is the most stable structure compared to the mutants. From the negative total binding free 
energy of the wild types we clearly see that this is a favorable protein-protein complex in pure 
water. The mutants also form a stable complex based on the negative total binding free energy. 
However, the mutant complex is less thermodynamically favorable than the wild type complex. 
The calculation indicated that the mutation of bulky polar side chain from the steric zipper 
structure leads to the less stable dimer (see example Table 3-4 to 3-7) giving mutant with 
smallest binding free energy, and indicating that these residues are important for stabilizing the 
structure. 
The widely accepted hypothesis on the amyloid disease is that soluble protein oligomers 
are the source for toxicity and are the primary pathogenic factor in these diseases and thus small 
molecules that prevent or reverse protein oligomerization may provide a mechanism to target the 
actual cause of the disease 
120, 121
. Peptidomimetics are promising class of small molecules 
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capable of inhibiting oligomerization. Most fibrillogenesis inhibitors of this type were designed 
rationally based on molecular recognition elements found in the site of aggregation.
122
  
Identification of this aggregation site is often based on the mutational data. Such data helps to 
pinpoint the small regions on the protein interaction interface that are responsible for a 
disproportionate contribution to the binding energy of the two proteins.
123-125
 In this work we 
have shown that most mutations at the aggregation site reduce the binding free energy and 
weaken the aggregation. Therefore, the computational studies can serve the same purpose of the 
rational design, as experimental mutation studies. 
Another potential application of the presented approach is design of imaging agents.    
The progress in therapeutic agents for treatment of neurodegenerative amyloid diseases calls for 
development of more specific biomarkers to detect early stages of amyloid diseases.
126
 Design of 
peptidomimetics based on the data obtained in the molecular dynamic simulation may provide 
the starting point for design of specific aggregation inhibitors drugs and diagnostic agents. Both 
structural and thermodynamic results reported in this study illustrate the higher fluctuation in 
RMSD values and less negative binding free energies for the mutated peptides. These mutants, 
therefore, may serve as aggregation inhibitors pending the experimental confirmation. 
 
3.4 Conclusions 
The major findings of this study can be summarized as follows:  
1. The stability of the VQIVYK, MVGGVV and LYQLEN peptides oligomers increases 
with increasing the number of β-strand;  
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2. The Sh2-St4 model acts as a stable seed in prompting amyloid fibril formation for all the 
cases considered;  
3. The binding energy calculated by MM-PBSA method and the analysis of individual 
contributions to the binding energy shows the hydrophobic interactions play an important role in 
stabilizing the structural organizations between β-sheet layers in the oligomers. The result of the 
binding free energy calculation also indicated that the wild type is the most stable structure 
compared to the mutants;  
4. The hydrophobic steric zipper on the intersheet interface contributes significantly to the 
stability of the entire aggregate structures. Mutations of the side-chains participating in the steric 
zipper interfaces of the oligomeric (VQIVYK, MVGGVV1 and LYQLEN) peptides to Gly 
resulted in decline of secondary structure content compared to corresponding wild type 
indicating that the role of the replaced amino acid in stabilizing the structure;  
5. A single glycine substitution at the steric zipper interface disrupts the hydrophobic steric 
zipper remarkably, indicating that the hydrophobic attraction is a major driving force for 
stabilizing and aggregation of oligomers. Consequently, the substantial reduction in the van der 
Waals intersheet interactions leads to destabilization of the oligomers. Overall, aggregation of 
both wild type and mutant peptides is driven by nonpolar interaction. 
Some evidence from the experimental work suggests that short peptides may share 
similar intermolecular interactions to their parent proteins while forming amyloid fibril.
127
 Thus, 
exploring the structural stability and aggregation behavior of the short peptides may gain insights 
into the self-assembly process at the early stage of fibril formation and provide a clue to 
understand the possible aggregation mechanism of their parent proteins. The hexapeptide 
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NFGAIL, a fragment truncated from human islet amyloid polypeptide (hIAPP, residues 22–27), 
is one of the shortest fragments that have been shown to form amyloid fibrils similar to those 
formed by the full polypeptide 
127
 and the fibrils are cytotoxic toward the pancreatic cell line. 
Therefore, this hIAPP „„amyloid-core‟‟ peptide has been used as a simplified model system to 
facilitate the discovery of key factors underlying amyloid fibril formation and the development 
of anti-amyloid agents. Porat et al 
128
 showed that whereas the NFGAIL was a minimal fibril 
forming fragment from hIAPP with Tyr substituted for Phe (i.e. 
22
NFGAILSS
29
 to 
22
NYGAILSS
29
 did not form fibrils by itself and even inhibited fibril formation. Along these 
lines one can envision a possible strategy to inhibit the formation of early aggregates that 
includes the design of specific inhibitor, breaking the hydrophobic steric zipper observed in the 
structure of hydrophobic region of the amyloid aggregate. Proof of principle for such a strategy 
has been published recently.
129,130
 Thus, designing new peptidomimetic inhibitors able to prevent 
the fibril formation based on the steric zipper motif of the oligomers, similar to the ones 
examined in this study may become a viable therapeutic strategy. The peptidomimetic approach 
can also be implemented in designing specific biomarkers for early stage detection of aggregate 
formation.
130,131
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Table 3-1 Summary of the VQIVYK oligomer models and simulation system  
 
Model  Systems Sheet/strand organization Simulation box size (Å) Simulation time (ns)  T(K) 
Wilde type 
A1 (Sh1-St2) 
A2  (Sh1-St3) 
A3 (Sh1-St4) 
A4 (Sh1-St5) 
A5 (Sh2-St2) 
A6 (Sh2-St3) 
A7 (Sh2-St4) 
A8 (Sh2-St5) 
VQIVYK (Sh2-St5) 
 
sheet1,  strands2 
sheet1,  strands3 
sheet1,  strands4 
sheet1,  strands5 
sheet2,  strands2 
sheet2,  strands3 
sheet2,  strands4 
sheet2,  strands5 
sheet2,  strands5 
  
----/parallel 
----/parallel 
----/parallel 
----/parallel 
Antiparallel / Parallel 
Antiparallel / Parallel 
Antiparallel / Parallel 
Antiparallel / Parallel 
Antiparallel / Parallel 
 
49.31×  49.31 ×49.31 
50.84×50.84×50.84 
51.67×51.67×51.67 
54.06×54.06×54.06 
60.97×60.97×60.97 
63.36×63.36×63.36 
64.84×64.84×64.84 
        65.88 ×65.88×65.88 
65.88 ×65.88×65.88 
 
10 
10 
10 
10 
10 
10 
10 
10 
10 
  
 300 
 300 
 300 
 300 
 300 
 300 
 300 
 300 
 300 
Mutants  
B1 
B2 
B3 
 
sheet2, strands5, V1G 
sheet2, strands5, I3G 
sheet2, strands5, Y5G 
 
Antiparallel / Parallel  
Antiparallel / Parallel  
Antiparallel / Parallel  
 
65.74×65.74×65.74 
65.71×65.71×65.71 
65.26×65.26×65.26 
 
10 
10 
10 
 
 300 
 300 
 300 
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Table 3-2 Summary of MVGGVV1 oligomer models and simulation system 
 
Model  Systems Sheet/strand  organization Simulation box size (Å) Simulation  time (ns)  T(K) 
Wilde type 
C1 (Sh1-St2) 
C2 (Sh1-St3) 
C3 (Sh1-St4) 
C4 (Sh1-St5) 
C5 (Sh2-St2) 
C6 (Sh2-St3) 
C7 Sh2-St4) 
C8 (Sh2-St5) 
MVGGVV1 
(Sh2-St6) 
 
sheet1, strands2 
sheet1, strands3 
sheet1, strands4 
sheet1, strands 5 
sheet2, strands2 
sheet2, strands3 
sheet2, strands4 
sheet2,  strands5 
sheet2,  strands6 
  
----/antiparallel 
----/antiparallel 
----/antiparallel 
----/antiparallel 
Antiparallel / Antiparallel 
Antiparallel /Antiparallel 
Antiparallel /Antiparallel 
Antiparallel / Antiparallel 
Antiparallel / Antiparallel 
 
52.59×52.59 ×52.59 
53.46×53.46×53.46 
54.14×54.14×54.14 
56.05×56.05×56.05 
63.02×63.02×63.02 
63.17×63.17×63.17 
66.36×66.36×66.36 
    67.13 ×67.13×67.13 
69.17 ×69.17×69.17 
 
10 
10 
10 
10 
10 
10 
10 
10 
10 
 
 300 
 300 
 300 
 300 
 300 
 300 
 300 
 300 
 300  
Mutants  
D1 
D2 
D3 
D4 
 
sheet2, strands6, M1G 
sheet2, strands6, V2G 
sheet2, strands6, V5G  
sheet2, strands6, V6G 
 
Antiparallel / Antiparallel 
Antiparallel / Antiparallel 
Antiparallel / Antiparallel 
Antiparallel / Antiparallel 
 
69.16 ×69.16×69.16 
69.02×69.02×69.02 
69.45×69.45×69.45 
     68.78 ×68.78×68.78 
 
10 
10 
10 
10 
 
300 
 300 
 300 
 300 
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Table 3-3 Summary of the MVGGVV2 models and simulation system 
 
Model  Systems Sheet/strand organization  Simulation box size (Å ) Simulation time (ns)  T(K) 
Wilde type 
E1 (Sh2-St2) 
E2 (Sh2-St3) 
E3 (Sh2-St3) 
E4 (Sh2-St5) 
MVGGVV2  (Sh2-St6) 
 
sheet2, strands2 
sheet2, strands3 
sheet2, strands4 
sheet2, strands5 
sheet2, strands6 
  
Antiparallel /Antiparallel 
Antiparallel /Antiparallel 
Antiparallel /Antiparallel 
Antiparallel /Antiparallel 
Antiparallel /Antiparallel 
 
60.58 ×60.58×60.58 
61.70 ×61.70×61.70 
63.24 ×63.24×63.24 
64.50 ×64.50×64.50 
66.83 ×66.83×68.83 
 
10 
10 
10 
10 
10 
 
 300 
 300 
 300 
 300 
 300 
Mutants  
       F1 
     F2 
     F3 
     F4 
 
sheet2, strands6, M1G 
sheet2, strands6, V2G 
sheet2, strands6, V5G 
sheet2, strands6, V6G 
 
Antiparallel /Antiparallel 
Antiparallel /Antiparallel 
Antiparallel /Antiparallel 
Antiparallel /Antiparallel 
 
64.15 ×64.15×64.15 
68.86×68.86×68.86 
66.40×66.40×66.40 
66.25 ×66.25×66.25 
 
10 
10 
10 
10 
 
 300 
 300 
 300 
 300 
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Table 3-4 Summary of the LYQLEN oligomer models and simulation system 
 
Model Systems Sheet/strand   organization Simulation box size (Å) Simulation  time (ns)  T(K) 
  Wilde type 
G1(Sh1-St2) 
G2(Sh1-St3) 
G3(Sh1-St42) 
G4(Sh1-St5) 
G5(Sh2-St2) 
G6(Sh2-St3) 
G7(Sh2-St4) 
G8(Sh2-St5) 
LYQLEN(Sh2-St6) 
 
sheet1, strands2 
sheet1, strands3 
sheet1,strands 4 
sheet1, strands5  
sheet2, strands2 
sheet2, strands3 
sheet2, strands4 
sheet2, strands5 
sheet2, strands6  
  
----/antiparallel 
----/antiparallel 
----/antiparallel 
----/antiparallel 
Antiparallel /Antiparallel 
Antiparallel /Antiparallel 
Antiparallel /Antiparallel 
Antiparallel /Antiparallel 
Antiparallel /Antiparallel 
 
50.43×50.43 ×50.43 
51.95×51.95×51.95 
51.93×51.93×51.93 
55.75×55.75×55.75 
65.67×65.67×65.67 
66.97×66.97×66.97 
68.59×68.59×68.59 
69.82 ×69.82×69.82 
70.46×70.46×70.46 
 
10 
10 
10 
10 
10 
10 
10 
10 
10 
 
 300 
 300 
 300 
 300 
 300 
 300 
 300 
 300 
 300   
  Mutants  
Y2G 
Q3G 
L4G 
N6G 
 
sheet2, strands6, Y2G 
sheet2, strands6, Q3G 
sheet2, strands6, L4G 
sheet2, strands6, V6G 
 
Antiparallel /Antiparallel 
Antiparallel /Antiparallel 
Antiparallel /Antiparallel 
Antiparallel /Antiparallel 
 
70.04 ×70.04×70.04 
70.35×70.35×70.35 
70.23×70.23×70.23 
 69.35×69.35×69.35 
 
10 
10 
10 
10 
 
 300 
 300 
 300 
 300 
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Table 3-5 Binding free energy components calculated with MM-PBSA for the wildtype and mutants of VQIVYK oligomer of tau 
peptide (Sh2-St5) 
 
Energy (Kcal/mol) Wild type 
Mean std 
Mutant -V1G 
Mean std 
Mutant  -I3G 
Meanstd 
Mutant –Y5G 
Meanstd 
Δ Eelec.  446.4724.29 396.4049.64 379.3622.97 396.2939.45 
Δ Evdw  -101.844.74 -85.054.29 -89.534.29 -80.014.47 
Δ Egas  344.6224.30 311.3550.17 289.8322.37 316.2838.48 
Δ GPB  -404.42 23.24 -359.2045.04 -331.3019.30 -370.8038.51 
Δ Gsur  -15.650.34 -14.050.48 -14.780.43 -13.680.33 
Δ Gpolar 42.057.58 37.2010.03 48.069.13 25.488.44 
Δ Gnon-polar -117.495.08 -99.14.77 -104.34.72 -93.694.80 
Δ GTOT  -75.446.22 -61.91  9.29 -56.258.34 -68.207.04 
    
* Evdw, and Eelec are the van der Waals and electrostatic binding terms. ΔGPB and ΔGsur are the solvation energies of polar and nonpolar 
residues, calculated by Amber 10 using the Generalized Born model. ΔGpolar and ΔGnon-polar are the sums of polar energy (ΔEelec+ 
ΔGPB) and non-polar energy components (ΔEvdw+ ΔGsur), respectively. ΔGTOT is the sum of ΔGpolar and ΔGnon-polar. ΔGTOT (the binding 
free energy can also be obtained using the equation, ΔGTOT = ΔEGAS + ΔGPB + ΔGSUR.  
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Table 3-6 Binding free energy components calculated with MM-PBSA for wildtype and mutants of MVGGVV1 oligomer of Abeta 
peptide (Sh2-St6) 
 
Energy (Kcal/mol) Wild type  Mutant- M1G   Mutant -V2G  Mutant -V5G   Mutant -V6G  
Mean std Mean std Mean std Meanstd Meanstd 
Δ E elec.  -214.2016.40 -200.0025.12 -262.6730.24 -187.4021.12 -239.1729.63 
Δ E vdw  -94.885.58 -74.936.31 -76.934.85 -78.134.56 -81.065.58 
Δ E gas  -309.0915.72 -275.6224.88 -339.6128.93 -265.5320.19 -320.2329.43 
Δ G PB  230.47 55.68 222.67 23.68 265.3426.56 199.0318.34 244.0428.33 
Δ G sur  -14.970.45 -12.970.76 -13.200.47 -13.190.49 -13.650.63 
Δ G polar 16.2752.64 21.988.22 2.668.03 11.636.42 4.877.37 
Δ G non-polar -109.856.03 -87.907.07 -90.135.32 -91.325.05 -94.706.21 
Δ GTOT  -93.5853.51 -65.916.36 -87.476.04 -79.695.17 -89.837.18 
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Table 3-7 Binding free energy calculated with MM-PBSA for the wildtype and mutants of MVGGVV2 of Abeta peptide (Sh2-St6) 
 
Energy (Kcal/mol) Wild type    
Mean std 
Mutant -M1G 
Mean std 
Mutant- V2G  
Mean std 
Mutant -V5G  
Meanstd 
Mutant- V6G  
Meanstd 
Δ E elec    -641.6738.91          -419.66 37.36   -592.7633.31     -527.91 54.10  -544.5426.74 
Δ E vdw   -132.127.26          -102.915.88    -98.906.73   -106.596.44  -117.32 6.79 
Δ E gas   -773.8035.40    -522.57 35.91  -691.6633.23 -634.50 54.88  -661.8624.16 
Δ G PB  631.05 33.17 432.44 32.78 580.1527.02 530.1749.25 538.0522.21 
Δ G sur   -22.81 0.32        -19.16 0.38     -19.830.63     -19.510.38  -20.520.36 
Δ G polar -10.62 10.21 12.789.91 -12.6110. 51 2.2610.51  -6.5010.27 
Δ G non-polar -154.937.58 -122.076.26 -1187.36 -126.106.82 -137.847.15 
Δ GTOT    -165.56  7.57      -109.297.85   -131.349.80  -123.849.09       -144.33 7.47 
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Table 3-8 Binding free energy components calculated with MM-PBSA for wildtype and mutants of LYQLEN of insulin (Sh2-St6) 
 
Energy (Kcal/ mol) Wild type   
Mean std 
Mutant – Y2G 
Meanstd 
Mutant – Q3G 
Meanstd 
Mutant –L4 G 
Meanstd 
Mutant – N6G 
Meanstd 
Δ Eelec  298.7936.86 374.3530.91 359.94 33.49 327.5036.68 304.0136.57 
Δ Evdw  -105.154.97 -80.864.71 -87.775.63 -86.634.87 -91.685.30 
Δ Egas  193.6535.14 293.4930.22 272.16  33.19 240.8736.64 212.3234.90 
Δ GPB  -280.31 32.94 -362.93 26.10 -345.0933.94 -307.9933.68 -289.8734.98 
Δ Gsur  -16.580.32 -14.110.48 -15.080.43 -15.270.42 -15.360.48 
Δ G polar 18.488.39 11.418.26 14.856.86 19.508.27 14.147.59 
Δ G non-polar -121.735.29 -94.975.19 -102.856.06 -101.905.29 -107.855.78 
Δ GTOT  -103.24 6.30  -83.567.25 -88.006.07 -82.40 7.42   -92.916.26 
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Figure 3-1 Chemical structure of VQIVYK (A), MVGGVV (B) and LYQLEN (C)
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A       B  
 
C      D  
 
Figure 3-2 The atomic representation of the aggregates of VQIVYK (A), MVGGVV1 B), 
MVGGVV2 (C) and LYQLEN (D) 
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Figure 3-3 Time evolution of the RMSD of the wildtype and mutants of single sheet with 
different number of strands:(A) tau oligomer (VQIVYK), (B) Abeta amyloid (MVGGVV1) and 
(C) insulin amyloid (LYQLEN) 
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Figure 3-4 Time evolution of the RMSD values of wildtype aggregates of two sheets with 
different number of strands: tau oligomer VQIVYK (A), Abeta amyloid MVGGVV1 (B) ,  Abeta 
amyloid MVGGVV2(C) and insulin amyloid LYQLEN (D)  
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Figure 3-5 Time evolution of the RMSD of wildtype and mutants of (A) VQIVYK oligomer of 
(Sh2-St6) tau peptide, (B) MVGGVV1 oligomer of (Sh2-St6) Abeta peptide, (C) MVGGVV2 
oligomer (Sh2-St6)  of Abeta petide and (D) LYQLEN oligomer of (Sh2-St6) insulin 
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Figure 3-6 Time evolution of the secondary structure contents for Sh2-St5 aggregate of 
VQIVYK and its mutants (A) Wild type, (B) Y5G, (C) I3G and (D) V1G 
 
85 
A
0 2000 4000 6000 8000 10000
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
 
 
S
e
c
o
n
d
a
r
y
 s
tr
u
c
tu
r
e
 c
o
n
te
n
t
Simultion time (ps)
 Antiparallel -sheet
 Turn
  B
0 2000 4000 6000 8000 10000
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
 
 
S
e
c
o
n
d
a
r
y
 s
tr
u
c
tu
r
e
 c
o
n
te
n
t
Simultion time (ps)
 Antiparallel -sheet
 Turn
 
C
0 2000 4000 6000 8000 10000
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
 
 
S
ec
o
n
d
a
ry
 s
tr
u
ct
u
re
 c
o
n
te
n
t
simulation time (ps)
 Antiparallel -sheet
 Turn
    D
0 2000 4000 6000 8000 10000
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
 
 
S
e
c
o
n
d
a
r
y
 s
tr
u
c
tu
r
e
 c
o
n
te
n
t
Simulation time (ps)
 Antiparallel -sheet
 Turn
 
E
0 2000 4000 6000 8000 10000
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
 
 
S
e
c
o
n
d
a
r
y
 s
tr
u
c
tu
r
e
 c
o
n
te
n
t
Simulation time (ps)
 Antiparallel -sheet
 Turn
 
Figure 3-7 Time evolution of the secondary structure contents for Sh2-St6 aggregates of 
MVGGVV1 Wild type and mutants (A) Wild type, (B) V6G, (C) V5G, (D) V2G and (E) M1G 
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Figure 3-8 Time evolution of the secondary structure contents for Sh2-St6 aggregate of 
MVGGVV2 wild type and mutants (A) Wild type, (B) V6G, (C) V5G, (D) V2G and (E) M1G 
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Figure 3-9 Time evolution of the secondary structure contents for Sh2-St6 aggregate of 
LYQLEN wildtype and mutants. (A) Wildtype (B) N6G, (C) L4G, (D) Q3G and (E) Y2G
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        5 ns, wild type  5 ns, V1G   5 ns, I3G   5 ns, V5G  
 
  
 
      10 ns, wild type  10 ns, V1G    10 ns, I3G    10 ns, V5G      
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Figure 3-10 Snapshots of Sh2-St5 aggregates of VQIVYK wild type and mutants at 5 ns (top) and 10ns (bottom). (A) Wild 
type, (B) V1G, (C) I3G and (D) I5G. While the wild type is the most stable, the mutant I3G is the least stable.  
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Figure 3-11 Snapshot of Sh2-St6 aggregate of MVGGVV1 and mutants at 5ns (top) and 10ns (bottom) (A) Wild type, (B) 
M1G, (C) V2G, (D) V5G and (E) V6G. The wild type is the most stable, while the V6G and M1g mutants are the least stable. 
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Figure 3-12 Snapshots of Sh2-St6 aggregates of MVGGVV2 and mutants at 5ns (top) and 10ns (bottom) (A) Wild type, (B) 
M1G, (C) V2G, (D) V5G and (E) V6G. the wild type is the most stable while the mutant V5G is the least stable. 
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Figure 3-13 Snapshots of Sh2-St6 aggregate of LYQLEN and mutants at 5ns (top) and 10ns (bottom) (A) Wild type, (B) Y2G, 
(C) Q3G, (D) L4G and (E) N6G.While the wild type is the most stable, the mutants Y2G and Q3G are the least stable. 
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CHAPTER 4 ALTERNATIVE PACKING MODES AS BASIS FOR 
AMYLOID POLYMORPHISM IN FIVE FRAGMENTS 
 
4.1 Background 
X-ray diffraction of amyloid fibrils indicated the structure is highly conserved along the 
fibril axis, with variation in the plane of the fibril cross-section.
132
 There are three major 
structural features that may decide the overall amyloid fibril morphologies: (1) backbone 
orientation; (2) backbone conformation; and (3) the way in which the oligomers associate. The 
combination of these three factors can give rise to an enormous variation in conformational detail 
and fibril morphology.
133
  
Eisenberg laboratory was able to grow three-dimensional microcrystals 
16,22,94,93,30,134
 and 
determine atomic resolution structures of about 50 short fibril-forming peptide segments of 
hexapeptide abd hepatpetide fragments of several amyloid proteins (inclusing insulin, A, tau, 
prion and amylin). These studies have identified examples for most out of eight possible packing 
classes (parallel and antiparallel β-sheetsstacked face to face or face to back in parallel or 
antiparallel manner). These common motifs called steric zippers, in which interdigitated side 
chain hold together pair of β-sheets.22,18 Further, some peptides are capable of forming different 
types of steric zipper, that offers a possible explanation for amyloid polymorphism.
22
 
Polymorphism of amyloid fibrils by a range of proteins including Aβ, prion, glucagon and 
amylin has been observed and is influenced by the environment in which the fibrillogenes 
occurs. The polymorphic nature of Aβ peptide fibrils has been suggested to alter their pathogenic 
action. Polymorphism of amyloid lead to difference in terms protofilament backbone regions, 
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secondary structure, chromophore alignment along the fibril axis, and fibril superstructure.
135
 
While the selection of the filament structure depends on the growth condition, which can be 
purely mechanical agitation, once a stable filament is formed, it continues to grow, keeping the 
atomistic order even if the growth condition changes.
136
 A fundamental question remains 
regarding how these structures are formed. The importance of oligomer polymorphism is 
increasingly recognized, explaining several observations, from propagation of prion strain 
infectivity and other protein polymorphism 
136, 137, 138, 139
 to the variable cytotoxicity of amyloids 
differently grown from the same peptides and proteins 
139, 140, 141, 142
, the appearance of in-path 
and off-path intermediates of fibril growth 
143, 142
 and the structural heterogeneity of amyloid 
fibrils and their precursors grown from the same peptide/protein under different environmental 
conditions.
144, 145
 
Hydrogen-bonding interactions are inherent to -sheet stability.146 The stacking of 
multiple β strands in amyloid fibrils has been, in part, ascribed to cooperative hydrogen 
bonding.
147 
Molecular modeling has shown that polar residues β-sheets are stabilized by 
hydrogen bonds between polar side chains, such as those between glutamine and asparagine. The 
glutamine- and asparagine-rich regions are commonly found in the N-termini of both mammalian 
and yeast prion proteins. Glutamine/asparagine (Q/N) rich domains show a greater tendency to 
form self propagating amyloid fibrils.  Gln and Asn rich sequence are prone to assemble into 
different amyloid structures, since they are able to form diverse array of molecular interactions. 
They can be donor or acceptor of both main-chain/side-chain and side-chain/main-chain 
hydrogen bonds.
148
 Our previous study comparing the aggregation behaviors of short segments 
100 
of amyloid peptides with small hydrophobic residues (VQIVYK, MVGGVV) and Q/N rich 
residues (LYQLEN) indicated there is a greater stability in LYQLEN segment from insulin.
78
 
The extra structural stability of the Q/N residues LYQLEN  aggregates may be related to the 
number of hydrogen bonds formed between the backbone and the side chains.
149
  
The significant role of steric zipper in the structural stability of short amyloidogenic 
peptides have been demonstrated by molecular dynamic studies. 
88, 98,150   
Park et al. 
95
 address 
the structural selection mechanism of different double layer peptides including GNNQQNY, 
NNQQ, VEALYL, KLVFFAE and STVIIE, and found that the patterns with the lowest binding 
free energy correspond to X-Ray structures. Wu et al 
151
 using MD simulation in combination 
with ssNMR data proposed two polymorphs of A9-40 peptide fibril. Papacone et al  
152
 presented 
a systemic study between two polymorphic forms of A9-40 suggesting double layer morphology 
is more stable than the three fold morphology.  Computational investigation on the structure, 
energy, and solvent interaction of four classes of A dodecamers by Ma et al 153 indicate that -
sheets packed orthogonally could be the most stable species for A dodecamers. Berryman et al 
154, 101
 investigated the thermodynamic stability of various possible polymorphic models of short 
segments of amyloid peptides. 
Here we report on multiple all-atomic MD simulations with explicit water at 
300K,conducted on five polymorphic pairs short amyloidogenic peptides oligomers aggregates 
in a crystal-free context. We performed the simulation starting with experimentally determined 
microcrystal structure. Our study focuses on investigating the stability of various polymorphic 
pairs. This study aims to answer the following questions: 
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1) What is the effect of side chain (polar versus nonpolar) on the stability of pair of steric 
zipper polymorphs forms of small amyloid segments? 
2) Among the studied pair of polymorphs which one of them are more stable in crystal free 
context under physiological conditions? 
3) Is there a relationship between hydrogen bond content and structural stability? 
4) What is the driving force for the association of the polymorph aggregates?  
 
5) How does a single point mutation of the N/Q side chains in the steric zipper of NNQNTF 
and GNNQQNY influence the stability of the aggregates? 
 
4.2 Methods 
The polymorphic pairs of five small peptides (VQIVYK,  SSTNVG, MVGGVV, 
GNNQQNY and NNQNTF)  were investigated. The aggregates were derived from the crystal 
structure with different packing polymorphs (Figure 4-1). The microcrystal structure and 
coordinate of the five peptides polymorphic forms I and II (VQIVYK, SSTNVG, MVGGVV, 
GNNQQNY and NNQNTF) assembled with two layers of β sheets was determined by Eisenberg 
group.
22, 93,16 
The detailed summery of the simulation conditions of each the peptides and single 
point mutation of N/Q residues with glycine in the steric zipper for are GNNQQNY and 
NNQNTF are shown in Table 4-1. The microcrystal structure chosen in this study represent three 
major groups: polar steric zipper rich with Q/N residues (GNNQQNY and NNQNTF), polar 
steric zipper not rich in Q/N residues (SSTNVG and VQIVYK) and nonpolar steric zipper 
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(MVGGVV). All of the studied structures were hexapeptide (except GNNQQNY, which consists 
of seven residues). 
The hexapeptide SSTNVG is a segment of amylin (residue 28-31) that forms fibrillar 
amyloid deposits among the pancreatic β-islet cells of type II diabetes. Microcrystals of 
SSTNVG grown from different solutions revealed two polymorphs. The SSTNVG form I 
features a pair of serine residues at the center. The structure of SSTNVG form II packing has the 
center of the interface Asn31, rather than Ser29 (Figure 4-1A).
16
 The hexapeptide VQIVYK, 
residue 306-311 of the tau, forms intracellular amyloid fibrils in Alzheimer‟s disease.22 The 
structural organization of VQIVYK is a parallel β-strand within the same β-sheet layer while 
maintaining anti-parallel organization between the adjacent β-sheet layers.22 The VQIVYK from 
tau protein shows polymorphism. The VQIVYK form I is characterized by an apolar dry 
interface made essentially by the side chains of V1 and I3 of the two sheets and polar interface 
involving Tyr and Gln side chains (Figure 4-1B). The VQIVYK form II is characterized by an 
apolar dry interface made essentially by the side chains of V1 and I3 of the two sheets (Figure 4-
1B).
16
 VQIVYK form I can be transformed to the VQIVYK form II by moving the top sheet to 
the right. The hexameric peptide segment 170-175 from elk prion with amino acid sequence 
NNQNTF forms two facial polymorphs. Both of them are found in the same crystal structure. 
One of them is with a face to face packing, with N1, Q3 and T5 of both sheets forming the 
interdigitated interface while the other one is a back to back, with side chains N2, N4 and F6 
interdigitated (Figure 4-1C).
16
 The microcrystals formed from Aβ (35-40) peptide under different 
incubation conditions gives two different crystal structures showing different conformations and 
103 
arrangements of the peptides MVGGVV from Aβ protein. The MVGGVV peptide consists of 
anti-parallel -strands within the same -sheet layers. The shape complementarity involves the 
side chains of Met1, Val2, Val5 and Val6 -sheet. The MVGGVV form II polymorph is different 
from the MVGGVV form I in that that there is 90
0
 bending in the upper sheet of MVGGVV 
form II (Figure 4-1D). The heptameric peptide with amino acid sequence GNNQQNY from the 
yeast prion Sup35 forms two crystalline forms.
30,22 
The -strands are stacked parallel and are 
oriented upwards within each -sheet, and the -sheets are face-to-face i.e. the same residues on 
each -strand interdigitate. Both of them share many similarities. The polar side chains of the dry 
interface (Asn 2, Gln 4, and Asn 6) are tightly interdigitated with the same three side chains of 
the mating sheet (Figure 4-1E). These opposing side chains do not form hydrogen bonds with 
each other; rather, their shapes complement each other closely, forming van der Waals 
interactions. They also exhibit some differences, particularly around the tyrosine residue, which 
appears to play a stabilizing role across sheets in the monoclinic form but not in the 
orthorhombic form.
30, 22
 
Computational mutation of the Q/N residues involved in the dry steric-zipper between the 
sheets for NNQNTF and GNNQQNY was preformed to examine the effect of a single point 
glycine mutation  All the starting structures of the mutants were built from the wild type 
93
 by 
replacing the side chains of the targeted residues with glycine, but without changing the 
backbone conformations of side-chain orientations using VMD.
155
 The simulation details for 
each model are summarized in Tables 4-1. 
104 
The trajectories obtained on the production stages were analyzed to examine the 
structural change of the oligomers aggregates. The root mean square deviation (RMSD), root 
mean square fluctuation, inter-sheet distance and inter-strand distance were calculated. To gain 
an insight into the driving force for association of the preformed oligomer we used a molecular 
mechanics/generalized Born-surface area method and normal mode analysis (NMA) to calculate 
various energy terms in binding free energy (G) .156 We also examined the stability of the 
oligomers by following the changes in the number of hydrogen bonds and their occupancy. 
 
4.3 Result  
4.3.1 Structural stability of wild type steric zipper packing polymorphs: RMSD and 
RMSF analysis. 
The conformational stabilities of the oligomers were monitored by the time evolution of 
the backbone root mean square (RMSD) and root mean square fluctuation (RMSF) relative to 
their initial energy minimized structure as shown in Table 4-2 and Figures 4-2. The RMSDs 
provide useful information on relative stability of the oligomers, and were previously used in 
stability analyses of amyloid oligomers with -sheet structure.21, 98, 157, 158 
The RMSD values for the studied oligomers were calculated for backbone heavy atoms against 
the corresponding energy minimized structures. To examine the effects of the polar versus 
nonpolar side chain steric zipper on the stability of amyloid oligomers the mean RMSD 
(<RMSD>) averaged over the five trajectories was determined. The <RMSD> for both nonpolar 
and polar dry interface of the five polymorphs are shown in Table 4-2 and Figure 2. The 
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<RMSD> of the polar Q/N oligomers (GNNQQNY and NNQNTF) were less than 2.0 Å 
suggesting the Q/N rich peptides maintained the initial structure (see Figure 4-3). The hepta-
peptide GNNQQNY with one additional amino acids was found to be relatively more stable with 
an <RMSD> less than 1 Å. The average RMSD for the other non Q/N rich systems was in the 
range of 2 to 5.0 Å within the 20 ns simulations.  The larger <RMSD> indicates the oligomers 
that are not rich in Q/N residues are more flexible than those with Q/N side chain at the steric 
zipper. The oligomers with largest <RMSD>, those with an RMSD  4 Å, were the two 
polymorphic forms of MVGGVV and polymorph form II of VQIVYK.  A closer look at the 
structure of these three models indicates that they are having the smallest sheet-to-sheet 
interface, consequently, their final solution conformations moves further away from the 
conformation of the initial model (Figure 4-3). The qualitative structural stability comparison of 
the oligomers based on RMSD of the may be used to predict which of the one of the polymorphs 
pair might exist outside of the crystal environment.
159
 The RMSD during the 20 ns simulation for 
the Q/N rich oligomer (NNQNTF and GNNQQNY) indicates both forms could exist with similar 
probability under physiologic condition. Among the other three pairs it might be possible to find 
the both polymorph form with similar probability for SSNTVG and MVGGVV. The polymorph 
form I of VQIVYK based on the <RMSD> is most likely to be a dominate structure under 
physiologic condition. A recent structure based design of amyloid aggregation for tau peptide 
inhibitor used the VQIVYK polymorph form I as a template
160
 indicating the significant of the  
determining  the difference in stability of the packing polymorph of the steric zipper segments of 
amyloid peptides. 
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The residue-based root mean square fluctuations (RMSF) of the backbones were used to 
assess the local dynamics and flexibility of each residue for the five polymorphic forms using 
ptraj tool in AMBER11. Figure 4-2 shows the RMSF profiles of the different oligomers of the 
wildtype of various studied amyloid oligomers. The RMSF values for all the five pairs of the 
amyloid peptide models from our simulations indicates both N- and C-terminal regions residues 
have a larger RMSF as they are exposed to the solvent water molecules with greater  mobility. 
The models GNNQQNY and NNQNTF have the smallest RMSF compared to other models (see 
Table 4-2 and Figure 4-2).  The RMSF values for the model VQIVYK-II, MVGGVV-I and 
MVGGVV-II are generally larger than other models. The RMSF analysis is consistence with the 
RMSD in that the structural stable Q/N rich oligomers have both smaller RMSF and RMSD 
while the structurally unstable models (VQIVYK-II, MVGGVV-I and MVGGVV-II) have a 
larger RMSD and RMSF. 
 
 
4.3.2 Inter-strand (dstrand) and inter-sheet (dsheet) distances 
To examine the structural stability of the wildtype of the five polymorphic forms 
oligomers we analyzed the inter-strand and inter-sheet. The dstrand is calculated by averaging the 
mass center distance between each residue in one strand and the respective in-register residue in 
the adjacent strand, whereas dsheet is calculated by averaging the mass center distance between 
sheets.
75
 The inter-sheet and inter-strand distances for wild type are shown in Table 4-2 and 
Figures 4-4. The inter-strand and inter-sheet distance from the simulations for the Q/N rich 
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models GNNQQNY and NNQNTF were found to be almost the same as the initial structures 
(see Table 4-2 and Figure 4-4). These results indicate the GNNQQNY and NNQNTF models 
have a greater structural stability (see Figure 4-3). The polar side chains of Asn and Gln with 
larger sheet-to-sheet interface keeps together the two neighboring sheets. Significant changes in 
inter-strand and inter-sheet distances were observed for the models with smaller sheet-to-sheet 
interface for the nonpolar small size side chain at the steric zipper (VQIVYK and MVGGVV). 
4.3.3 Sheet-to-sheet association energy 
To further quantify the driving force underlying the β-sheet association of the studied 
wildtype amyloid polymorph models, we calculated the interaction energy between β-sheets for 
the three pairs (SSNTVG, NNQNTF and GNNQQNY) using the MM-PBSA module 
80
 in the 
AMBER package. The VQIVYK and MVGGVV pairs showed a larger RMSD values with 
significant conformational changes making it difficult to apply the MM-PBSA single trajectory 
approach for calculating sheet to sheet association energy.
80
 The entropy calculation is and thus 
the -T∆S was averaged over 100 frames of the MD trajectory (1 frame taken at an interval of 50 
frames from the total of 5000 frames).  
The non covalent association of the -sheets of amyloid aggregates takes place  
spontaneous only if it is associated with a negative binding free energy.
88
 Detailed 
characterization of individual energy terms of the calculated binding free energy are shown in 
Table 4-3. The individual energy terms may be of similar or opposite in sign.  An inspection of 
the free energy components for the wild types investigated in this study reveals that the 
electrostatic component of the solvation free energy ΔGPB is destabilizing (positive), while the 
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nonpolar component GSA is stabilizing (negative). This is expected, since the complex formation 
desolvates the monomers, and reduces solvent-accessible surface area. Entropy component was 
found to contribute unfavorably to binding, since complexation reduces freedom of motion for 
the monomers. The electrostatic interaction between sheets is stabilizing. These observations are 
consistent with previous calculations of the components of the free energy of solvation.
88
 
However, the less favorable electrostatics in each case is compensated by highly favorable 
nonpolar component of the free energy. In each case, favorable nature of the nonpolar interaction 
mostly originates from the van der Waals interaction energy ΔGvdW, as opposed to the nonpolar 
component of solvation ΔGSA. Despite the fact that the -sheets association for the oligomers 
(see Table 4-3) shows a more favorable binding enthalpy, there is an entropy penalty (-5.27 to -
9.91). The order water molecules around the amino acid residues in the peptide upon the -sheets 
association are released and to an increase in entropy. 
In order to identify the residues that contribute the most to the calculated overall binding 
energy, we used a residue-by-residue decomposition protocol. Binding free energy 
decomposition at the atomic level allows evaluating the contribution of each residue to the total 
binding free energy, as well as the contributions of its side-chain and backbone. The 
MMPBSA.py script in AMBER11 implements per-residue decomposition with both PB and GB 
implicit solvent models.
54
 The PB non-polar solvation component is currently not decomposable. 
However, the non-polar solvation remains constant about -1.50Kcal/mol (see Table 4-3) and is 
much smaller than the other energy terms. Thus, we used the MM-PBSA decomposition and the 
results are show in Figure 4-5 to 4-7. The residues making the most favorable contributions to 
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the binding free energy between the two sheets are the residues situated at the interface between 
the two sheets and form stable hydrogen bonds between their backbone atoms and van der Waals 
interactions between their side-chains (Figure 4-5 to 4-7). The contribution of the N/Q side-
chains to the association of the 5 stranded double layer oligomers is larger than the other 
nonpolar and small size amino acids at the interface, underlining the importance of Q/N amino 
acid in stabilizing the short segment amyloid peptides in crystal free context.  
 
4.3.4 Structural stability of the wildtype oligomers: hydrogen bond analysis  
The amyloid configuration and properties primarily depend on the density of hydrogen 
bonds involving the backbone of the polypeptides, while the side chains hydrogen bonds are 
involved in the geometrical details and extension of the disordered parts of the structure.
161,162
  
To further characterize the structural stability of the studied oligomer models we determined the 
number of the hydrogen-bonds as the function of the MD simulation.  The numbers of hydrogen 
bonds in the GNNQQNY and NNQNTF systems are larger than the corresponding hydrogen in 
the other remaining models (see Figure 4-8). The amyloid configuration and properties primarily 
depend on the density of hydrogen bonds involving the backbone of the polypeptides, while the 
side chains hydrogen bonds are involved in the geometrical details and extension of the 
disordered parts of the structure.
162
 Figure 4-8 shows the number of hydrogen bonds throughout 
the simulation for the various models studied. The results of the analysis of total, main chain and 
side chain hydrogen bonds indicate the Q/N rich models content more hydrogen bonds. The 
hydrogen bond analysis indicates the GNNQQNNY and NNQNTF are more stable with an 
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average of 8 and 5.5 hydrogen bonds per strand. The remaining other models with hydrogen 
bond of less than 3.5 are less stable. The hydrogen bond analysis in combination with the 
geometric stability analysis (RMSF, RMSD etc.) were found to support that an increase in side 
chain and main chain hydrogen bonds increase the stability of the short peptide oligomers.  
We also performed statistical analysis on the number of hydrogen bonds to determine 
their occupancy. Hydrogen bond occupancy is defined as ratio of times where the hydrogen bond 
is present relative to the total time length of the considered trajectory. Hence, hydrogen bonds 
that are never disrupted correspond to unit occupancy. Hydrogen bonds were characterized 
according to their temporal occupancy during the 20 ns simulation using criteria based on angle 
and distance. The strength of a hydrogen bond can be characterized by two geometric quantities 
which govern the hydrogen bond energy: hydrogen bond angle, D–H · ·A atoms  and optimal 
hydrogen bond length, H · ·A (or D · ·A) distance 
76
. Hydrogen bond occupancies and structure 
RMSDs was calculated using PTRAJ module available within AMBER. A hydrogen bond is 
assigned if the distance between donor D and acceptor A is ≤3.5 Å and the angle D-H 
…A≥120o.75 Those hydrogen bonds in the backbone with a fractional occupancy greater than 
50% (considered to be strong hydrogen bonds) are detailed in Figure 4-9. The hydrogen bond 
occupancy analysis revealed that a large value of average occupancy of hydrogen bonds is in 
general associated with small average structural fluctuations and greater stability (see Figure 4-9 
and Figure 4-3). The stability of the Q/N rich oligomers was found be supported by large values 
of average hydrogen bond occupancy compare to the oligomer lacking Q/N amino acid side 
chains. The MVGGVV segment pairs with antiparallel arrangement of strand per sheets lacks 
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side chain hydrogen bonds. The absence of the side chain hydrogen bond, despite a similar 
number of total hydrogen bond contents and occupancy as in the slightly stable SSNTV forms , 
might be the main reason for it instability. The highly stable Q/N rich models contents a greater 
number of side chain hydrogen bond which responsible for retaining the initial microcystal 
structure in crystalline free physiological environment.  
 
4.3.5 Effect of mutation of Q/N residues at steric zipper on the stability of NNQNTF and 
GNNQQNT 
Side chain mutagenesis has proven to be a very effective means of identifying energetically 
important backbone H-bonds and side chain interactions (including hydrophobic and electrostatic 
interactions) in peptides.
163
 To test the hypothesis that the stability of the Q/N rich oligomers is 
due to the presence of the extra side chain hydrogen bonding we did Gly-mutations of the Q and 
N side chains involved in the steric zipper for GNNQQNY and NNQNTF wildtype oligomers 
with Hydrogen (performed in silico mutations) The summary of the structural stability of the 
mutants are shown in Table 4-2. The simulation revealed that mutation of the Q and N residues 
at the steric zipper for the GNNQQNY oligomer affect the structural stability.  In the case of 
mutants Q4G and N6G after the 20 ns simulation one of the -strands starts to separate from the 
remaining aggregates (see Figure 4-10).  The mutation of Asn-2, Gln-4, or Asn-6 by Gly could 
disrupt the steric zipper, leading to unstable oligomers. The hydrogen bond analysis showed the 
mutants had a smaller backbone-backbone and side chain-side chain hydrogen bonds compared 
to the wildtype.  The simulation of the NNQNTF mutants (N1G and Q3G) showed mutant Q4G 
is having a larger RMSD, RMSF and smaller hydrogen bond contents with significant structural 
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instability compared to the wildtype (Table2 and Figure 4-10).  The mutation of the polar Asn 
and Gln side chains at the steric zipper with Gly revealed the polar side chains of Asn and Gln 
are important for the stability the oligomers of GNNQQNY and NNQNTF. 
 
4.4 Conclusions  
The major findings of our 20 ns multiple MD simulation suggests the following 
qualitative conclusions: 
1. The short segments amyloid peptide rich in Q/N amino acid are have greater structural 
and the packing polymorphs are stable and under crystal free contents and physiological 
environments they might have similar probability of occurrence. 
2. The short segments amyloid peptide lacking the Q/N amino acid have been found to be 
structurally unstable  and the packing polymorphs show different stability with greater chance 
different probability of occurrence under crystal free contents and physiological environments. 
3. The simulations of Q/NG mutants disrupted the steric zipper, leading to unstable 
oligomers. The comparison of the structural stability of the wildtype and mutants stability of the 
Q/N rich oligomers was found be supported by large values of average hydrogen bond 
occupancy of the wild type compare to mutants. 
4. The Q/N residue rich short amyloid segments have larger hydrogen bond contents and 
hydrogen bond occupancy. The overall increase of hydrogen bond in the Q/N residue rich 
peptides with smaller RMSD, RMSF and greater stability suggesting the stability of oligomer 
models is associated with an increase in side chain and total hydrogen bond contents.  
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5. The MM-PBSA binding free energy method was applied to the study of the -sheet 
association. The nonpolar component of free energy is more favorable, while the electrostatic 
solvation is unfavorable for sheet to sheet interaction.  The decomposition of the binding energy 
per residue showed the contribution of the N/Q side-chains to the association of the 5 stranded 
double layer oligomers is larger than the other nonpolar and small size amino acids at the 
interface, underlining the importance of Q/N amino acid in stabilizing the short segment amyloid 
peptides in crystal free context. 
Our simulations provide detailed insight into the structural stability of various short 
segment amyloid oligomer aggregates Exploring the structural stability and aggregation behavior 
of the short peptides may gain insights into the self-assembly process at the early stage of fibril 
formation and provide a clue to structure based design of amyloid aggregation inhibitors.  The 
rational design of successful therapeutic strategies requires detailed characterization of amyloid 
formation. Polymorphism in amyloid peptides with the same sequence is due to difference in β-
sheet packing (steric zipper).
22
 Landau et al 
16
 found that different aggregation inhibitor 
molecules bind to different polymorphs of amyloid peptides and suggested a combination of 
aggregation inhibitors might be required to bind to the various morphologic form of a given 
amyloid peptide. Sievers et al 
164
 using known atomic structures of segments of amyloid fibrils 
as templates have designed amyloid aggregation inhibitors. Our simulations indicate that there is 
a difference in the stability polymorphs of a given sequence and certain amino acids are 
significantly important for stability. Results from this work might be useful in designing 
114 
peptidomimetic aggregation inhibitors by single amino acid change or shuffling the sequence so 
as to disrupt the steric zipper and prevent amyloid aggregation. 
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Table 4-1 Summary of simulation system and condition of double layer models of amyloid peptide segments with packing 
polymorphism  
 
 
Model name  
 
Sheet organization 
# peptide/ 
water mol. 
PDB 
code 
Length (ns) 
simulation 
Simulation box size (Å) T., K Number of 
simulation  
SSTNVG 1 (SH2-ST5) Parallel/parallel 760/2633 3DG1 20 58.01×58.01×58.01 300 5 
SSTNVG 2 (SH2-ST5) Parallel/parallel 760/2689 3FTR 20 58.41×58.41×58.41 300 5 
VQIVYK 1 (SH2-ST5) Parallel/parallel 1140/4575 2ON9 20 69.00×69.00×69.00 300 5 
VQIVYK 2 (SH2-ST5) Parallel/parallel 1140/3890 3FQP 20 65.88×65.88×65.88 300 5 
NNQNTF 1 (SH2-ST5) Parallel/parallel 960/2967 3FVA 20 60.50×60.50×60.50 300 5 
N1G (SH2-ST5) Parallel/parallel 890/3006 - 20 60.64×60.64×60.64 300 1 
Q3G(SH2-ST5) Parallel/parallel 860/3021 - 20 60.74×60.74×60.74 300 1 
NNQNTF 2 (SH2-ST5) Parallel/parallel 960/3482 3FVA 20 63.35×63.35×63.35 300 5 
GNNQQNY 1 (SH2-ST5) Parallel/parallel 1070/3284 1YJP 20 62.42×62.42×62.42 300 5 
N2G(SH2-ST5) Parallel/parallel 1000/3351 - 20 62.88×62.88×62.88 300 1 
Q4G(SH2-ST5) Parallel/parallel 970/3397 - 20 63.09×63.09×63.09 300 1 
N6G(SH2-ST5) Parallel/parallel 1000/3340 - 20 62.76×62.76×62.76 300 1 
GNNQQNY 2 (SH2-ST5) Parallel/parallel 1070/3241 2OMM 20 62.25×62.25×62.25 300 5 
MVGGVV 1 (SH2-ST5)  Parallel/antiparallel 820/4200 2ONA  20 67.13×67.13×67.13 300 5 
MVGGVV 2 (SH2-ST5) Parallel/antiparallel 820/3785 2OKZ 20 64.98×64.98×64.98 300 5 
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Table 4-2 Summary of structural analysis of double layer amyloid peptide segments with packing polymorphism 
 
 
Model name  
 
<RMSD> 
 
<RMSF> 
Simulation (Å) Crystal (Ås) Average number  of hydrogen bonds 
<dsheet> <dstrand > <dsheet>* <dstrand>‡ <Total H-bond> Main-chain Side-chain 
SSNTVG-I 3.52(1.22) 1.76(0.52) 7.75(1.04) 6.33(1.01) 6.22 4.79 39.09(1.92) 24.70(1.21) 16.84(0.88) 
SSNTVG-II 3.53(0.46) 1.64(0.36) 10.06(0.22) 5.69(0.37) 8.96 4.79 36.68(0.85) 21.35(1.38) 13.15(1.21) 
VQIVYK-I 2.45(0.55) 1.34(0.2) 13.64(0.5) 5.57(0.27) 11.03 4.86 35.41(1.81) 29.67(1.43) 4.7(0.77) 
VQIVYK-II 5.49(1.12) 1.99(0.22) 15.61(2.65) 5.81(0.16) 9.16 4.86 30.54(1) 26.79(1.11) 3.59(1.11) 
NNQNTF-I 1.73(0.45) 0.79(0.09) 8.85(0.19) 5.18(0.08) 8.50 4.84 58.41(2.11) 24.63(0.90) 29.34(3.25) 
N1G 1.78(0.41) 0.78(0.50) 7.85(0.29) 5.17(0.13) 8.50 4.84 49.22(4.08) 26.9(1.93) 20.86(2.87) 
Q3G 2.39(0.53) 0.80(0.58) 6.83(0.18) 5.08(0.20) 8.50 4.84 37.49(4.23) 20.53(2.38) 18.48(2.34) 
NNQNTF-II 2.06(1.43) 0.85(0.28) 10.97(0.37) 5.08(0.08) 10.52 4.84 51.95(0.52) 25.90(1.60) 13.19(1.10) 
GNNQQNY-I 0.93(0.07) 0.55(0.03) 9.74(0.04) 4.96(0.01) 9.61 4.87 79.93(0.94) 29.38(0.68) 48.80(1.46) 
N2G 0.84(0.19) 0.55(0.41) 8.62(0.14) 6.98(0.09) 8.50 4.84 73.48(2.89) 31.06(0.98) 41.64(2.70) 
Q4G 2.52(0.77) 1.41(0.97) 8.74(0.55) 5.35(0.22) 8.50 4.84 37.49(4.23) 20.46(3.79) 13.01(3.64) 
N6G 1.77(0.21) 0.79(0.57) 8.91(0.23) 5.48(0.240 8.50 4.84 68.71(2.94) 29.21(1.42) 37.57(2.45) 
GNNQQNY-II 0.86(0.05) 0.53(0.02) 9.66(0.06) 4.93(0.01) 10.04 4.93 76.43(0.86) 21.45(0.67) 51.11(1.60) 
MVGGVV-I 4.06(0.94) 2.09(0.34) 8.53(0.89) 5.36(0.29) 7.50 4.84 33.14 (2.7) 32.27(1.94) 0.7(0.40) 
MVGGVV-II 4.49(0.95) 2.13(0.25) 8.86(0.86) 5.53(0.26) 8.01 4.76 33.17(2.94) 32.07(2.65) 0.6(0.41) 
 
*  
The inter-sheet distance (dsheet) was calculated by averaging pair-wise residue Cα-Cα distances between the adjacent β-sheet as the shortest distance 
between two the main chain atoms of two opposing strands in the dry interface: (SSNTVG-I: S-N,S-T,T-S and  N-S; SSNTVG-II: S-V,T-N, N-T and V-S; 
VQIVYK-I:   V-Y, I-I and Y-V, VQIVYK-II : V-I and I-V; NNQNTF-I and NNQNTF-II:N-F, N-T ,Q-N , N-Q, T-N , and F-N;  GNNQQNY-I and 
GNNQQNY-II: G-Y, N-N, N-Q , Q-Q , Q-N, N-N and Y-G;  MVGGVV-I: V-G,G-V and G-M , and;  MVGGVV-II: ,G-M,V-G , and G-V) 
‡ 
Angular brackets < > indicate time averaging and the mean values and standard deviation (SD) were calculated by using the five trajectories for each 
models.  Mutations were done using the initial structure of the on the most stable polymorphic forms and the analysis was done on a single trajectory 
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Table 4-3 Summary of the MM-PBSA components of the double layer amyloid peptide segments with packing polymorphism  
 
 
Contribution 
 
Model name 
SSNTVG-I SSNTVG-II NNQNTF-I NNQNTF-II GNNQQNY-I GNNQQNY-II 
<∆Evdw> -14.83(1.80) -14.14(0.65) -23.58(0.53) -19.76(0.42) -20.54(0.13) -20.62(0.05) 
<∆Eele> -228.34(17.87) -209.97(13.82) -187.71(2.91) -97.40(4.50) -174.86(1.98) -176.04(1.18) 
<∆GPB> 230.13(16.81 210.46(12.04) 193.04(4.80) 104.50(4.59) 178.55(2.24) 179.95(1.34) 
<∆GSA> -1.40(0.10) -1.39(0.07) -1.95(0.05) -1.53(0.04) -1.56(0.01) -1.57(0.01) 
<∆Gsolv> 228.73(16.72) 209.06(12.08) 191.08(4.76) 102.97(4.55) 176.99(2.24) 178.38(1.13) 
<∆Gsubtotal> -14.44(2.33) -15.05(2.06) -20.204(1.89) -14.19(0.37) -18.41(0.18) -18.28(0.10) 
<-T∆S> -9.16(0.58) -9.28(0.50) -10.29(0.48) -7.52(0.28) -8.97(0.32) -9.12(0.13) 
<∆G(per stand)> -5.27(1.77) -5.77(1.77) -9.91(2.14) -6.68(0.48) -9.44(0.31) -9.16(0.06) 
 
 
  Binding free energy components (kcal mol
−1
) and standard deviations calculated with MM-PBSA for oligomer double-layers 
(SH2-ST5 ) models: Average over 5000 snapshots of the trajectory. 
b
 Entropy calculations were based on normal modes analysis using 
100  snapshots (1 frame taken at an interval of 50 frams from the total of 5000 frames). Δ Evdw, non-bonded van der Waals energy; 
ΔEele, non-solvent electrostatic potential energy; ΔGPB, electrostatic contributions to the solvation free energy calculated with Poisson-
Boltzmann equation; ∆GSA , ∆GSolv are nonpolar and total solvation energies; -TΔS; Entropic contributions to binding. ΔS; sum of 
rotational, translational and vibrational entropies; ΔG (per stand), per strand binding energy of the system. All energies are in kcal/mol. 
ΔGsubtotal = ΔEvdw + ΔEele + ΔGsol; ΔGsol = ΔGPB + ΔGSA; ΔEgas = ΔEelect + ΔEvdW and ∆G(per stand)= ΔGsubtotal-TΔS 
 
* Mean values were calculated by using the five trajectories for each model from the multiple simulations. Standard deviation 
(SD) was also calculated by using the five trajectories. 
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A             B                       
SSTNVG form I SSTNVG form II    VQIVYK form I             VQIVYK form I     
C     D                  
       MVVGGVV form I         MVVGGVV form II    NNQNTF form I NNQNTF form II                           
E      
GNNQQNY form I   GNNQQNY form I   
Figure 4-1 Structure of polymorphism of steric zippers of amyloid peptide segments studied (A) SSTNVG from IAPP, (B) VQIVYK 
from tau protein, (C) NNQNTF from elk prion, ) GNNQQNY form yeast prion Sup35 and  (D) MVGGVV from Abeta. 
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Figure 4-2 RMSD and RMSF values as a function of time. The RMSD and RMSF were calculated by averaging over five trajectories 
compared to the starting structure in each models. (A) RMSD for polymorph form I, (B) RMSD for polymorph form II, (C) RMSF for 
polymorph form I and (D) RMSF for polymorph form II.  The RMSF values are average for 10 -strands. 
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A                 B                        
GNNQQNY form I       GNNQQNY form II           NNQNTF form I        NNQNTF form II   
 C      D    
 SSNTVG form I    SSNTVG form II    VQIVYK form I VQIVYK form II           
E   
MVGGVV form I           MVGGVV form II 
Figure 4-3 Superposition of the backbone atoms of the staring conformation with the conformation at 20 ns.  The initial structures are 
colored in blue while the structure after 20 ns simulation is shown in red. The structure for the conformation after 20 ns was taken 
from the trajectory with the smallest RMSD and RMSF values out of the five trajectories for each system. 
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Figure 4-4 The averaged inter-strand distances (A and B) and inter-sheet distances (C and D) calculated by averaging over five 
trajectories. The distances were measured in comparison with the corresponding initial structure in each model. 
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Figure 4-5 MM-PBSA per residue decomposition of total binding free energy.  (A) SSNTVG 
polymorph form I and II , (B) NNQNTF polymorph form I and II  and (C) GNNQQNY 
polymorph form I and II. 
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Figure 4-6 MM-PBSA per residue decomposition of side chain contribution to binding free 
energy. (A) SSNTVG polymorph form I and II , (B) NNQNTF polymorph form I and II  and (C) 
GNNQQNY polymorph form I and II. 
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Figure 4-7 MM-PBSA per residue decomposition of backbone contribution to binding free 
energy. (A) SSNTVG polymorph form I and II , (B) NNQNTF polymorph form I and II  and (C) 
GNNQQNY polymorph form I and II. 
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Figure 4-8 Comparison of the number of H-bonds as a function of MD simulation, for five pairs 
of polymorphic packing of amyloid oligomers: SSTNVG, VQIVYK, MVGGVV, NNQNTF and 
GNNQQNY. The hydrogen bonds were determined with respect to the energy minimized 
structures. 
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Figure 4-9 The hydrogen bond occupancy for the side-chain–side-chain and main-chain–side-
chain atoms throughout the simulations. The cut off used for H-bond distance and angle for each 
system was 3.5 Å and 1200. The average occupancy of the main chain and side chain hydrogen 
bonds were calculated by using five trajectories. The average is over the entire simulation 
trajectories.  Hydrogen bonds with occupancy   50% are considered here 
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GNNQQNY mutants:  N2G     Q4G     N6G 
      
NNQNTF mutants:    N1G    Q3N   
       
Figure 4-10 Superposition of the backbone atoms of the staring conformation of the Q/N rich mutants with the conformation at 20 ns.  
The initial structures are colored in blue while the structure after 20 ns simulation is shown in red. The structure for the conformation 
after 20 ns was taken from the trajectory with the smallest RMSD and RMSF values out of the five trajectories for each system.  
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CHAPTER 5 CONTROLLING THE AGGREGATION AND RATE OF 
RELEASE IN ORDER TO IMPROVE THE INSULIN FORMULATION 
 
Chapter 5, in part, is a reprint of the material as it appears in Journal of Molecular Modeling, 
2011, Workalemahu M. Berhanu  Artem E. Masunov, Published online: 15 June 2011; DOI 
10.1007/s00894-011-1123-3 
 
 
5.1 Background 
Insulin is a 51-residue protein hormone consisting of two polypeptide chains: the chain A 
(comprising 21 residues) and the chain B (comprising 30 residues), linked together by three 
disulfide bonds (Figure 5-1A). Insulin is stored in the body in the secretory vesicles of the 
pancreas as a zinc-containing hexamer. When in the blood stream, insulin is present in its 
biologically active monomeric form.
165,166
 The underproduction of insulin or lack of receptor 
sensitivity to insulin is known to cause diabetes that is affecting 171 million people 
worldwide.
167
 Insulin is the mainstay of drug therapy for patients with type I diabetes, and can 
reduce the morbidity in the long term. The disease is caused by autoimmune destruction of 
insulin secreting  cells of the pancreas. Without sufficient levels of insulin, these patients 
cannot properly utilize glucose and typically have markedly elevated blood glucose 
(hyperglycemia) while intracellular glucose levels are generally low. The chronic complications 
of a consistently high blood sugar level are serious and include retinopathy (diabetes is the most 
common cause of blindness), neuropathy, nephropathy (diabetes is a leading cause of chronic 
renal failure), cardiovascular disease, peripheral vascular disease (diabetes is the leading cause of 
limb amputation) and makes the patient more susceptible to infection.
168
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 Similar to many other proteins, insulin can misfold and form highly ordered fibrillar 
amyloid aggregates. Insulin fibrils have been observed in vivo following continuous 
subcutaneous insulin infusion 
169
 and repeated insulin injections 
170
; they are the main factor in 
the pathogenesis called injection amyloidosis.
2,17
 These insulin fibrils that form in vivo display 
the defining characteristics of amyloid aggregates associated with neurodegenerative diseases 
111
 
including binding to the dye Congo red with “apple-green” birefringence, they show an 
elongated, unbranched fibrillar morphology
17
, they exhibit nucleation-dependent polymerization, 
and they present a cross-β X-ray diffraction pattern.2 Recently, serum samples from patients with 
Parkinson‟s disease have been found to display an autoimmune response to insulin oligomers 
and fibrils 
110
, possibly indicating the presence of insulin aggregates in this disease too. Insulin 
also forms amyloid-like fibrils in vitro, which are promoted by elevated temperatures, low pH, 
and increased ionic strength.
112,111
 In addition, insulin fibril formation has been a limiting factor 
in long-term storage of insulin for treatment of diabetes. Amyloid fibrillation may cause 
problems during both production, storage and drug delivery of protein based pharmaceuticals.
94,6
 
In the case of commercial insulin, fibril formation is a problem in some of the isolation and 
purification steps, when  pH is lowered 1-3.
111
 The agitation of insulin solutions during 
transportation and in portable delivery systems may also induce fibrillar  aggregation.
171,94,6
 
Moreover, in therapeutic use of protein drugs, it is essential to avoid the fibril formation, since 
amyloid fibrillated protein is biologically inactive 
111,172
 and may cause immunological responses 
in patients.
172,173
 Future drug development may be aim to either stabilize native structure, inhibit 
the formation of crucial intermediates on the pathway of fibril formation, or to prevent 
interaction between fibrillation intermediates such as the partially unfolded monomer and 
oligomers.
6,111
 Modifications of the amino acid sequence of insulin, such as single point 
135 
mutations, influence both insulin activity and protein aggregation.
174 The newer insulin 
analogues have several improvements due to their modified action profile.
175
 Main advantages of 
short-acting preparations include faster onset of action and shorter duration time. Long-acting 
analogues afford structural changes that delay the onset of action, allow slow and continuous 
absorption into the systemic circulation, and prolong the duration, thus producing a time-
concentration profile that imitates the normal insulin basal level and leads to physiological basal 
glycaemic control with less nocturnal hypoglycaemias.
176
 
Upon aggregation, the molecule of insulin undergoes structural changes from a 
predominantly -helical state to a β-sheet rich conformation, and many models of insulin fibrils 
have been suggested
6,111,177 
repeatedly. The segment B11-B17 with sequence LVEALYL is the 
smallest segment that can both nucleate and inhibit the fibrillation of full-length insulin, 
depending on the molar ratio. This fact is suggesting that this segment is central to the cross-beta 
spine of the insulin fibril.
94
 In addition, the point mutations H10D and L17Q in the chain B of 
insulin prolong the lag phase of insulin fibrillation, further supporting the importance of this 
segment in fibril formation.
178
 Also, exposing this fibril-prone segment by truncating the five 
residues of the chain B C-terminal increases the propensity of insulin for fibril formation.
179
 
Recent studies have shown that the chain A also contributes to insulin fibrillation. Both 
chain A and chain B can form fibrils on their own 
108,109
 and seeds of these chains can nucleate 
the fibrillation of full length insulin.
108
 In addition, it was reported that segments as short as six 
residues from either chain A (residues A13–A18) or chain B (residues B12–B17) can form fibrils 
by themselves.
180
  
The first atomic-resolution view of the fibrillar spine came from single crystal structures 
of the segments LYQLEN (residues A13–A18) and VEALYL (residues B12–B17).22 The 
136 
combination of several complementary techniques (including X-ray diffraction of insulin fibrils 
and scanning-transmission electron microscopy analysis of the morphology of insulin fibrils) 
allowed a highly reliable structure of full-length insulin amyloid fibrils to be 
constructed.
94,181,182,183
 This model has a β-solenoid structure consisting of repeated structural 
units of similar but not identical peptides, covalently connected by 2 disulfide bonds. 
94,183
 The 
solenoids are linked by a dry steric zipper formed by the mating of the central two LVEALYL 
(residues B11-B17) strands. Because LYQLENY contains a Tyr residue in the second position, 
this side chain superimposes on a Tyr from LVEALYL preserving the „„kissing tyrosine‟‟ 
interaction observed across the wet interface of the crystal of LVEALYL (Figure 5.1).  
Computational studies have complemented experiment to provide insights into insulin 
aggregation. All-atom molecular dynamics (MD) simulations have been applied to study the 
amyloid oligomer stability by testing different candidate β-sheet arrangements of preformed 
oligomers mimicking possible nucleus seeds at the very early stage of fibril formation.
21,184,185
 
Mark et al.
186
 performed series of shorter molecular dynamics simulations to investigate the 
structure of monomeric and dimeric insulin in aqueous solution. Their simulation showed that in 
the absence of crystal contacts both monomeric and dimeric insulin have a high degrees of 
intrinsic flexibility in the absence of crystal contacts. Monomer MD simulations
187,188
 established 
that the proposed binding site for glucose is stable, both statically and dynamically.
189
 Other MD 
simulations of the insulin dimer (but not monomer) have been published.
190,191
 They reveal 
details concerning the dynamics of the dimer during the simulation, including the hydrogen bond 
pattern and correlated motions. 
In this study, we report on an MD study of the single layer insulin aggregates based on 
the high resolution models of insulin fibril with the purpose of understanding the nature of 
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insulin self-assembly. We present the information on energetics of the insulin association at an 
atomistic level that could be used to design new short- and long- acting insulin analogues. 
Mutant forms of insulin with altered aggregation properties that could potentially be used to in 
slow- or fast- acting therapeutic formulations are suggested on the basis of the observed contacts 
at the aggregates interface. There has been no pervious systemic study on how mutation affects 
the stability of the insulin oligomer aggregates. Our MD simulations of the different size of the 
insulin oligomer may contribute to a better understanding of the nucleation process and 
conformation change at the very early stage of fibril formation. This study aims to answer the 
following questions: 
1. Which regions of the wild-type insulin oligiomer aggregate are flexible? 
2. How do the single point mutations influence the structure and flexibility of these regions? 
3. What are the effects of single glycine mutations of the side chains involved in the steric 
zipper?  
4. What are the conformational differences among the aggregates of various sizes?  
 
5.2 Methods 
We conducted a total of ~0.35μs of explicit-solvent molecular dynamics (MD) simulation 
on the insulin single layer insulin aggregate oligomer and mutated sequences with intact 
disulfide bridges, using temperatures 330 K to emulate the experimental conditions of in vitro 
insulin fibrillization.
66,67
 
In this study we rely on insulin fibrillar model constructed by Ivanova et al 
94
 using crystal 
structure of the LVEALYLV, SLYQLENY and fiber diffraction patterns. The C-terminal region 
of chain B (residues 20–30) is not involved in amyloid fibrillization 183, and was omitted. 
138 
Comparison of amino acid sequence of the insulin sequences from five different mammalian 
species (porcine, bovine, sheep, mouse and rate) in the residue 20-30 shows nine of the amino 
acids residues are conserved and B30 Tyr in human is replaced with Ala in the other species.
176
 
These residues are missing in the insulin model used in this study. Therefore, only the 40 amino 
acids are taken into account in the fibrils model.
94
 The starting coordinates (Figure 5-1) for the 
MD simulations was taken from the amyloid fibril home page of David Eisenberg group 
available at: (http://people.mbi.ucla.edu/sawaya/jmol/fibrilmodels). 
Ten different single point glycine mutant simulations were conducted to examine the 
effects of steric zipper. In chain A the following three single point glycine mutations were done: 
a) tyrosine (Y) in position 14 replaced with glycine (G), b) leucine (L) in position 16 replaced 
with glycine (G), c) asparagines (N) in position 18 replaced with glycine (G). While in chain B a 
total of seven mutations were done: d) leucine (L) in position 11 replaced with glycine (G), e) 
valine (V) in position 12 replaced with glycine (G), f) glutamic acid (E) on position 13, replaced 
with glycine(G), g) alanine (A) in position 14 replaced with glycine (G), h) leucine (L) in 
position 15 replaced with glycine (G),  i) tyrosine (Y) in position 16 replaced with glycine (G), j) 
leucine (L) in  position 16 replaced with glycine (G). The three mutants in chain A will be 
termed: Y14GA, L16GA and N18GA. The other seven mutants in chain B will be termed: L11GB, 
V12GB, E13GB, A14GB, L15GB, Y16GB and L17GB, respectively. All the starting structures of 
the mutants were built from the wild type 
93
 by replacing the side chains of the targeted residues 
with glycine, using VMD.
155
 Such analogues may possibly allow increasing the potency of 
insulin-based medicines, extending the time of action and controlling it using prodrugs, as well 
as enhancing the bioavailability. Insulin analogues were developed to try and achieve more 
physiological insulin replacement from injection in the subcutaneous site. 
139 
The insulin single layer oligomer aggregates studied contains multiple protein-protein 
interfaces; the calculation of the free energy of the associations of monomers in single layer 
oligomer aggregates requires a suitable interface. Because the present study aimed to assess the 
stability of the insulin oligomer with respect to the increase in the number of strand (the 
longitudinal growth) and the effect of mutation of amino acids involved in intra-chain, we 
measured the interaction energy between the edge (B) chains and the central double layer (A) as 
shown in Figure 5-2. A molecular mechanics–Generalized Born surface area (MM-GBSA) 
method was used to calculate the binding free energies in the insulin single layer complex. The 
free energy analysis was done using a single trajectory approach. 
 
5.3 Results  
5.3.1 Relative structure stability of insulin oligomers 
The conformational change and the conservation of the oligomers were monitored by the 
time evolution of the backbone root mean square (RMSD) and root mean square fluctuation 
(RMSF). The RMSDs provide useful information on relative stability of the oligomers, and were 
previously used in stability analyses of amyloid oligomers with -sheet structure.21,78,86,157,158 In 
Figure 5-3 we plot RMSD of the wild type and mutants oligomer aggregates relative to the 
corresponding initial structure as a function of simulation time. 
 The conformation change and conservation of oligomers stability of the different size 
wild type insulin oligomer was monitored by the time evaluation of the RMSD. In Figure 5-3, we 
plot the RMSD of the insulin oligomers of the main-chain heavy atoms relative to the 
corresponding initial structure as a function of simulation time. The profiles of RMSD deviation 
appear to reach reasonable plateaus during the 10 ns production run, indicating that statistical 
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convergence has been attained in these simulations. The average main-chain RMSD between the 
MD simulation and the initial structure were found in the range of 4.3 to 4.9 Å for WT and 3.75 
to 4.75 Å for the mutants. Along the trajectories the systems tend to keep the original 
conformation. In the case of the wildtype monomer and dimer a large conformational flexibility 
is observed as indicated by the RMSD, RMSF (Figure 5-3 and 5-4), average secondary structure 
content (Table 5-1) and cluster analysis (Figure 5-6). The RMSF and cluster analysis presented 
in Figure 5-3 and Figure 5-6 for the monomer indicates it undergoes larger conformational 
changes forming a globular structure instead of the initial solenoid form. The C-terminus of the 
monomer bends to the central region, and forms an anti-parallel β-sheet between residues 12-16 
and residues 35-40. The dimer largely preserves the solenoid conformation, but exhibits larger 
per residue fluctuation values in the beta sheet region in chains A (11SLYQLENY19) and B 
(12VEALYL17), that are twice as large as the RMSF in other cases (Figure 5-4). 
The residue-based root mean square fluctuation (RMSF) of the backbones was used to 
assess the local dynamics and flexibility of each residue using ptraj tool in AMBER11. Detailed 
analysis of RMSF of the Cα, C, N atoms versus the residue number for insulin wild type and 
mutants oligomer aggregates is shown in Figure 5-4. The large size oligomer such as SH1-ST8 
and SH1-ST10 are more flexible at their N- and C-termini as compared to its smaller size 
oligomers (except SH1-ST2). The relatively larger RMSF per residue of the SH1-ST1 and SH1-
ST2 is found the β-sheet region indicates their instability and the loss of the initial fibril 
conformation (Figure 5-4A). The other oligomers (SH1-ST4 to SH1-ST10) the β-sheet region 
exhibits significantly smaller structural fluctuation from the fibril conformation. Figure 5-4B and 
C shows the RMSF values of atomic positions by each residue, computed throughout the 
simulation for wildtype of insulin (SH1-ST10) and corresponding single point glycine mutants. 
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The RMSF of single point mutants were found to be larger than the wildtype. The smallest 
fluctuation of the average RMSF in for chain A and chain B was found in the segments 
LYQLENY and LVEALYL respectively. The RMSF results for the wildtype and the mutants 
indicates that all chains have common characteristics of small variation in the residue located 
within the β-sheet region whereas large variations for residues in the termini regions. The larger 
flexibility of the two termini residues were due to the reduction of hydrogen bonds between the 
peptides. The side chains of the termini residues are more exposed to the water and tend to form 
hydrogen bonds with water molecules.
88
 
 
5.3.2 Secondary structure content 
We carried out secondary structure analysis using DSSP tool in AMBER11. Table 5-1 
reports the average number of residues in a given secondary structure as a function of simulation 
time and the corresponding initial structure. When the average secondary structure content over 
time is considered differences between smaller oligomers and larger size oligomer are evident 
from the simulations. The single and double stranded aggregates exhibits lower -sheets and 
more residues in helices and in coil-like conformation. The larger oligomers (such as SH1-ST4 
to SH1-ST10) exhibit exhibits more -sheets contents and fewer residues in helices and in coil-
like conformation. The larger aggregates retain the fibril conformation mainly due to an 
increased number of backbone hydrogen bonds.
88
 
 
5.3.3 Cluster Analysis 
Cluster analysis or in short clustering puts similar samples of data into groups called 
clusters, such that an ensemble of data, for example, the different structures obtained from a MD 
142 
trajectory, is partitioned into groups of similar objects. Structural clustering is useful to 
understand the molecular motion within conformational space.
192
 Conventional clustering 
algorithms are reducing any large MD trajectory to a set of conformational basins. To identify 
the most populated conformations sampled, clustering of all snapshots from the trajectories was 
performed using the ptraj program of AMBER11. The standard approach, which has been used 
with considerable success, is to cluster the configurations in terms of an RMSD. For clustering, 
we utilized the average linkage algorithm implemented in ptraj.
77
 The uniqueness or equivalence 
of different clusters was assessed based on visual comparison of representative structures. The 
clustering was performed on a 5000-frame reference set (4 ps sampling rate). Figure 5-6 shows 
the superposition of the initial structure and the most populated cluster structure for single-layer 
insulin aggregates of different sizes. The analysis of the structures indicated the most populated 
clusters detected from the smaller size oligomers (single and double strand) indicating larger 
structural rearrangements compared to the initial conformation taken from the fibril model. The 
conformation was preserved for larger aggregate (SH1-ST8 and SH1-ST10). 
 
5.3.4 Free energy calculation 
Detailed characterization of individual energy terms of the calculated binding free energy 
of the studied insulin oligomer aggregates are shown in Table 5-2. An inspection of the free 
energy components for the wild types and mutants reveals that the electrostatic component of the 
free energy of binding (ΔEele) contributes unfavorably to binding (ΔG > 0). The nonpolar 
component contributes favorably (ΔG < 0) as expected, since formation of complexes reduces 
solvent-accessible surface area. In most cases the electrostatic component of the solvation free 
energy ΔGGS is consistently favorable. The interaction energy due to electrostatic interaction 
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(ΔEvdw) between strands led to unfavorable binding. These observations are consistent with 
previous calculations of the electrostatic component of the free energy of solvation. However, 
the less favorable electrostatics in each case is compensated by highly favorable nonpolar 
component of the free energy. In each case, favorable nature of the nonpolar interaction mostly 
originates from nonpolar component of solvation (ΔGGB) and the van der Waals interaction 
energy (ΔEvdw).  
The result of the binding free energy calculation (Table 5-2) indicates the structurally 
stable models have the lowest binding free energy, while the models which are structurally 
unstable were found to have the largest binding free energy. The difference in binding free 
energy between the wild-type and mutated complex is defined as:  
Δ∆Gmut = ΔGmut-ΔGwild     (1) 
A positive and negative Δ∆Gmut values indicate the unfavorable and favorable contributions. The 
positive Gmut values of 37.3 to 1.4 kcal/mol of the mutants in the -sheet region (except 
Y14GA and L15GB) indicate their lower tendency to aggregation compared to the wildtype. This 
result from our simulation could be used in rational design new insulin analogues with decreased 
propensity for self-association avoiding injection amyloidosis of insulin. The relatively larger 
positive value of Δ∆Gmut for mutants (Y14GA, L11GB, V12GB and E12GB) indicates the less 
favorable association compared to the wildtype. In general substitution of -sheet region of chain 
A and B by a small, short Gly disrupts the steric zipper shape complementary and weakens 
hydrophobic interactions (see Table 5-2).The single point glycine mutation reduces the 
unfavorable electrostatic interaction. The mutation of the negatively charged glutamate (E) to G 
in the mutant E12GB reduces the electrostatic repulsion in the wildtype as is evidence in the 
significant reduction of the unfavorable electrostatic interaction (Table 5-2). Mutation of Tyr14 
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in chain A with glycine eliminates the hydrogen bond between the residues Tyr14 of chain and 
the Tyr16 of chain B as the result the calculated binding free energy was high.  The negative 
value of value of Δ∆Gmut for a mutant is due to the increased hydrophobic interaction in the 
steric zipper between the chains. Complete hydrophobic side chain by Gly substation impedes 
fibril growth.
193
 The trend in the calculated binding free energy is in agreement with the 
observed instability based on RMSD, RMSF. Those aggregate oligomer models which show 
structural instability were found to have unfavorable binding energy compared to the stable once.  
 
5.3.5 Decomposition free energy on a per-residue basis  
The free energy decomposition not only identifies the binding energy hot spots, but also 
gives insight into the nature of the key interactions.
189
 To provide the basic information on the 
intermolecular interactions contributed from the individual residues in the insulin single layer 
aggregate interaction decomposition of free energy (the per residue total, side chain and 
backbone binding free energy) was evaluated using the decomposition energy module in 
AMBER11. The calculation was performed over the 2500 MD snapshots taken from the 20 ns 
simulation. The summations of per residue interaction free energies were separated into the 
residue backbone (G backbone bind) and the side chain (G side chain bind). The energy 
contributions from the selected residues are summarized in Figure 5-5. 
The result form the energy decomposition shows the major contribution to the binding energy of 
insulin oligomer aggregate is gained from the key amino acid residues (those with a Gbinding -
0.50 kcal/mol) occurring mainly in the -sheet region. These residues are in chain A (Q5, L13, 
Y14, Q15, L16, N18 and Y19) and in chain B (S9, L11, V12, L15, L17 and V18).The result of 
the per residue decomposition indicates the important of the particular residues in the -sheet 
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region with regards to the formation and stabilization of insulin and this is in agreement with 
experimental observation.
94
 To establish the interaction associated with these residues, their 
electrostatic, van der Waals and solvation energy terms are shown in Table 5-3 . Table 5-3 shows 
that favorable contributions to the binding free energy arising from these  residues relates to  Eele, 
Evdw, ∆GGS, while  unfavorable comes from ∆GGB. The favorable Eele terms from the residue in 
the β-sheet region are compensated by highly unfavorable repulsion from three glutamate 
between adjacent insulin layers. 
 
5.3.6 Fibril nucleation and the structure of insulin oligomers 
Understanding the process of amyloid fibril formation is an important goal of protein 
aggregation studies.
47
 Amyloids grow in a nucleation-dependent manner.
35,47
 Fibrillation kinetics 
is typically characterized by an initial apparent lag phase related to the formation of oligomers, 
protofibrils, and aggregation nuclei.
194
 The typical fibril formation process is characterized by a 
lag phase in which no detectable fibers are formed. This is then followed by an elongation phase 
in which fiber is formed over a time period often shorter than the lag phase. Eventually, the 
process reaches equilibrium when most soluble proteins are converted into fibrils.
195
 On the other 
hand, if fibers (oligomers, protofibrils, and fibrils) are already formed they grow extremely fast 
with very short lag-times. A recent experimental work on oligomers capability to stabilize fibril 
nucleation activity by Ono et al.
196
 on Aβ amyloid, on amylin 195, and on insulin in various labs 
197, 198, 199,200
 have indicated the oligomers and the fibril showed different capability to act as 
seeds. Anselm et al  
184
 used the degree of structural similarity to the fibril conformation detected 
for the oligomers in their  simulation as an possible reason for  difference among various size of 
oligomer with respect to the effective as nucleation seeds. The degree of structural similarity 
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between fibril conformation and the conformation of the oligomers after MD simulation could be 
used in explaining the shorting of the lag phase in the present of different size of oligomers. The 
trend in retaining the initial fibril conformation will help us in getting an atomic level 
explanation to the observed difference in the seed effects of various sizes of oligomers. The 
results from our simulation show the single layer insulin oligomer as small as the trimer is 
capable of preserving the conformation present in the fibril (See Figure 5-6). The dimer shares 
some properties of the mature fibril. The monomer adopts a structure that differs significantly 
from that of the fibril.  
The secondary structure content and clustering analysis on the trajectories from the 
various size single layer insulin oligomer shows the larger aggregates retain the fibril 
conformation and the smaller ones (SH1-ST1 and SH1-ST2) lose this conformation. The 
observation could be used to explain the shortening of the nucleation lag phase of insulin 
aggregation with oligomer seeds. Insulin like other amyloid peptides follow an apparent 
nucleation-dependent polymerization kinetics
47,201
 whereby a small number of monomers 
associate through a free energy barrier corresponding to a critical nucleus size, beyond which 
initiates gradient of favorable free energy or “down-hill” polymerization. Based on the result of 
the secondary structure and cluster analysis we proposed the SH1-ST4 to be a critical nucleus for 
the single insulin fibril oligomer growth. To characterize the critical nucleation we computed the 
association energy different between our proposed minimum nuclei and the larger size oligomers 
(SH1-ST6, SH1-ST8 and SH1-ST10) we using the equation. 
∆∆G(n)= G(n)- (G4);  n=4,6,8,10    (2) 
The results are shown in Table 5-2. Our calculation shows that, for a high number of strands, the 
oligomer is stable and its free energy is favorable for the addition of the new chains. The result 
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of our semi-quantative approaches for insulin single layers of limited size of insulin single layer 
are in agreement with those obtained from pervious extensive simulations done on Aβ amyloid 
critical nucleus and mechanism of fibril elongation.
202,203
 
 
5.4 Conclusions 
The results from this work provided valuable insight into the forces that drive the stability 
of the peptide-peptide complexes of the single layer aggregate oligomer models of insulin and 
those that lead to unstable complexes. The study of the wild type and mutants in an explicit 
solvent will provide valuable to future efforts aimed at the design of short –and long-acting 
insulin analogs. The major findings of this study can be summarized as follows:  
1. The stability of the insulin single layer peptides oligomers increases as the number the 
number of strands increases (dynamic cooperative effect) . 
2. The binding energy calculated by MM-GBSA method shows the hydrophobic 
interactions play an important role in stabilizing the structural organizations of the single layer 
insulin. Per residue decomposition shows the key amino acid residues (those with a Gbinding -
1.00 kcal/mol) occur mainly in the -sheet region of both chain A and chain B. Due to the 
electrostatic repulsion between the three negatively charged glutamates in adjacent insulin 
strands, electrostatic repulsion to the binding energy is unfavorable. 
3. A single glycine substitution at the steric zipper interface disrupts the hydrophobic 
contacts and reduces the van der Waals interactions in the mutants thus reducing the binding free 
energy. The result of the binding free energy calculation indicated that the wild type is more 
structurally stable than most of the mutants. A comparison of the binding free energy between 
the wildtype and the chain A mutants (Y14GA, L16GA and N18GA) indicates shape 
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complementarity between neighboring strands plays a key role to stabilize the entire oligomeric 
structure.  
4. The secondary structure contents and clustering analysis of the trajectories of the single 
layer insulin oligomers shows the larger aggregates retain the fibril conformation but the smaller 
once (SH1-ST1 and SH1-ST2) lose this conformation. This observation could explain the 
observed shortening of the nucleation lag phase of insulin aggregation with oligomer seeds. 
Based on the result of the secondary structure and cluster analysis we proposed the SH1-ST4 is a 
critical nucleus for the single-layer insulin fibril oligomer growth. 
Our simulations provide detailed insights into understanding the structural stability and 
aggregation behavior of the insulin single layer aggregates (obtained from a high resolution 
insulin fibril model) at atomic level. In the search for clinically advantageous fast acting insulin 
analogs several approaches were found to be useful for altering the monomer/monomer interface. 
One of them is disruption of β-sheet interactions in the β-chain through charge repulsion, or 
changes in hydrophobic interactions in the C-terminus of chain B 
176
. Our simulations on the 
wildtype and single glycine mutants at the steric zipper region show other parts of insulin 
molecule can be targeted in the design of both short and long action insulin analogs as well. 
Aside from the design of such insulin analogs, the present study may prove useful for rational 
design of insulin aggregation inhibitors which could be used in stabilizing insulin formulations, 
leading to their safer handling and more cost-effective storage especially in developing countries. 
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Table 5-1 Average secondary structure contents of different size insulin wildtype and its (SH1-ST10) single point glycine mutants 
 
 Starting Average Starting Average Starting Average Starting Average Starting Average 
 WT (SH1-ST2) WT (SH1-ST4) WT (SH1-ST6) WT (SH1-ST8) WT (SH1-ST10) 
β-Sheet 0(0) 0(0) 0(0) 0(0),[0] 0(0) 0(0),[0] 0(0) 0(0),[0] 0(0) 0(0),[0] 
β-Bridge 23(63.9) 15.3(56.1),[3.6] 47(63.5) 42.3(62.3),[3.1] 83(68) 69.9(79.6), [5.2] 115(68.1) 114(69.2), [5.7] 158(73.8) 135.6,(70.1),[7.6] 
coil 0(0) 0(0) 0(0) 0(0),[0] 0(0) 0(0),[0] 0(0) 0(0),[0] 0(0) 0(0),[0] 
turn 2(5.5) 6.4(23.5),[2.4] 9(12.2) 10.3(15.2),[3.4] 25(20.5) 16.4,(18.7).[4] 35(20.7) 28.1,(17.1).[6.1] 45(21) 28.1,(17.1).[6.1] 
-Helix 11(30.6) 3.9(14.3), [2.9] 14(18.9) 12.1(17.8),[4.6] 8(6.6) 14.4,(8.7),[5.9] 12(7.1) 14.4,(8.7),[5.9] 8(3.7) 11.2(5.8),[4.3] 
310-Helix 0(0) 1.6(5.9),[2.0] 2(2.7) 2.7(4.0). [2.8] 6(4.9) 8.4,(9.6), [3.9] 7(4.1) 5.7(3.5), [4.1] 3(1.4) 11.8,(6.1),[4.6] 
-Helix 0(0) 0.05(0.2),[0.1] 2(2.7) 0.5(0.7), [1.2] 0(0) 1.3,(1.5), [1.9] 0(0) 2.4(1.5), [2.7] 0(0) 0.5(0.3),[1.0] 
 L11GB (SH1-ST10) V12GB(SH1-ST10) E13GB (SH1-ST10) A14GB (SH1-ST10) L15GB (SH1-ST10) 
β-Sheet 0(0) 0(0) 0(0) 0(0),[0] 0(0) 0(0),[0] 0(0) 0(0),[0] 0(0) 0(0),[0] 
β-Bridge 135(71) 127.7,(68.3),[7.9] 146(72.3) 128,(68.8),[6.4] 131(68.6) 130.5(69.6), [7.9] 134(69.1) 120.9(69.2), [7.7] 157(70.7) 142.5,(70.2),[7.6] 
coil 0(0) 0(0) 0(0) 0(0),[0] 0(0) 0(0),[0] 0(0) 0(0),[0] 0(0) 0(0),[0] 
turn 28(14.7) 31.5(16.8),[4.9] 36(17.8) 37.6,(20.2),[5.0] 45(23.6) 34.9,(18.6).[5.7] 46(23.7) 38.8,(21.6).[5.2] 40(18) 32.6,(16.1).[6.7] 
-Helix 16(8.4) 16.5(8.8), [4.9] 9(4.5) 11.5,(6.2),[4.6] 4(2.1) 12.6,(6.7),[5.3] 8(4.1) 7.0,(3.9),[3.6] 18(8.1) 17.5,(8.6),[6.2] 
310-Helix 9(4.7) 8.8,(4.7),[4.7] 6(3.0) 8.4, (4.5). [4.3] 9(4.7) 9.5,(5.1), [4.2] 6(3.1) 9.8,(5.4), [4.1] 7(3.2) 8.2,(4.0),[4.5] 
-Helix 2(1) 2.5,(1.4),[2.2] 5(2.5) 0.5(0.3), [1.3] 4(2.1) 0.3,(0.2), [1.0] 0(0) 1.4,(0.8), [2.4] 0(0) 2.3,(1.1),[3.0] 
 Y16G (SH1-ST10) L17GA (SH1-ST10) Y14GA (SH1-ST10) L16GA (SH1-ST10) N18GA (SH1-ST10) 
β-Sheet 0(0) 0(0) 0(0) 0(0),[0] 0(0) 0(0),[0] 0(0) 0(0) 0(0) 0(0),[0] 
β-Bridge 133(72.3) 127.7,(68.3),[6.0] 146(72.6) 135.1,(71.5),[6.7] 143(69.1) 121.1,(66.0),[7.9] 139(67.8) 127.8,(65.8),[6.8] 151(70.9) 122.9,(68.7),[8.2] 
coil 0(0) 0(0) 0(0) 0(0),[0] 0(0) 0(0),[0] 0(0) 0(0) 0(0) 0(0),[0] 
turn 39(21.2) 31.5(16.8),[4.9] 23(11.4) 30.6,(16.2),[5.4] 29(14) 30.0,(16.4).[5.9] 38(18.5) 39.0,(20.1),[5.8] 36(16.9) 36.4,(20.4),[4.4] 
-Helix 10(5.4) 16.5(8.8), [4.9] 24(12) 17.9,(9.5),[5.2] 24(11.6) 21.0(11.4),[7.6] 13(6.3) 16.3,(8.4), [5.1] 10(4.7) 7.3,(4.1),[5.6] 
310-Helix 0(0) 8.8,(4.7),[4.7] 3(1.5) 3.1, (1.6). [2.8] 6(2.9) 10.2,(5.6),[5.6] 3(1.5) 9.8,(5.0),[4.5] 9(4.2) 9.0, (5.0). [4.1] 
-Helix 2(1.1) 2.5,(1.4),[2.2] 5(2.5) 2.5(1.2), [2.2] 5(2.4) 1.2,(0.6),[2.0] 12(5.8) 1.2,(0.6),[2.0] 7(3.3) 3.2, (3.2), [2.4] 
 
*Percentages and standard deviations are given in parenthesis and square brackets, respectively 
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Table 5-2 Individual energy components of the binding free energy of insulin amyloid aggregate peptide 
 
MM-GBSA binding energy components of the different size of the single layer insulin amyloid aggregates   
System  ∆Evdw ∆Eele ∆GGB ∆GGS ∆Gsolv ∆Gtotal Δ∆G(6-n) 
WT(SH1-ST4) -163.960.18 576.651.02 -502.400.95 -21.350.02 -523.750.95 -111.060.17 11.43 
WT(SH1-ST6) -177.210.28 1149.660.91 -1071.500.86 -23.430.03 -1094.940.86 -122.490.24 0.0 
WT(SH1-ST8) -149.640.19 1514.622.27 -1433.422.22 -25.810.02 -1459.272.22 -142.290.22 -19.8 
WT(SH1-ST10) -196.310.14 1827.75 -1742.521.00 -25.200.02 -1767.280.13 -136.280.13 -13.79 
MM-GBSA binding energy components of   single layer insulin amyloid aggregates mutant of chain A (SH1-ST10)  
System ∆Evdw ∆Eele ∆GGB ∆GGS ∆Gsolv ∆Gtotal Δ∆Gmut 
Y14GA (chain A) -165.160.12 1974.310.84 -1887.760.84 -20.360.02 -1908.110.84 -98.96016 37.3 
L16GA (chain A) -208.140.14 1710.421.74 -1628.031.73 -27.100.03 -1655.151.73 -152.870.16 -16.59 
N18GA (chain A) -201.2720.12 1623.990.93 -1527.810.91 -26.020.01 -1553.820.91 -131.110.15 5.17 
MM-GBSA binding energy components of   single layer insulin amyloid aggregates mutant of chain B (SH1-ST10) 
System ∆Evdw ∆Eele ∆GGB ∆GGS ∆Gsolv ∆Gtotal Δ∆Gmut 
L11GB (chain B) -171.70.23 1598.83.4 -1522.23.4 -22.00.02 -1544.23.4 -117.10.2 19.2 
V12GB (chain B) -167.10.2 1789.91.1 -1715.791.0 -21.50.01 -1737.21.0 -114.40.2 21.9 
E13GB (chain B) -186.70.3 981.41.0 -893. 71.0 -25.30.02 -918.91.06 -124.20.25 12.1 
A14GB (chain B) -191.20.2 1620.84.0 -1533.34.0 -25.40.03 -1558.74.0 -129.20.25 7.1 
L15GB (chain B) -209.30.2 1622.92.4 -15292.4 -26.60.02 -1555.62.4 -142.03 -5.7 
Y16GB (chain B) -194.80.2 1752.61.9 -1663.11.9 -23.30.03 -1686.41.9 -128.6220.2 7.6 
L17GB (chain B) -204.40.3 1823.92.3 -1728.422.2 -26.00.02 -1754.432.3 -134.9040.2 1.4 
 
Evdw and Eelec are the van deer waals and electrostatic binding terms, ∆GGB, ∆GGS, ∆Gsolv are the polar, non polar and total solvation 
energies.  Data are shown as meanSD. Standard error of the mean ∆Gtotal = ∆Evdw,+ ∆Eele + ∆Gsol  , ∆Gsol = ∆GGB + ∆GGS, ΔGmut = ∆Gmut- 
Gwild, the change of mutant binding free energy as to wildtype. Δ∆G(n-6) = Oligomer free energies expressed relative to the hexamer state for β-sheet oligomers. 
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Figure 5-1 Amino acid sequence and structure of single-layer insulin oligomer (A) Amino acid 
sequence of insulin (chain B top and chain A bottom). Segments LVEAYLV of chain B and 
SLYQLENT of chain A are colored in green. Disulfide bonds are colored in blue. The C-
terminal region of chain B underlined and in italic, is not involved in amyloid fibrillization. The 
residues underlined are missing in the insulin model used in this study. Therefore, only the 40 
amino acids are taken into account in the fibrils model. (B) Single -layered structural models of 
insulin oligomers (10 stranded). Two chains are associated together via interdigitated pair of 
LYQLENY molecules of chain A and LVEALYL molecules of chain B which interlock tightly 
to form the dry steric zipper. The chain A is red and the chain B is blue. Disulfide bonds are 
indicated in the yellow. 
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A B C  
 
 
Figure 5-2 Schematic drawing of the setup used for estimating the internal stability of insulin 
single layer aggregates and mutants. Free energies of interaction were calculated between the 
middle chains A (cyan) and the remaining edge chains B(red) reflecting the strength by which 
chain A clamps the insulin stack in the β-solenoid structure. 
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Figure 5-3 Backbone RMSDs of single layered insulin models and single glycine mutants (SH1-
ST10) 
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Figure 5-4 Plot of the root mean square fluctuation (RMSF) of single layered insulin models and 
single point glycine mutants (SH1-ST10) 
155 
A
-3.0
-2.5
-2.0
-1.5
-1.0
-0.5
0.0
0.5
1.0
G I V E Q C C T S I C S L Y Q L E N Y C N
 
 

G
b
in
d
in
g
(K
c
a
l/
m
o
l)
 Total
 Side chain
 Backbone
 
B
-2.5
-2.0
-1.5
-1.0
-0.5
0.0
0.5
F V N Q H L C G S H L V E A L Y L V C
 
 

G
b
in
d
in
g
 (
K
c
a
l/
m
o
l)
 Total
 Side chain
 Backbone
 
 
Figure 5-5 Decomposition of the free energy on a  per residue basis for chain A (A) and chain B 
(B) of the single layer insulin aggregate (SH1-ST10) 
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A 59.0%    B 50.6%            C     43.5% 
 
D 35.6%    E 49.2%   F  38.5% 
Figure 5-6 Superposition of insulin single layer oligomer aggregates of the initial structure and representative structures of the 
most populated clusters.(A: SH1-ST1, B: SH1-ST2, C: SH1-ST4, D: SH1-ST6, E: SH1-ST8, and F: SH1-ST10). The initial 
structures are shown in blue and the most populated cluster with the corresponding percentages is shown in red. 
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CHAPTER 6 THE ATOMIC LEVEL INTERACTION OF 
POLYPHENOLS WITH THE OLIGOMER AGGREGATE OF VQIVYK 
SEGMENT FROM TAU PEPTIDE  
 
6.1 Background 
The presence in tissues of amyloid plaques consisting mainly of amyloid fibrils arising 
from the polymerization of specific peptides/proteins is a key hallmark of several degenerative 
conditions including Alzheimer's, Parkinson's and type II diabetes.
137
 In Alzheimer's disease, the 
tau peptide forms intracellular amyloid in the form of paired helical filaments (PHF).
204,205
 The 
tau protein consisting of 441 residues binds and stabilizes microtubules.
204
 The tau peptides 
aggregate via cross- hydrogen bonding, where two monomer -sheet structures adhere 
together.
205
 The most important amino acid sequence in the tau peptide is 
306
VQIVYK,
311
 as this 
sequence has been shown to be necessary for amyloid formation through the cross- 
interactions.
205
 The hexapeptide VQIVYK by itself forms insoluble -sheet aggregates 
spontaneously in aqueous solution. 
22
 The VQIVYK segment of tau was suggested as the 
minimal interaction motif for fiber formation.
205
 Landau et al 
206
 recently determined the atomic 
structures of VQIVYK segment from the tau in complex with small molecule binders, 
determined by X-ray micro-crystallography. The fiber-like complexes consist of pairs of β-
sheets, with small molecules binding between the sheets, roughly parallel to the fiber axis.
206
  
Landau et al 
206
 proposed that the tube-like cavity along the β-sheets provides an adequate site 
for the binding various aromatic compounds, such as polyphenols.
207
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 Amyloid fibrils exhibit a common molecular architecture in which arrays of β-strands are 
connected by hydrogen bonds oriented parallel to the fiber long axis, into an array known as a 
cross-β structure. The substructure of mature fibrils consists of one or more protofilament units, 
which can assemble laterally or intertwine in various ways as rope-like or ribbon-like 
modifications to the common fibrillar framework. 
2
 The finding that amyloid fibrils are stabilized 
primarily by hydrogen bonds involving the polypeptide main chain explains why fibrils formed 
from polypeptides of different sequence are morphologically and structurally similar.
208
 
Presently, prefibrillar aggregates of different proteins and peptides are considered the most toxic 
amyloid species, whereas mature fibrils are substantially devoid of cytotoxicity.
137
 Accordingly, 
intra-cellular or extracellular prefibrillar aggregates are considered the main factors for cell 
impairment and tissue degeneration in amyloid diseases.
209,210
 Therefore, agents that interfere 
with early oligomerization are expected to be especially valuable for use in the therapy or 
prevention of amyloid diseases. The toxic effects of amyloid aggregates to exposed cells, 
includes nonspecific membrane permeabilization, oxidative stress, mitochondria impairment and 
eventually apoptosis.
211,212
 A lot of many efforts are presently spent to find out naturally 
occurring molecules, including polyphenols, or to design synthetic ones, that are capable to 
protect cells against oxidative stress or the inhibition of the amyloid formation at its earliest 
stages and disruption of the fibrillar structures.
42,212
 At present, there are no approved therapies 
that target amyloid formation directly, but many organic molecules have been shown to inhibit 
fibrillation in vitro, and thus represent an increasing list of proposed antiamyloid lead 
compounds. Natural polyphenolic compounds from foods and traditional herbal medicines, 
having broad pharmacological activities and exhibiting inhibition of amyloid formation, have 
165 
been extensively investigated in the disruption of mature amyloid fibrils and reduction of the 
toxicity of fibrils to living cells.
213, 214, 215,216
 Recent publications 
217, 218, 219
, have studied the 
antiamyloid effects of natural polyphenols on three consecutive processes: formation of nascent 
fibrils, elongation or extension of the fibrils, and destabilization of the formed mature 
assemblies. The destabilizing effects include disaggregation/fragmentation of the fibrils and 
conversion of the fibrils into amorphous deposition.
220 Although many attempts have been made 
to elucidate the molecular mechanism of natural polyphenols against amyloidogenesis, the 
structure-activity relationship is still obscure and remains to be further explored.  
Recent in vitro evidence has suggested that polyphenolic compounds (flavonoids) from 
food products such as red wine and green tea have been reported to show antiamyloid activity. 
221 222, 223, 219
 Despite progress in experimental observations, there are still many questions about 
amylin-resveratrol or amylin polyphenol interactions on a molecular level. For example, 1) What 
are the physicochemical factors controlling polyphenol binding? 2)  What are the molecular 
interactions between polyphenols and the VQIVYK oligomers? 3) Does the polyphenols binding 
induce changes the VQIVYK oligomers structure? 4) Are there difference in binding affinity 
among the different polyphenols? Answering these questions will be important to our 
understanding of the mechanism of VQIVYK oligomer fibril dissociation induced by polyphenol 
and may aid in designing new antiaggregation agents. Many compounds have been reported to 
show antiamyloid activity in various in vitro and in vivo experiments. Detailed structural studies 
of the mechanism of action of already available antiamyloids can help in future development and 
characterization of druggable modalities. All-atom computer simulations, such as molecular 
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dynamics (MD), are well suited to provide molecular-level details of VQIVYK oligomer –
polyphenol interactions.  
There have been several theoretical attempts to study the interactions between current 
inhibitors and oligomers at the atomic level. Using all-atom molecular dynamics simulations 
with explicit solvation model, Wu et al. 
100
 have identified and characterized two specific 
binding modes of Congo red molecules to protofibrils formed by GNNQQNY. Binding of the 
fluorescence dye thioflavin T (ThT) to the fibrils formed by Aβ fragments, Aβ16–22, has been 
probed using all-atom MD.
224
 Two ThT binding sites were identified, one in the hydrophobic 
groove on the fibril side and another on the fibril edge. From MD simulations, the binding 
energetics for ThT was also computed. More recently, binding of tricyclic planar ligands (9, 10-
anthraquinone and anthracene) to fibril forming Aβ fragments (Aβ14–20) was investigated using 
MD.
225
 The results showed that 9, 10-anthraquinone interferes with the formation of inter-strand 
hydrogen bonds and reduces the accumulation of ordered aggregates. Dmitri and coworkers 
226, 87
 
using replica exchange molecular dynamics and atomistic implicit solvent model, studied the 
mechanisms of binding of naproxen and ibuprofen to the A beta fibril. Liu et al. 
227
 investigated 
the molecular mechanism of the inhibition effect of trehalose on Aβ16–22 and Aβ40 peptides 
with MD in explicit solvent. Neil et al 
228
 using molecular dynamics simulations compared the 
mode of interaction of an active (LPFFD) and inactive (LHFFD) β-sheet breaker peptide with an 
Aβ fibril structure. They found that LHFFD had a weaker interaction with the fibril than the 
active peptide, LPFFD, from geometric and energetic considerations. 
228
 Recently we performed 
an implicit solvent molecular simulations of amyloidogenic peptides (GNNQNNY) co-incubated 
with polyphenols to probe the interaction between the ligand the amyloid aggregate models 
86
. 
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Lemkul et al 
229
 using multiple dynamic simulations found the flavoniod morin can bind to the 
ends of the fibrils blocking the attachment of an incoming peptide, penetrate into the 
hydrophobic core to disrupt the Asp23−Lys28 salt bridges. They found combination of 
hydrophobicity, aromaticity, and hydrogen bonding capacity of morin as a main factor 
destabilizing the Aβ42 protofibril. Various labs  reported that polyphenols  physically disrupt tau 
aggregates.
230,231,232,233
 It is this information that motivates this study. Clearly, there is great 
interest in understanding how small molecules might interact with, and ultimately destabilize, 
amyloid assemblies.  
Polyphenolic compounds are attractive therapeutic candidates, as they are found in 
natural food products, are capable of crossing the blood−brain barrier, and are nontoxic in 
clinically relevant doses.
234,235
 Studies of the interaction of polyphenols such as epigallocatechin 
236
 and resveratrol 
237
 with α-synuclein and Aβ lead to the proposal, based in part on seeding 
studies, that polyphenols functions as amyloid aggregation inhibitor by diverting polypeptides 
from their normal amyloid formation pathway into nonproductive off-pathway states. 
Polyphenols are characterized by the presence of several phenolic hydroxyl groups with acidic 
property and with their planar structures their planar structure forms hydrogen bonds  with 
peptides.
238
  
The VQIVYK segment of tau was suggested as the critical for tau polymerization. 
Therefore, the tau peptide segment (VQIVYK) has been used as a simplified model system to 
facilitate the discovery of key factors underlying amyloid fibril formation and the development 
of antiamyloid agents. The structure of the hexapeptide with an amino acid sequence VQIVYK 
(Residues 306-311) from tau protein in complex with small molecules has been recently been 
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determined by Landau et al.
206
 The atomic structures of small molecules bound to amyloid reveal 
the molecular framework of small-molecule binding, within cylindrical cavities running along 
the -spines of the fibers. These complexes reveal a molecular framework which partially 
defines the amyloid pharmacophore, the structural features responsible for the binding of small 
molecules to amyloid aggregates. 
MD studies of polyphenols binding to VQIVYK oligomer of tau peptide to the best of 
our knowledge have not been performed. We used MD simulations with explicit-solvent to study 
the interaction of curcumin, myricetin and exifone with a preformed oligomers aggregate of 
VQIVYK from tau peptide. Detailed binding free energies between curcumin, exifone and 
myricetin and individual protein residues of the oligomers of VQIVYK were computed by using 
a per-residue basis decomposition method, which provides insights into the inhibitor-protein 
binding mechanism and also explains the mechanisms of the aggregation inhibitor effect of 
polyphenols. 
 
6.2 Methods 
The structure of the oligomer aggregate of the hexapeptide with an amino acid sequence 
VQIVYK (Residues 306-311) from tau protein in complex with small inhibitor molecules has 
been recently been determined by Landau et al 
206
  The X-ray structure of VQIVYK oligomer 
bound the polyphenol curcumin, taken from the web page 
http://people.mbi.ucla.edu/meytal/CoCrystalPaper/#V6K-CUR, served as the starting point for 
modeling VQIVYK complex with myricetin and exifone. The myricetin and exifone were 
docked to the peptide fibrillar structure using Sirius graphics program 
169 
(http://www.ngbw.org/sirius/)  The schematic representation for the strcutureof the polyphenols 
is shown in Figure 6-1. The molecular dynamic (MD) simulation was performed using 
AMBER11 packcage 
63
 with an all atom amber99SB force field and explicit TIP3P water 
models. Each of the VQIVYK oligomer models with and without the polyphenols were solvated 
by explicit water molecules that extends 10 Å from any edge of the octahedral box to the protein 
atoms. Table 6-1 shows a summary of the simulations. Each system was simulated for 20 ns and 
the trajectories were saved at 8.0 ps intervals for further analysis. A hydrogen bond was assigned 
if the distance between donor D and acceptor A is  3.5 Å and the angle D-H …A  1200 239. 
Structural analysis was performed using the PTRAJ module of the AMBER 11
63
 software 
package. VMD (visual molecular dynamics) 
155
 program was used for the visualization of 
trajectories. The MM-PBSA single trajectory approach implemented as script (MMPBSA.py) in 
Amber11, was used to calculate the binding energy. Solute entropic contributions were not 
calculated in this study since they are only crudely estimated by normal mode analysis. Although 
the MM-GBSA(MM-PBSA) calculations may overestimate the absolute binding free energy due 
to the missing terms (e.g., conformational entropy change of the solute upon binding) and 
underestimate the desolvation free energy, they usually give a reasonable qualitative estimate on 
the relative binding free energy when two similar ligands are compared.
80,240
 
 
6.3 Results  
To examine the structural stability of the VQIVYK oligomers with and without 
curcumin, exifone and myricetin we analyzed, the Cα root-mean-square deviation (RMSD) 
versus time, the Cα root-mean-square fluctuation (RMSF) as a function of the residue number, 
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twist angle and hydrogen-bonding pattern.  All the reported quantities have been computed over 
the 20 ns of the production simulations of each system. The conformational stabilities of the 
VQIVYK oligomers with and without the ligands were monitored by the time evolution of the 
backbone root mean square (RMSD) and root mean square fluctuation (RMSF) relative to their 
initial energy minimized structure as shown in Table 6-2 and Figures 6-2. The RMSDs and 
RMSF provide useful information on relative stability of the oligomers, and were previously 
used in stability analyses of short amyloid oligomers with -sheet structure.86, 241, 149  To compare 
the effect of polyphenols binding to the VQIVYK oligomer we calculated the RMSD of C of 
the apo form and in complex with the ligand of the oligomer as shown in Figure 6-2A. The 
overall structure of the aggregates of the VQIVYK segment of tau peptide in complex with the 
polyphenol ligands is changing as is evidence by larger (2.0 Å) deviation in C of the complex 
compared to the negative control aggregate model. The lowest deviation from the starting 
structure is detected for VQIVYK when bound to exifone. The highest rms deviations for 
VQIVYK oligiomer was observed when the oligomer is bound to curcumin. Root mean square 
fluctuation(in Å) from the initial structure of the VQIVYK-backbone  atoms over the time course 
of the molecular dynamics simulation when bound to different polyphenol ligands is shown in 
Figure 6-2B. The complexation with the ligand also affects the RMSF compared to the apo form 
of the aggregate (see Figure 6-3). The RMSD of the ligands along the simulation time is shown 
in Figure 6-2B curcumin shows largest RMSD (1-3.5 Å), the RMSD of myricetin was within 0.5 
to 1.0 Å while the RMSD of exifone remains about 0.5 Å. Armstrong et al.
242
 have suggested the 
planar structure of phenolic compounds could contribute to their effectiveness as inhibiting 
aggregation by allowing them to intercalate between monomer layers. The hydrogen bond 
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analysis of curcumin (the most flexible ligand with few hydroxyl groups) indicates ligand 
flexibility and number of strong hydrogen bond acceptor (the ketone carbonyl: two in curcumin 
versus one in the other ligand) plays an important role in interaction of the ligand with the 
peptides. A proper balance between molecular flexibility and number of strong hydrogen bond 
donor/acceptor group could play a role in the designing of more potent polyphenols as 
aggregation inhibitor.
229
 
 
6.3.1 Average twist angle  
Amyloid fibrils typically exhibit twisted β-sheets, as observed by electron microscopy 
and solid state NMR. Since twisted β-sheets optimize the hydrogen bonds, side chain stacking, 
and electrostatic interactions, it is commonly accepted that twisted sheets are more stable than 
flat ones. While twisting, the β-sheets pairs remain to be complimentary via the steric 
zippers.
88
The twisting in the SH4-ST7 aggregate of VQIVTK hexapeptide was evaluated by 
considering pairs of dihedral angles, one per each sheet of the pair. Each dihedral angle is 
calculated from the coordinates of the Cα(Gln2) and the Cα(Tyr6) atom of the second and the six 
strand of the sheet. Twisting angles have been computed by using the five inner strands.
79
 As 
shown in Table 6-2, for the VQIVYK oligomer with and without polyphenolic ligand, the 
average twist angle of the oligomer with the ligand is larger than without the ligands. A large 
twist angle between two adjacent strands may lead them to tear away from one another at a 
relatively early stage of the simulation by disrupting the main chain and side-chain interactions 
necessary for maintaining the bulk structure. The presence of the ligand leads is structural 
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disruption exposing hydrophobic segments towards the polar solvent and the consequent 
destabilization of the bulk organization.  
 
6.3.2 Hydrogen bonding analysis  
The ordered oligomer of VQIVYK is stabilized by an extensive network of inter-peptide 
H-bonds. Hydrogen bonds contents of β-sheets were used previously to judge the structural 
integrity and stability of the various β-sheet aggregates. We did an inter-peptide hydrogen 
analysis and found the inter-peptide hydrogen bond content of VQIVYK oligomer with and 
without polyphenols was stable across all simulations (see Figure 6-3A and Table 6-2). 
Experimental and theoretical studies have suggested that the protein–polyphenol strong 
association is driven by hydrophobic effects and stabilized by hydrogen-bonding interactions. 
88
  
The polyphenol with hydroxyl groups, competitively interact with peptides through hydrogen 
bonds. The analysis of the hydrogen bonds present between the oligomer aggregates and 
polyphenols with time was obtained from a trajectory using ptraj module in AMBER11 and is 
shown in Table 6-2 and Figure 6-3B. Polyphenols binds reversibly and relatively weakly with 
peptide molecules. The pattern of H-bond formation between the polyphenols and VQIVYK 
oligomer have been analyzed in detail by considering percentage of occupancy (percentage of 
structures exhibiting the particular type of H-bond) and are shown in Table 6-3. We investigated 
the hydrogen bonds between polyphenols and the adjacent residues. The hydrogen bond 
occupancy (Table 6-4) shows the hydrogen bond with significantly high occupancy between the 
ligand and the peptide occurs with tyrosine and lysine residues that are close to the ligand as 
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shown in Table 6-3. In the case of curcumin the hydrogen bond acceptor with highest percentage 
occupancy is from the carbonyl ketones (see Table 6-3). 
 
6.3.3 Energetic Analysis of the binding 
By the MM-PB(GB)SA  analysis, the total free energy of binding could be separated into 
electrostatic, van der Waals, and solute-solvent interactions, gaining, additional insights into the 
physics of the VQIVYK oligomer-polyphenol association process. A single trajectory method 
was employed such that the snapshot coordinates for both the bound and unbound states were 
obtained from a single molecular dynamics simulation.  For this analysis, 2500 equally spaced 
snapshots were taken at intervals of 80 ps from the 20.0 ns production simulation of each MD 
trajectory. The binding free energy and the energy components of the polyphenols and VQIVYK 
oligomer complexes are summarized in Table 6-4. Both van der Waals and electrostatic 
contributions are relevant to the interaction. According to Table 6-4, electrostatic (ΔEele) and van 
der Waals (ΔEvdw) terms in the gas phase provide the major favorable contributions to the 
polyphenols binding, whereas polar solvation energies (ΔGPB(GB)) impair the binding. The 
nonpolar solvation energies (ΔGSA), which correspond to the burial of SASA upon binding, 
barely contribute to the polyphenols binding. Further insight into the forces involved in 
polyphenols and VQIVYK oligomer complex formation can be obtained by analyzing the 
electrostatic and non-electrostatic contributions in Table 6-4. As demonstrated by numerous 
studies, the electrostatic contribution generally disfavors the docking of ligand and receptor 
molecules because the unfavorable change in the electrostatics of solvation is mostly, but not 
fully, compensated by the favorable electrostatics within the resulting ligand-receptor complex
243
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Indeed, from Table 6-4, despite the favorable electrostatic energies in the gas phase (ΔEele), the 
contributions of polar solvation energies to binding (ΔGPB(GB)) are unfavorable for the 3 
complexes, and the sum of ΔEele and ΔGPB(GB), does not favor the binding. Table  6-4 also 
suggests that the net result of non-electrostatic interaction which is the sum of ΔEvdw and ΔGSA, 
is favorable for the formation of the complexes, and it this behavior has been proposed 
previously as a general trend for noncovalent ligand-receptor associations.
244
 From the above 
results, we can conclude that the binding free energies obtained for these complexes are driven 
by more favorable nonpolar interactions rather than by electrostatic interactions. To provide 
basic information on the most important residues in the binding of polyphenols to the VQIVYK 
oligomer an inhibitor-residue free energy decomposition analysis was performed. The 
calculation was done over the 2500 MD snapshots taken from the 20 ns simulation. According to 
the free energy decomposition analysis (Figure 6-4), the binding between the VQIVYK and the 
polyphenol is driven by selected “hot spots” that play a major role in VQIVYK −polyphenol 
recognition. The most important residues are Ile9, Ile33, Ile57, Ile81, Ile129 and Tyr149. 
Myricetin and exifone have been reported as tau aggregation inhibitors with a 1.2 μM and 3.2 
μM IC50 respectively. The binding energy analysis is in qualitative agreement with the 
experimental observation.
231
 The result form the simulation indicates that using the VQIVYK 
oligomer structure as a pharmacophore for tau amyloid in combination with docking and MD 
simulation could be effective in the virtual screening for lead discovery of small molecule 
aggregation inhibitors. Recently Okimoto et al 
83
used MD simulation of a protein-ligand 
conformation obtained from molecular docking to estimate the binding free energies using MM-
PBSA method and for ligand ranking. The combined docking and MD simulation was found to 
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improve by 1.6 to 4.0 time the enrichment performance compared to the used of docking method 
alone. The binding of the polyphenols with the peptide disrupts the surface pattern thus increases 
the solubility of small protofibrils. Such interaction remodels the tau oligomer into a 
confirmation that is different from the peptide without the ligand (see Figure 6-5). The 
remodeling of the peptide by the polyphenols will prevent the growth of the aggregate and will 
lead to disaggregation of the tau.  
 
6.4 Conclusions  
The results from this work provide a valuable insight into the mechanism of the 
interaction of polyphenols with the short segment of tau amyloid peptide. The study of the 
VQIVYK oligomer pharmacophore of tau amyloid with polyphenols in an explicit solvent may 
prove valuable in the future design and search of tau amyloid aggregation inhibitor. 
1. Polyphenol planarity with certain flexibility and presence of a strong hydrogen bond 
acceptor (the ketone carbonyl) for formation of hydrogen bond with the residues of the peptide 
closer to the ligand. 
2. The overall structure of the aggregates of the VQIVYK segment of tau peptide in 
complex with the polyphenol ligands compared to the negative control aggregate model is 
changing as is evidence by larger RMSD, RMSF and twist angles indicating the remodeling of 
the aggregate by the polyphenol molecules. 
3. The binding free energy calculation showed electrostatic (ΔEele) and van der Waals 
(ΔEvdw) terms in the gas phase provide the major favorable contributions to the polyphenols 
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binding, whereas polar solvation energies (ΔGPB(GB)) impair the binding. The nonpolar solvation 
energies (ΔGSA), which correspond to the burial of SASA upon binding, barely contribute to the 
polyphenols binding. The free energy decomposition analysis of the binding between the 
VQIVYK and the polyphenol is driven by selected “hot spots” that play a major role in 
VQIVYK −polyphenol recognition. The most important residues are Ile9, Ile33, Ile57, Ile81, 
Ile129, and Tyr149. 
4. The MM-PBSA (MM-GBSA) ranking of the polyphenols is in qualitative agreement with 
their experimental binding ranking.  Thus use of VQIVYK oligomer as pharmacophore for tau 
amyloid in combination with docking and MD simulation could be an effective strategy in the 
virtual screening for lead discovery of small molecule tau aggregation inhibitors. 
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Table 6-1 Summary of simulated system of polyphenols with tau peptide segment VQIVYK and control oligomer 
 
ID
†
 Content Number of 
water 
molecules  
Systems Box size Simulation 
length  (ns) 
1 VQIVYK oligomer with  
a single of curcumin 
5774 Four sheets, seven  strands (SH4-ST7) 
 
77.2177.2177.21 20 
2 VQIVYK oligomer with a 
single  of exofine 
5434 Four sheets, seven  strands (SH4-ST7) 
 
75.9975.99 75.99 20 
3 VQIVYK oligomer with a 
single of myricetin 
5767 Four sheets, seven  strands (SH4-ST7) 
 
77.2477.2477.24 20 
4 Control 5956 Four sheets, seven  strands (SH4-ST7) 
 
77.9677.9677.96 20 
 
     † 
The VQIVYK oligomer consists of a total four sheets with seven strands per sheets. The oligomer is organization with parallel -
sheet between strand per sheet and antiparallel between two sheets).  
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Table 6-2 Summary of structural analysis VQIVYK oligomers with and without polyphenols 
 
 
 
Geometric parameters 
Models name  
VQIVYK oligomer, 
control 
VQIVYK oligomer 
with curcumin  
VQIVYK oligomer 
with exofine 
VQIVYK oligomer with 
myricetin 
<RMSD> 5.45(1.69) 10.58(2.61) 7.21(1.14) 8.82(1.87) 
<RMSF> 2.59(1.95) 4.70(1.93) 2.66(0.98) 3.51(1.22) 
A
v
er
ag
e 
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Sheet 1 18.16(14.69) -8.70(3.85) -17.45( 3.04) -4.50(2.75) 
Sheet 2 -13.60(1.18) -14.22 (1.46) -14.41(1.32) -15.37(3.83) 
Sheet 3 -21.47(2.16) 5.16(9.96) -11.33(3.13) -12.83(3.03) 
Sheet 4 -12.06(1.34) -13.67(1.22) -19.60(3.19) -13.84(1.41) 
Oligomer inter-peptide H-bonds  
 
87.31(3.43) 
 
85.22(3.32) 84.41(4.30) 
 
81.42(5.06) 
H-bond of ligand with oligomer 
 
- 
 
0.92(1.41) 0.51(0.86) 
 
1.02(0.69) 
 
 Each number is averaged over 20 ns trajectory and the numbers in parenthesis are standard deviations. 
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Table 6-3 Hydrogen bond occupancy between the polyphenols and the oligomer of VQIVYK segment of tau peptide 
 
VQIVYK with curcumin 
Hydrogen bond type 
(%) VQIVYK with exifone 
Hydrogen bond type 
(%) VQIVYK with myricetin 
Hydrogen bond type 
(%) 
donor Acceptor   donor Acceptor   donor Acceptor   
curcumin@O34 TYR131@HH 71.8 exifone @O20 TYR 35@HH 16.8 myricetin @O12 TYR35@HH 60.5 
curcumin @O33 TYR131@HH 34.8 exifone @H30 TYR35@HH 14.6 TYR11@OH myricetin @H30 46.4 
curcumin @O33 TYR11@HH 26.2 exifone @O18 TYR35@HH 8.9 TYR131@OH myricetin @H31 21.0 
curcumin @OXT curcumin @H36 15.8 exifone @O18 TYR11@HH 5.7 myricetin 169@O22 TYR11@HH 12.2 
curcumin @O34 TYR155@HH 13.4 LYS54@OXT LYS103@H1 2.9 LYS54@OXT myricetin @H29 12.0 
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Table 6-4 Summary of the MM-GB(PB)SA  energy component analysis of the polyphenols with the VQIVYK oligomers 
 
MMGBSA 
 
Model name 
VQIVYK oligomer with curcumin VQIVYK oligomer with exifone VQIVYK oligomer with 
myricetin 
<∆Evdw> -28.29 4.53 -22.062.86 -32.395.35 
<∆Eele> -18.589.09 -8.718.38 -15.628.31 
<∆GPB> 36.719.06 29.147.96 38.848.66 
<∆GSA> -5.260.59 -3.890.33 -4.830.36 
<∆Gsolv> 31.459.08 25.257.97 34.018.67 
<∆Gbinding> -15.423.26 -5.51472.64 -14.024.33 
MMPBSA    
<∆Evdw> -28.294.53 -22.062.86 -32.395.35 
<∆Eele> -18.589.09 -8.718.38 -15.628.31 
<∆GPB> 35.67 9.67 28.35 8.46 41.03 10.85 
<∆GSA> -3.02 0.45 -1.840.25 -2.530.25 
<∆Gsolv> 32.66 9.68 26.51 8.46 38.50 10.85 
<∆Gbinding> -14.213.88 -4.254.59 -9.514.25 
 
*  Binding free energy components (kcal mol
−1
) and standard deviations calculated with MM-PBSA/ MM-GBSA for VQIVYK 
oligomer (SH4-ST7): Average over 2500 snapshots of the trajectory. 
b
 Δ Evdw, non-bonded van der Waals energy; ΔEele, non-solvent 
electrostatic potential energy; ΔGPB, electrostatic contributions to the solvation free energy calculated with Poisson-Boltzmann 
equation; ∆GSA , ∆GSolv are nonpolar and total solvation energies;  ΔG binding binding energy of the system. All energies are in kcal/mol:  
ΔGbinding = ΔEvdw + ΔEele + ΔGsol; ΔGsol = ΔGPB + ΔGSA;  
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Figure 6-1 Chemical structures of curcumin (A), exifone (B) and myricetin (C) 
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Figure 6-2 RMDS as a function of the simulation time (A) Comparative RMSD analyses of 
VQIVYK oligomer control and in complex with curcumin, exifone and myricetin and (B) 
comparative RMSD of the inhibitor molecules with respect to the first snapshot 
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Figure 6-3 Comparative RMSF analysis of the VQIVYK oligomer control and in complex with 
curcumin, exifoneand myricetin 
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Figure 6-4 Time evolution of the number of hydrogen bonds (A) Total inter peptide hydrogen 
bonds  (B) hydrogen bonds between the polyphenols and VQIVYK oligomer 
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Figure 6-5 Decomposition of the free energy on a per residue basis for VQIVYK oligomer and 
the polyphenol interaction  
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Figure 6-6 The structure of the initial and final structure after 20 ns for the VQIVYK oligomer with and without polyphenols 
 
 
187 
6.5 Refereneces 
204. Chisato Nishiuraa, K. T., Katsuhiko Minouraa, Miho Sumidab, Taizo Taniguchib, Koji 
Tomooa, and Toshimasa Ishidaa, Importance of Tyr310 residue in the third repeat of microtubule 
binding domain for filament formation of tau protein. J Biochem 2010, 147, 405-414. 
205. M. von Bergen, P. F., J. Biernat, J. Heberle, E.-M. Mandelkow, and E. Mandelkow, 
Assembly of τ protein into Alzheimer paired helical filaments depends on a local sequence motif 
(306VQIVYK311) forming β structure. Proc Natl Acad sci 2000, 97, 5129-5134. 
206. Landau M, S. M., Faull KF, Laganowsky A, Jiang L, Sievers SA, Liu J, Barrio JR, 
Eisenberg D., Towards a Pharmacophore for Amyloid. PLoS Biol. 2011, 9(6):e1001080. 
207. Porat Y, A. A., Gazit E Inhibition of amyloid fibril formation by polyphenols: structural 
similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 
2006, 67, 27–37. 
208. Dobson, C. M., Protein folding and misfolding. Nature 2003, 426, (6968), 884-890. 
209. Stefani, M.; Dobson, C. M., Protein aggregation and aggregate toxicity: new insights into 
protein folding, misfolding diseases and biological evolution. Journal of Molecular Medicine-
Jmm 2003, 81, (11), 678-699. 
210. Haataja, L.; Gurlo, T.; Huang, C. J.; Butler, P. C., Islet amyloid in type 2 diabetes, and 
the toxic oligomer hypothesis. Endocrine Reviews 2008, 29, (3), 303-316. 
211. Bucciantini, M.; Calloni, G.; Chiti, F.; Formigli, L.; Nosi, D.; Dobson, C. M.; Stefani, 
M., Prefibrillar amyloid protein aggregates share common features of cytotoxicity. Journal of 
Biological Chemistry 2004, 279, (30), 31374-31382. 
188 
212. Butterfield, D. A., Amyloid beta-peptide (1-42)-induced oxidative stress and 
neurotoxicity: Implications for neurodegeneration in Alzheimer's disease brain. A review. Free 
Radical Research 2002, 36, (12), 1307-1313. 
213. Zhu, M.; Rajamani, S.; Kaylor, J.; Han, S.; Zhou, F. M.; Fink, A. L., The flavonoid 
baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. Journal of 
Biological Chemistry 2004, 279, (26), 26846-26857. 
214. Zhu, J. T. T.; Choi, R. C. Y.; Chu, G. K. Y.; Cheung, A. W. H.; Gao, Q. T.; Li, J.; Jiang, 
Z. Y.; Dong, T. T. X.; Tsim, K. W. K., Flavonoids possess neuroprotective effects on cultured 
pheochromocytoma PC12 cells: A comparison of different flavonoids in activating estrogenic 
effect and in preventing beta-amyloid-induced cell death. Journal of Agricultural and Food 
Chemistry 2007, 55, (6), 2438-2445. 
215. Akaishi, T.; Morimoto, T.; Shibao, M.; Watanabe, S.; Sakai-Kato, K.; Utsunomiya-Tate, 
N.; Abe, K., Structural requirements for the flavonoid fisetin in inhibiting fibril formation of 
amyloid beta protein. Neuroscience Letters 2008, 444, (3), 280-285. 
216. Kim, H.; Park, B. S.; Lee, K. G.; Choi, C. Y.; Jang, S. S.; Kim, Y. H.; Lee, S. E., Effects 
of naturally occurring compounds on fibril formation and oxidative stress of beta-amyloid. 
Journal of Agricultural and Food Chemistry 2005, 53, (22), 8537-8541. 
217. Masuda, M.; Suzuki, N.; Taniguchi, S.; Oikawa, T.; Nonaka, T.; Iwatsubo, T.; Hisanaga, 
S.; Goedert, M.; Hasegawa, M., Small molecule inhibitors of alpha-synuclein filament assembly. 
Biochemistry 2006, 45, (19), 6085-6094. 
218. Shoval, H.; Lichtenberg, D.; Gazit, E., The molecular mechanisms of the anti-amyloid 
effects of phenols. Amyloid-Journal of Protein Folding Disorders 2007, 14, (1), 73-87. 
189 
219. Porat, Y.; Abramowitz, A.; Gazit, E., Inhibition of amyloid fibril formation by 
polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism. 
Chemical Biology & Drug Design 2006, 67, (1), 27-37. 
220. He, J.; Xing, Y. F.; Huang, B.; Zhang, Y. Z.; Zeng, C. M., Tea Catechins Induce the 
Conversion of Preformed Lysozyme Amyloid Fibrils to Amorphous Aggregates. Journal of 
Agricultural and Food Chemistry 2009, 57, (23), 11391-11396. 
221. Ho, L.; Pasinetti, G. M., Polyphenolic compounds for treating neurodegenerative 
disorders involving protein misfolding. Expert Review of Proteomics 2010, 7, (4), 579-589. 
222. Ono, K.; Yamada, M., Antioxidant compounds have potent anti-fibrillogenic and fibril-
destabilizing effects for alpha-synuclein fibrils in vitro. Journal of Neurochemistry 2006, 97, (1), 
105-115. 
223. Bastianetto, S.; Krantic, S.; Quirion, R., Polyphenols as potential inhibitors of amyloid 
aggregation and toxicity: Possible significance to Alzheimer's disease. Mini-Reviews in 
Medicinal Chemistry 2008, 8, (5), 429-435. 
224. Wu, C.; Wang, Z. X.; Lei, H. X.; Duan, Y.; Bowers, M. T.; Shea, J. E., The Binding of 
Thioflavin T and Its Neutral Analog BTA-1 to Protofibrils of the Alzheimer's Disease A beta(16-
22) Peptide Probed by Molecular Dynamics Simulations. Journal of Molecular Biology 2008, 
384, (3), 718-729. 
225. Convertino, M.; Pellarin, R.; Catto, M.; Carotti, A.; Caflisch, A., 9,10-Anthraquinone 
hinders beta-aggregation: How does a small molecule interfere with A beta-peptide amyloid 
fibrillation? Protein Science 2009, 18, (4), 792-800. 
190 
226. Takeda, T.; Chang, W. L. E.; Raman, E. P.; Klimov, D. K., Binding of nonsteroidal anti-
inflammatory drugs to A beta fibril. Proteins-Structure Function and Bioinformatics 2010, 78, 
(13), 2849-2860. 
227. Liu, F. F.; Ji, L.; Dong, X. Y.; Sun, Y., Molecular Insight into the Inhibition Effect of 
Trehalose on the Nucleation and Elongation of Amyloid beta-Peptide Oligomers. Journal of 
Physical Chemistry B 2009, 113, (32), 11320-11329. 
228. Bruce, N. J.; Chen, D. L.; Dastidar, S. G.; Marks, G. E.; Schein, C. H.; Bryce, R. A., 
Molecular dynamics simulations of A beta fibril interactions with beta-sheet breaker peptides. 
Peptides 2010, 31, (11), 2100-2108. 
229. Lemkul, J. A.; Bevan, D. R., Destabilizing Alzheimer's A beta(42) Protofibrils with 
Morin: Mechanistic Insights from Molecular Dynamics Simulations. Biochemistry 2010, 49, 
(18), 3935-3946. 
230. Ho, L.; Yemul, S.; Wang, J.; Pasinettia, G. M., Grape Seed Polyphenolic Extract as a 
Potential Novel Therapeutic Agent in Tauopathies. Journal of Alzheimers Disease 2009, 16, (2), 
433-439. 
231. Taniguchi, S.; Suzuki, N.; Masuda, M.; Hisanaga, S.; Iwatsubo, T.; Goedert, M.; 
Hasegawa, M., Inhibition of heparin-induced tau filament formation by phenothiazines, 
polyphenols, and porphyrins. Journal of Biological Chemistry 2005, 280, (9), 7614-7623. 
232. Wang, J.; Santa-Maria, I.; Ho, L.; Ksiezak-Reding, H.; Ono, K.; Teplow, D. B.; Pasinetti, 
G. M., Grape Derived Polyphenols Attenuate Tau Neuropathology in a Mouse Model of 
Alzheimer's Disease. Journal of Alzheimers Disease 2010, 22, (2), 653-661. 
233. Yang, F. S.; Lim, G. P.; Begum, A. N.; Ubeda, O. J.; Simmons, M. R.; Ambegaokar, S. 
S.; Chen, P. P.; Kayed, R.; Glabe, C. G.; Frautschy, S. A.; Cole, G. M., Curcumin inhibits 
191 
formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. 
Journal of Biological Chemistry 2005, 280, (7), 5892-5901. 
234. Amijee, H.; Scopes, D. I. C., The Quest for Small Molecules as Amyloid Inhibiting 
Therapies for Alzheimer's Disease. Journal of Alzheimers Disease 2009, 17, (1), 33-47. 
235. Ho, L.; Pasinetti, G. M., Polyphenolic compounds for treating neurodegenerative 
disorders involving protein misfolding. Expert Review of Proteomics 7, (4), 579-589. 
236. Meng, F. L.; Abedini, A.; Plesner, A.; Verchere, C. B.; Raleigh, D. P., The Flavanol (-)-
Epigallocatechin 3-Gallate Inhibits Amyloid Formation by Islet Amyloid Polypeptide, 
Disaggregates Amyloid Fibrils, and Protects Cultured Cells against IAPP-Induced Toxicity. 
Biochemistry 49, (37), 8127-8133. 
237. Ladiwala, A. R. A. L., J. C.; Bale, S. S.; Marcelino-Cruz, A. M.; Bhattacharya, M.; 
Dordick, J. S.; Tessier, P. M., , Resveratrol Selectively Remodels Soluble Oligomers and Fibrils 
of Amyloid A beta into Off-pathway Conformers. Journal of Biological Chemistry 2010, 285, 
(31), 24228-24237. 
238. Bulic B, P. M., Schmidt B, Mandelkow EM, Waldmann H, Mandelkow E., Development 
of tau aggregation inhibitors for Alzheimer's disease. Angew Chem Int Ed Engl. 2009, 48, 1740-
1752. 
239. Fabiola, F.; Bertram, R.; Korostelev, A.; Chapman, M. S., An improved hydrogen bond 
potential: Impact on medium resolution protein structures. Protein Science 2002, 11, (6), 1415-
1423. 
240. Gilson, M. K.; Zhou, H. X., Calculation of protein-ligand binding affinities. Annual 
Review of Biophysics and Biomolecular Structure 2007, 36, 21-42. 
192 
241. Berhanu, W. M. M., A. E., Controlling the aggregation and rate of release in order to 
improve insulin formulation: molecular dynamics study of full-length insulin amyloid oligomer 
models. Journal of Molecular Modeling published online: 15 June 2011; DOI 10.1007/s00894-
011-1123-3. 
242. Armstrong, A. H.; Chen, J.; McKoy, A. F.; Hecht, M. H., Mutations That Replace 
Aromatic Side Chains Promote Aggregation of the Alzheimer's A beta Peptide. Biochemistry 
2011, 50, (19), 4058-4067. 
243. Gutierrez, L. J.; Enriz, R. D.; Baldoni, H. A., Structural and Thermodynamic 
Characteristics of the Exosite Binding Pocket on the Human BACE1: A Molecular Modeling 
Approach. Journal of Physical Chemistry A 2010, 114, (37), 10261-10269. 
244. Miyamoto, S. K., P. A.,, What determines the strength of noncovalent association of 
ligands to proteins in aqueous-solution. Proceedings of the National Academy of Sciences of the 
United States of America 1993, 90, (18), 8402–8406. 
 
193 
SUMMARY 
This Thesis describes Molecular dynamic study aimed at understanding the effect steric 
zipper mutation, polymorphic packing and polyphenols on the aggregation of amyloid peptides.  
First we investigated the effect of various sizes and arrangements of oligomer seeds of 
the wild-type and mutants of the three hexa-peptides fragments of Tau, Insulin and Aβ peptide 
(VQIVYK, MVGGVV and LYQLEN) on their structural stability and dynamics. We found the 
stability of the VQIVYK, MVGGVV and LYQLEN peptide oligomers increases with increasing 
the number of β-strand. The Sh2-St4 model was found to stable enough that could possible act as 
a stable seed in prompting amyloid fibril formation for all the three peptides. The binding energy 
calculated by MM-PBSA method and the analysis of individual contributions to the binding 
energy shows the hydrophobic interactions play an important role in stabilizing the structural 
organizations between β-sheet layers in the oligomers. The result of the binding free energy 
calculation also indicated that the wild type is the most stable structure compared to the mutants. 
The single glycine substitution at the steric zipper interface disrupts the hydrophobic steric 
zipper remarkably, indicating that the hydrophobic attraction is a major driving force for 
stabilizing and aggregation of oligomers. Consequently, the substantial reduction in the van der 
Waals intersheet interactions leads to destabilization of the oligomers. Overall, aggregation of 
both wild type and mutant peptides is driven by nonpolar interaction. Thus, designing new 
peptidomimetic inhibitors able to prevent the fibril formation based on the modification of steric 
zipper motif of the oligomers, similar to the ones examined in this study may become a viable 
therapeutic strategy.  
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Next we investigated effects of sequence and packing arrangements on five pairs of short 
segments of amyloid peptides with steric zipper polymorphism. The simulation revealed the 
amyloid peptide rich in Q/N amino acid (GNNQQNY and NNQNTF) have a greater structural 
stability than the short segments amyloid peptide lacking the Q/N amino acids (SSTNVG, 
VQIVYK and MVGGVV).  The Q/N residue rich short amyloid segments have larger hydrogen 
bond contents and hydrogen bond occupancy. The overall increase of hydrogen bond in the Q/N 
residue rich peptides with smaller RMSD, RMSF and greater stability suggests their stability is 
mainly associated with an increase in side chain interaction and hydrogen bond contents. The 
simulations of Q/NG mutants disrupted the steric zipper, leading to unstable oligomers. The 
The MM-PBSA binding free energy method was applied to the study of the -sheet association. 
The nonpolar component of free energy is more favorable, while the electrostatic solvation is 
unfavorable for sheet to sheet interaction. This explains the acceleration of aggregation by 
adding nonpolar co-solvents (methanol, trifluoroethanol, and hexafluoroisopropanol).The 
decomposition of the binding energy per residue showed the contribution of the N/Q side-chains 
to the association of the 5 stranded double layer oligomers is larger than the other nonpolar and 
small size amino acids at the interface, underlining the importance of Q/N amino acid in 
stabilizing the short segment amyloid peptides in crystal free context. 
Next we investigated the structural stability of the wild type and mutants of a single layer 
models of insulin aimed at the design of short- and long-acting insulin analogs. We found the 
stabilities of the single-layer insulin peptide oligomers increase as the number of strands 
increases (dynamic cooperative effect). The binding energy calculated by the MM-GBSA 
method shows that hydrophobic interactions play an important role in stabilizing the structural 
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organization of the single-layer insulin. Per-residue decomposition shows that the key amino 
acid residues for single layer insulin stability occur mainly in the β-sheet regions of chains A and 
B. The binding energy decomposition also reveals due to the electrostatic repulsion between the 
three negatively charged glutamates in adjacent insulin strands, electrostatic contribution to the 
binding energy is unfavorable. The single glycine substitution at the steric zipper interface was 
found to disrupts the hydrophobic contacts and reduces the van der Waals interactions in the 
mutants, thus reducing the binding free energy. The binding free-energy calculation indicated 
that the wild type is more structurally stable than most of the mutants. A comparison of the 
binding free energy between the wild type and the chain-A mutants (Y14GA, L16GA and 
N18GA) indicated that shape complementarity between neighboring strands plays a key role in 
stabilizing the entire oligomeric structure. The secondary structure contents and the clustering 
analysis of the trajectories of the single-layer insulin oligomers of various sizes showed that the 
larger aggregates retain the fibril conformation but the smaller ones (SH1-ST1 and SH1-ST2) 
lose this conformation. This observation could explain the observed shortening of the nucleation 
lag phase of insulin aggregation with oligomer seeds. Based on the secondary structure contents 
and the cluster analysis, we propose that SH1-ST4 is a critical nucleus for single-layer insulin 
fibril oligomer growth.  Our simulations of wildtype and single glycine mutants at the steric 
zipper region can be targeted in the design of both short- and long-acting insulin analogs as well. 
Aside from the design of such insulin analogs, the present study may prove useful in the rational 
design of insulin aggregation inhibitors that can be used to stabilize insulin formulations, leading 
to safer handling and more cost-effective storage of such formulations, especially in developing 
countries. 
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Finally we investigated the interaction of polyphenols with short amyloid aggregates. The 
results from this work provide a valuable insight into the mechanism of the interaction of 
polyphenols with the short segment of tau amyloid peptide. The study of the VQIVYK oligomer 
pharmacophore of tau amyloid with polyphenols in an explicit solvent may prove valuable in the 
future design and search of tau amyloid aggregation inhibitor. Polyphenol planarity with certain 
flexibility and presence of a strong hydrogen bond acceptor (the ketone carbonyl) for formation 
of hydrogen bond with the residues of the peptide closer to the ligand. The overall structure of 
the aggregates of the VQIVYK segment of tau peptide in complex with the polyphenol ligands 
compared to the negative control aggregate model is changing as is evidence by larger RMSD, 
RMSF and twist angles indicating the remodeling of the aggregate by the polyphenol molecules. 
The binding free energy calculation showed electrostatic (ΔEele) and van der Waals (ΔEvdw) 
terms in the gas phase provide the major favorable contributions to the polyphenols binding, 
whereas polar solvation energies (ΔGPB(GB)) impair the binding. The nonpolar solvation 
energies (ΔGSA), which correspond to the burial of SASA upon binding, barely contribute to the 
polyphenols binding. The free energy decomposition analysis of the binding between the 
VQIVYK and the polyphenol is driven by selected “hot spots” that play a major role in 
VQIVYK −polyphenol recognition. The most important residues are Ile9, Ile33, Ile57, Ile81, 
Ile129, and Tyr149. The MM-PBSA (MM-GBSA) ranking of the polyphenols is in qualitative 
agreement with their experimental binding ranking. Thus use of VQIVYK oligomer as 
pharmacophore for tau amyloid in combination with docking and MD simulation could be an 
effective strategy in the virtual screening for lead discovery of small molecule tau aggregation 
inhibitors. 
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In summary, we conclude MD simulation could be used in the atomic level understanding 
of amyloid aggregation formation, could contributes to elucidating the driving force for the 
thermodynamics of the aggregation, could contribute in the structure based designing of 
aggregation inhibitors and in combination with docking and MM-PBSA binding free energy 
calculation could be useful in the virtual screening of inhibitors. 
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